false
FY
0001642159
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
P5Y
0001642159
2023-01-01
2023-12-31
0001642159
2023-06-30
0001642159
2024-02-16
0001642159
2023-12-31
0001642159
2022-12-31
0001642159
2022-01-01
2022-12-31
0001642159
us-gaap:PreferredStockMember
2021-12-31
0001642159
us-gaap:CommonStockMember
2021-12-31
0001642159
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001642159
us-gaap:RetainedEarningsMember
2021-12-31
0001642159
2021-12-31
0001642159
us-gaap:PreferredStockMember
2022-12-31
0001642159
us-gaap:CommonStockMember
2022-12-31
0001642159
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001642159
us-gaap:RetainedEarningsMember
2022-12-31
0001642159
us-gaap:PreferredStockMember
2022-01-01
2022-12-31
0001642159
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001642159
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001642159
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001642159
us-gaap:PreferredStockMember
2023-01-01
2023-12-31
0001642159
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0001642159
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-12-31
0001642159
us-gaap:RetainedEarningsMember
2023-01-01
2023-12-31
0001642159
us-gaap:PreferredStockMember
2023-12-31
0001642159
us-gaap:CommonStockMember
2023-12-31
0001642159
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001642159
us-gaap:RetainedEarningsMember
2023-12-31
0001642159
SIGYD:ShareExchangeAgreementMember
SIGYD:IssuedAndOutstandingSharesMember
2020-10-19
0001642159
SIGYD:ShareExchangeAgreementMember
2020-10-18
2020-10-19
0001642159
SIGYD:SigynStockholdersMember
SIGYD:ShareExchangeAgreementMember
2020-10-19
0001642159
us-gaap:SubsequentEventMember
2024-02-16
0001642159
us-gaap:OfficeEquipmentMember
2023-12-31
0001642159
us-gaap:OfficeEquipmentMember
2022-12-31
0001642159
us-gaap:ComputerEquipmentMember
2023-12-31
0001642159
us-gaap:ComputerEquipmentMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2020-01-26
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2020-06-23
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2020-06-21
2020-06-23
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2020-09-17
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2020-09-16
2020-09-17
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2022-03-22
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2022-04-28
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2022-04-27
2022-04-28
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2022-05-10
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2022-05-09
2022-05-10
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2022-06-01
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2022-05-31
2022-06-01
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2022-06-22
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2022-06-21
2022-06-22
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2022-07-30
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2022-08-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2022-08-01
2022-08-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2022-09-09
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2022-09-20
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2022-09-08
2022-09-09
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2022-09-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2022-09-19
2022-09-20
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2022-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2022-10-19
2022-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2022-11-09
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2022-11-08
2022-11-09
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2022-11-14
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2022-11-13
2022-11-14
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2022-12-22
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2022-12-21
2022-12-22
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2022-07-30
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOtherMember
2021-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOtherMember
2022-01-01
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOtherMember
2022-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOtherMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteOtherMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
SIGYD:BrioCapitalMasterFundLtdMember
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-06-02
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2023-10-31
0001642159
SIGYD:ConvertiblePromissoryNoteSeventeenMember
2023-10-31
2023-10-31
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-12-22
0001642159
SIGYD:ConvertiblePromissoryNoteSixteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-12-22
2022-12-22
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-11-14
0001642159
SIGYD:ConvertiblePromissoryNoteFifteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-11-13
2022-11-14
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-11-09
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-11-08
2022-11-09
0001642159
SIGYD:ConvertiblePromissoryNoteFourteenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteThirteenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-10-19
2022-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
SIGYD:OsherCapitalPartnersLLCMember
2022-09-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
SIGYD:OsherCapitalPartnersLLCMember
2022-09-19
2022-09-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwelveMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-09-09
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-09-08
2022-09-09
0001642159
SIGYD:ConvertiblePromissoryNoteElevenMember
SIGYD:BrioCapitalMasterFundLtdMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-08-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-08-30
2022-08-31
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-08-30
0001642159
SIGYD:ConvertiblePromissoryNoteTenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
SIGYD:OsherCapitalPartnersLLCMember
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
SIGYD:OsherCapitalPartnersLLCMember
2022-07-30
2022-07-31
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
SIGYD:OsherCapitalPartnersLLCMember
2023-10-03
0001642159
SIGYD:ConvertiblePromissoryNoteNineMember
SIGYD:OsherCapitalPartnersLLCMember
2023-06-02
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
SIGYD:OsherCapitalPartnersLLCMember
2022-06-22
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
SIGYD:OsherCapitalPartnersLLCMember
2022-06-21
2022-06-22
0001642159
SIGYD:ConvertiblePromissoryNoteEightMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-06-01
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
SIGYD:OsherCapitalPartnersLLCMember
2022-05-31
2022-06-01
0001642159
SIGYD:ConvertiblePromissoryNoteSevenMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-05-10
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-05-09
2022-05-10
0001642159
SIGYD:ConvertiblePromissoryNoteSixMember
SIGYD:BrioCapitalMasterFundLtdMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
SIGYD:OsherCapitalPartnersLLCMember
2022-04-28
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
SIGYD:OsherCapitalPartnersLLCMember
2022-04-27
2022-04-28
0001642159
SIGYD:ConvertiblePromissoryNoteFiveMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:OsherCapitalPartnersLLCMember
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:OsherCapitalPartnersLLCMember
2022-03-22
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:BrioCapitalMasterFundLtdMember
2022-03-22
2022-03-23
0001642159
SIGYD:ConvertiblePromissoryNoteFourMember
SIGYD:BrioCapitalMasterFundLtdMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:SecuritiesPurchaseAgreementMember
2020-09-17
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-09-17
2020-09-17
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:AmendedConvertibleDebtAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-09-17
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:AmendedConvertibleDebtAgreementMember
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:AmendedConvertibleDebtAgreementMember
2020-10-18
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:AmendedConvertibleDebtAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-19
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:AmendedConvertibleDebtAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:AmendedConvertibleDebtAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-27
2021-10-28
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:AmendedConvertibleDebtAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-28
0001642159
SIGYD:ConvertiblePromissoryNoteThreeMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-06-23
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-06-21
2020-06-23
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:AmendedConvertibleDebtAgreementTwoMember
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-10-18
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-19
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteTwoMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-01-27
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2020-08-20
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:AmendedConvertibleDebtAgreementMember
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:AmendedConvertibleDebtAgreementMember
2020-01-27
2020-01-28
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:SecuritiesPurchaseAgreementMember
2021-10-19
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:OsherCapitalPartnersLLCMember
SIGYD:SecuritiesPurchaseAgreementMember
2020-10-20
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteOneMember
SIGYD:SecuritiesPurchaseAgreementMember
SIGYD:OsherCapitalPartnersLLCMember
2023-09-14
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:ThirdPartyInvestorMember
SIGYD:SecuritiesPurchaseAgreementMember
2022-11-21
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:ThirdPartyInvestorMember
SIGYD:SecuritiesPurchaseAgreementMember
2022-11-20
2022-11-21
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:ThirdPartyInvestorMember
SIGYD:SecuritiesPurchaseAgreementMember
2022-11-23
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:ThirdPartyInvestorMember
us-gaap:CommonStockMember
2022-11-23
0001642159
us-gaap:SeriesBPreferredStockMember
2023-01-01
2023-12-31
0001642159
us-gaap:SeriesBPreferredStockMember
2023-12-31
0001642159
2023-06-01
2023-06-02
0001642159
us-gaap:CommonStockMember
2023-06-01
2023-06-02
0001642159
SIGYD:ConvertiblePromissoryNoteMember
2021-10-18
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteMember
2021-10-22
0001642159
SIGYD:ConvertiblePromissoryNoteMember
2023-01-01
2023-12-31
0001642159
SIGYD:ConvertiblePromissoryNoteMember
2022-01-01
2022-12-31
0001642159
2021-05-26
2021-05-27
0001642159
SIGYD:ASC842Member
2021-06-15
0001642159
SIGYD:EmploymentAgreementsMember
SIGYD:MrJoyceMember
2023-01-01
2023-12-31
0001642159
SIGYD:MrJoyceMember
2023-01-01
2023-12-31
0001642159
SIGYD:MrJoyceMember
2022-01-01
2022-12-31
0001642159
SIGYD:MrDeCiccioMember
SIGYD:EmploymentAgreementsMember
2023-12-06
0001642159
SIGYD:MrDeCiccioMember
SIGYD:EmploymentAgreementsMember
2023-12-06
2023-12-06
0001642159
SIGYD:MrDeCiccioMember
SIGYD:EmploymentAgreementsMember
2023-01-01
2023-12-31
0001642159
SIGYD:MrDeCiccioMember
SIGYD:EmploymentAgreementsMember
2023-12-31
0001642159
SIGYD:MrDeCiccioMember
SIGYD:EmploymentAgreementsMember
2022-12-31
0001642159
SIGYD:DrMarleauMember
SIGYD:EmploymentAgreementsMember
2023-04-01
0001642159
SIGYD:DrMarleauMember
SIGYD:EmploymentAgreementsMember
2023-04-01
2023-04-01
0001642159
SIGYD:DrMarleauMember
SIGYD:EmploymentAgreementsMember
2023-01-01
2023-12-31
0001642159
SIGYD:DrMarleauMember
SIGYD:EmploymentAgreementsMember
2022-01-01
2022-12-31
0001642159
SIGYD:ChiefTechnologyOfficerMember
SIGYD:EmploymentAgreementsMember
2023-01-01
2023-12-31
0001642159
SIGYD:ChiefTechnologyOfficerMember
SIGYD:EmploymentAgreementsMember
2022-01-01
2022-12-31
0001642159
us-gaap:ConvertibleNotesPayableMember
2023-01-01
2023-12-31
0001642159
us-gaap:ConvertibleNotesPayableMember
2022-01-01
2022-12-31
0001642159
us-gaap:RestrictedStockUnitsRSUMember
2023-01-01
2023-12-31
0001642159
us-gaap:RestrictedStockUnitsRSUMember
2022-01-01
2022-12-31
0001642159
us-gaap:WarrantMember
2023-01-01
2023-12-31
0001642159
us-gaap:WarrantMember
2022-01-01
2022-12-31
0001642159
SIGYD:MrChrisWetzelMember
2022-10-10
0001642159
SIGYD:MrChrisWetzelMember
2022-10-09
2022-10-10
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:BrioCapitalMasterFundLtdMember
us-gaap:SubsequentEventMember
2024-01-08
0001642159
SIGYD:ConvertiblePromissoryNoteMember
SIGYD:BrioCapitalMasterFundLtdMember
us-gaap:SubsequentEventMember
2024-01-08
2024-01-08
0001642159
us-gaap:SubsequentEventMember
2024-01-09
2024-01-09
0001642159
us-gaap:SubsequentEventMember
2024-01-19
2024-01-19
0001642159
us-gaap:SubsequentEventMember
srt:ChiefExecutiveOfficerMember
2024-01-01
2024-01-31
0001642159
us-gaap:SubsequentEventMember
srt:ChiefExecutiveOfficerMember
2024-02-15
0001642159
SIGYD:TwentyTwentyFourConvertibleNotesMember
us-gaap:SubsequentEventMember
2024-02-29
0001642159
SIGYD:TwentyTwentyFourConvertibleNotesMember
us-gaap:SubsequentEventMember
2024-02-01
2024-02-29
0001642159
SIGYD:TwentyTwentyFourConvertibleNotesMember
us-gaap:SubsequentEventMember
2024-01-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the fiscal year ended December 31, 2023
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from __________ to _________
Commission
File Number 000-55575
SIGYN
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
84-4210559 |
(State
or other jurisdiction
of
incorporation) |
|
(IRS
Employer
File
Number) |
2468
Historic Decatur Road Ste., 140, San Diego, California |
|
92106 |
(Address
of principal executive offices) |
|
(zip
code) |
(619)
353-0800
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
None |
|
|
|
|
Securities
registered pursuant to Section 12(g) of the Act:
Common
Stock, $0.0001 Par Value
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
|
|
|
|
Emerging
Growth Company |
☒ |
If
an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. ☐
If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As
of June 30, 2023 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market
value of the issued and outstanding common stock held by non-affiliates of the registrant was $1,859,140. For purposes of the above statement
only, all directors, executive officers and 10% shareholders are assumed to be affiliates. This determination of affiliate status is
not necessarily a conclusive determination for any other purpose.
As
of February 16, 2024, there were 1,224,315 shares of common stock outstanding.
SIGYN
THERAPEUTICS, INC.
2023
ANNUAL REPORT ON FORM 10-K
TABLE
OF CONTENTS
DISCLOSURE
REGARDING FORWARD LOOKING STATEMENTS
This
report contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled “Description
of Business,” “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results
of Operations.” These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any future results, performances or achievements expressed or implied by
the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,”
“believes,” “seeks,” “could,” “estimates,” “expects,” “intends,”
“may,” “plans,” “potential,” “predicts,” “projects,” “should,”
“would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current
views with respect to future events and are based on assumptions and subject to risks and uncertainties. These risks and uncertainties
include, but are not limited to, the factors described in the section captioned “Risk Factors” below. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. Such statements may include, but are not limited to, information
related to: anticipated operating results; licensing arrangements; relationships with our customers; consumer demand; financial resources
and condition; changes in revenues; changes in profitability; changes in accounting treatment; cost of sales; selling, general and administrative
expenses; interest expense; the ability to secure materials and subcontractors; the ability to produce the liquidity or enter into agreements
to acquire the capital necessary to continue our operations and take advantage of opportunities; legal proceedings and claims.
Also,
forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and
the documents that we reference and filed as exhibits to this report completely and with the understanding that our actual future results
may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements
publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even
if new information becomes available in the future.
USE
OF CERTAIN DEFINED TERMS
Except
as otherwise indicated by the context, references in this report to “we,” “us,” “our,” “our
Company,” or “the Company” is of Sigyn Therapeutics, Inc.
In
addition, unless the context otherwise requires and for the purposes of this report only:
|
● |
“Sigyn”
refers to Sigyn Therapeutics, Inc., a Delaware corporation; |
|
● |
“Commission”
refers to the Securities and Exchange Commission; |
|
● |
“Exchange
Act” refers to the Securities Exchange Act of 1934, as amended; and |
|
● |
“Securities
Act” refers to the Securities Act of 1933, as amended. |
PART
I
Item
1. Business
Background
Business
Overview
Sigyn
Therapeutics, Inc. (“Sigyn”, the “Company” “we,” “us,” or “our”) is a development-stage
company that creates blood purification technologies to overcome clearly defined limitations in healthcare.
Sigyn
Therapy™, our lead product candidate, is being advanced to treat life-threatening conditions that are not addressed with market-cleared
drug agents. Candidate treatment indications include endotoxemia, sepsis (a leading cause of hospital deaths), community acquired pneumonia
(a leading cause of infectious disease deaths), drug-resistant bacterial infections, and emerging pandemic viral threats.
We
plan to initiate first-in-human feasibility studies of Sigyn TherapyTM in End-Stage Renal Disease (“ESRD”) patients with endotoxemia
and concurrent inflammation, whose incidence is elevated among ~550,000 U.S. dialysis patients. To support the initiation of our proposed
study, we have drafted an Investigational Device Exemption (“IDE”) for submission to the U.S. Food and Drug Administration (“FDA”).
Our clinical study plan proposes to enroll 12-15 ESRD subjects to evaluate the safety of Sigyn Therapy at three clinical site locations
that have already been identified and evaluated by a contract research organization that specializes in ESRD related clinical studies.
Beyond our clinical objective to demonstrate safety, we will also quantify changes in endotoxin levels as well as markers of inflammation
as secondary endpoints. However, the clinical plan proposed in our IDE has not yet been communicated to FDA and there is no assurance
that FDA will approve the initiation of our proposed feasibility study. Additionally, there is no assurance that we will receive FDA
market approval of Sigyn TherapyTM as a Class III medical device.
Our
Therapeutic Pipeline
Our
therapeutic pipeline is comprised of technologies that we have designed to improve the targeted delivery of cancer drug agents. ChemoPrepTM
and ChemoPureTM are components of a therapeutic system to improve the delivery of chemotherapy and reduce its toxicity.
ImmunePrepTM is a novel platform to enhance the potential efficacy of immunotherapeutic antibodies (including checkpoint inhibitors).
At present, we have no market approved medical products and there is no assurance that we will be able to commercialize any of our product
candidates.
ChemoPrepTM
and ChemoPureTM
On
October 6, 2022, we disclosed that a provisional patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY
AND REDUCE TOXICITY” had been filed with the United States Patent and Trademark Office (“USPTO”). The provisional
patent submission established the priority date for our patent pending invention and provided us up to one year to submit a non-provisional
patent application. On October 4, 2023, we subsequently disclosed that a non-provisional Patent Cooperation Treaty (“PCT”) submission had
been filed to support the continued advancement of this patent. Related to these patent submissions, trademark applications to register
ChemoPrep™ and ChemoPure™ have been filed with the USPTO. However, there is no assurance that we will receive a registered
trademark for either the ChemoPrep™ or ChemoPureTM name, nor is there any assurance that patent submissions associated
with ChemoPrep™ and ChemoPureTM will result in an issued patent.
Chemotherapeutic
agents are the most commonly administered drug to treat cancer, which is the second leading cause of death in the United States. Despite
therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy. To
overcome these challenges, our patent submission describes a therapeutic device system whose primary objective is to enhance tumor site
delivery of chemotherapy and reduce its toxicity. A secondary objective of the system is to reduce treatment dosing without sacrificing
patient benefit.
Our
proposed chemotherapy enhancement system is comprised of two blood purification technologies. ChemoPrepTM, administered prior
to chemotherapy to optimize tumor site delivery with lower chemotherapy doses and ChemoPureTM, which is deployed post-chemotherapy
to further reduce toxicity through the extraction of circulating chemotherapeutic agents that were not delivered to the target tumor
site.
ImmunePrepTM
On
May 17, 2023, we disclosed that a provisional patent application entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC
ANTIBODIES” had been submitted to the USPTO. The provisional patent submission established the priority date of this patent
pending invention and provides us up to one year to submit a non-provisional patent application. Associated with this patent submission,
we further disclosed that a trademark application to register the name ImmunePrepTM had also been filed with the USPTO. However,
there is no assurance that we will receive a registered trademark for the ImmunePrepTM name, nor is there any assurance that
patent submissions associated with ImmunePrepTM will result in an issued patent.
We
intend for ImmunePrepTM to become a platform that allows for antibody-based immunotherapies to be incorporated within plasma
extraction devices to enhance the targeted delivery of therapeutic antibodies without increased drug toxicity.
Therapeutic
antibodies are market-cleared to treat a variety of indications, including cancer. However, patient response to these therapies is often
suboptimal as just a small portion of infused antibodies reach their intended therapeutic target. In many cases, infused antibodies are
bound by drug decoys that display the antibody’s antigen binding site on their surface. As a result, these decoys are empowered
to bind and sequester antibodies from being delivered to their intended therapeutic targets.
ImmunePrepTM
is designed to extract bloodstream decoys that would subsequently block the infused delivery of therapeutic antibodies. The mechanistic
objective of this pre-treatment strategy is to increase the availability of antibodies to interact with their intended therapeutic targets.
Conversely, the ability of therapeutic targets to evade antibody interactions would be diminished.
Merger
Transaction
On
October 19, 2020, Sigyn Therapeutics, Inc, a Delaware corporation (the “Registrant”) formerly known as Reign Resources Corporation,
completed a Share Exchange Agreement (the “Agreement”) with Sigyn Therapeutics, Inc., a private entity incorporated in the
State of Delaware on October 19, 2019.
In
the Share Exchange Agreement, we acquired 100% of the issued and outstanding shares of privately held Sigyn Therapeutics common stock
in exchange for 75% of the fully paid and nonassessable shares of our common stock outstanding (the “Acquisition”). In conjunction
with the transaction, we changed our name from Reign Resources Corporation to Sigyn Therapeutics, Inc. pursuant to an amendment to our
articles of incorporation that was filed with the State of Delaware. Subsequently, our trading symbol was changed to SIGY. The Acquisition
was treated by the Company as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(“GAAP”). For accounting purposes, Sigyn is considered to have acquired Reign Resources Corporation as the accounting acquirer
because: (i) Sigyn stockholders own 75% of the combined company, on an as-converted basis, immediately following the Closing Date, (ii)
Sigyn directors hold a majority of board seats in the combined company and (iii) Sigyn management held all key positions in the management
of the combined company. Accordingly, Sigyn’s historical results of operations will replace Reign Resources Corporation’s
historical results of operations for all periods prior to the Acquisition and, for all periods following the Acquisition, the results
of operations of the combined company will be included in the Company’s financial statements. The Acquisition was treated as a
“tax-free exchange” under Section 368 of the Internal Revenue Code of 1986 and resulted in the private Sigyn Therapeutics
corporate entity (established on October 29, 2019) to become a wholly owned subsidiary of Reign Resources Corporation. Among the conditions
for closing the acquisition, the Reign Resources Corporation extinguished all previously reported liabilities, its preferred class of
shares, and all stock purchase options. As a result, the reported liabilities totaling $3,429,516 were converted into a total of 197,684
common shares. Additionally, assets held on the books of Reign Resources Corporation, such as Gem inventory, was kept in the Company
and therefore recorded as assets on the Share Exchange date. Upon the closing of the Acquisition, we appointed James A. Joyce and Craig
P. Roberts to serve as members of our Board of Directors.
As
of February 16, 2024, we had a total 1,224,315 shares issued and outstanding, of which 647,415 shares are held by non-affiliate shareholders.
Post-Merger
Developments
Since
the consummation of the merger transaction on October 19, 2020, we have advanced Sigyn Therapy from conceptual design through completion
of in vitro studies that have quantified the reduction of relevant therapeutic targets from human blood plasma with small-scale
versions of Sigyn Therapy. These include endotoxin (gram-negative bacterial toxin); peptidoglycan and lipoteichoic acid (gram-positive
bacterial toxins); viral pathogens (including SARS-CoV-2); hepatic toxins (ammonia, bile acid, and bilirubin); and tumor necrosis factor
alpha (TNF alpha), interleukin-1 beta (IL-1b), and interleukin 6 (IL-6), which are pro-inflammatory cytokines whose dysregulated production
(the cytokine storm) precipitate sepsis and play a prominent role in each of our therapeutic opportunities.
Subsequent
to these studies, we disclosed the completion of in vivo animal studies. In these studies, Sigyn Therapy was administered via
standard dialysis machines utilizing conventional blood-tubing sets, for periods of up to six hours in eight (8) porcine (pig) subjects,
each weighing approximately 40-45 kilograms. The studies were comprised of a pilot phase (two subjects), which evaluated the feasibility
of the study protocol in the first-in-mammal use of Sigyn Therapy; and an expansion phase (six subjects) to further assess treatment
feasibility and refine pre-treatment set-up and operating procedures. There were no serious adverse events reported in any of the treated
animal subjects. Of the eight treatments, seven were administered for the entire six-hour treatment period. One treatment was halted
early due to the observation of a clot in the device, which was believed to be the result of a procedural deviation in the pre-treatment
set-up. Important criteria for treatment feasibility – including hemodynamic parameters, serum chemistries and hematologic measurements
– were stable across all subjects.
The
studies were conducted by a clinical team at Innovative BioTherapies, Inc. (“IBT”), under a contract with the University
of Michigan to utilize animal care, associated institutional review oversight, as well as surgical suite facilities located within the
North Campus Research Complex. The treatment protocol of the study was reviewed and approved by the University of Michigan Institutional
Animal Care and Use Committee (“IACUC”).
The
animal studies were conducted to correspond with FDA’s best practice guidance. The number of animals enrolled in our study and
the amount of data collected was based on the ethical and least burdensome principles that underly the FDA goal of using the minimum
number of animals necessary to generate valid scientific data to demonstrate reasonable feasibility and performance of a medical device
prior to human study consideration. A porcine animal model is a generally accepted model for the study of extracorporeal blood purification
devices intended to treat infectious disease and inflammatory disorders. Regardless of these factors, FDA may require that we conduct
additional animal studies.
The
data resulting from our in vivo and in vitro studies is being incorporated into an Investigational Device Exemption (IDE) that
we are drafting for submission to the FDA to support the potential initiation of a
human feasibility study in ESRD patients with endotoxemia and concurrent inflammation. As per the study protocol,
Sigyn Therapy is to be administered in combination with the regularly scheduled dialysis treatments of enrolled subjects. The primary
study objective will be to evaluate the safety of Sigyn Therapy in health compromised ESRD patients. A secondary objective will be to
quantify changes in circulating levels of endotoxin, tumor necrosis factor-αlpha (TNF-α), interleukin-1β (IL-1β),
and interleukin-6 (IL-6) before and after each Sigyn Therapy administration. Endotoxin and excess TNF-α, IL-1β, and IL-6 production
are commonly associated with each of our candidate treatment indications, including sepsis and community-acquired pneumonia.
Based
on our previous experience in developing extracorporeal blood purification therapies, we believe that we have collected sufficient data
to support first-in-human studies of Sigyn Therapy. Sigyn Therapy, as a significant risk Class III device, which requires extensive pre-clinical
and clinical studies to be conducted along with the submission of a Pre-Market Approval (PMA) application prior to market clearance consideration
by FDA. At present, we are identifying candidate clinical site locations and then plan to submit an IDE application to FDA related to
the potential initiation of a human feasibility study to demonstrate the safety of Sigyn Therapy. Our clinical strategy has not yet been
communicated to FDA and there is no assurance that FDA will approve the initiation of our feasibility study. Additionally, while we believe
the data from our in vivo and in vitro studies provides support for our IDE submission, FDA may request that we conduct additional
animal or pre-clinical studies prior to approving our IDE. Among our previous experiences in developing extracorporeal blood purification
therapies, our CEO oversaw the development of the Aethlon Hemopurifier, a blood purification device that received an FDA “Breakthrough
Device” designation for the treatment of life-threatening viruses and was awarded a second FDA “Breakthrough Device”
designation related to the treatment of cancer. The Hemopurifier has not yet been approved by FDA and remains in clinical trials.
Sigyn
Therapy Mechanism of Action
We
designed Sigyn Therapy to be a candidate to treat pathogen-associated inflammatory conditions that are life-threatening. To date, pre-clinical
in vitro studies have quantified the reduction of viral pathogens, bacterial toxins, and inflammatory mediators from human blood
plasma with small-scale versions of Sigyn Therapy. Such capabilities establish Sigyn Therapy as a candidate to treat pathogen-associated
conditions that precipitate Sepsis, Community Acquired Pneumonia, Emerging Bioterror and Pandemic threats, and End-Stage Renal Disease
patients with endotoxemia and elevated inflammatory cytokine production.
To
support widespread implementation, Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of
hemodialysis and continuous renal replacement therapy (CRRT) machines already located in hospitals and clinics. To reduce the risk of
blood clotting and hemolysis, the anticoagulant heparin is administered, which is the standard-of-care drug administered in dialysis
and CRRT therapies. During animal studies conducted at the University of Michigan, Sigyn Therapy was deployed for use on a hemodialysis
machine manufactured by Fresenius Medical Care, the global leader in the dialysis industry.
Incorporated
within Sigyn Therapy is a “cocktail” of adsorbent components formulated to optimize the broad-spectrum reduction of therapeutic
targets from the bloodstream. In the medical field, the term “cocktail” is a reference to the simultaneous administration
of multiple drugs (a drug cocktail) with differing mechanisms of actions. While drug cocktails are emerging as potential mechanisms to
treat cancer, they are life-saving countermeasures to treat HIV and Hepatitis-C viral infections. However, dosing of multi-drug agent
cocktails is limited by toxicity and adverse events that can result from deleterious drug interactions.
Sigyn
Therapy is not constrained by such limitations as active adsorbent components are maintained within Sigyn Therapy and not introduced
into the body. As a result, we are able to incorporate a substantial quantity of adsorbent components to capture therapeutic targets
outside of the body as they circulate through Sigyn Therapy. Each adsorbent component has differing capture characteristics that contribute
to optimizing the potential of Sigyn Therapy to reduce the presence of pathogenic and inflammatory targets that precipitate the cytokine
storm that underlies sepsis and other life-threatening inflammatory disorders.
The
adsorbent components incorporated within Sigyn Therapy provide more than 200,000 square meters (~50 acres) of surface area on which to
adsorb and remove circulating viruses, bacterial toxins, and inflammatory mediators. Beyond a potential capacity to reduce therapeutic
targets from human blood plasma, we believe that Sigyn Therapy offers an efficient treatment methodology. Based on targeted blood flow
rates of 350ml/min, a patient’s entire bloodstream can pass through Sigyn Therapy more than fifteen times during a single four-hour
treatment period.
From
a technical perspective, Sigyn Therapy is a 325mm long polycarbonate column that internally contains polyethersulphone hollow fibers
that have porous walls with a median pore size of ~200 nanometers (nm). As blood flows into Sigyn Therapy, plasma and therapeutic targets
below 200nm travel through the porous walls as a result of blood-side pressure. As the hollow fiber bundle within Sigyn Therapy creates
a resistance to the flow of blood, a pressure drop is created along the length of the device such that the blood-side pressure is higher
at the blood inlet and lower at the blood outlet. This allows for plasma and therapeutic targets to flow away from the blood and into
the extra-lumen space (inside the polycarbonate shell, yet outside the hollow-fiber bundle) to interact with Sigyn Therapy’s adsorbent
components in a low shear force environment. In the distal third of the fiber bundle, the pressure gradient is reversed, which allows
for plasma to flow back through the fiber walls to be reconvened into the bloodstream without the presence of therapeutic targets that
were captured or bound by adsorbent components housed in the extra-lumen space of Sigyn Therapy.
Overview
of Candidate Treatment Indications
Based
on data resulting from in vitro blood purification studies, our candidate treatment indications include, but are not limited to;
endotoxemia, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic viral threats. However,
there is no assurance that human feasibility and pivotal studies will demonstrate Sigyn Therapy to be a safe and efficacious treatment
for these or any other treatment indications.
End-Stage
Renal Disease, Endotoxemia and Inflammation
According
to the United States Renal Data System (“USRDS”), more than 550,000 individuals suffer from ESRD, which results
in approximately 85 million kidney dialysis treatments being administered in the United States each year. Persistent inflammation is
a hallmark feature of ESRD as reflected by the excess production of inflammatory cytokines, including tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β) and interleukin-6 (IL-6), which contribute to increased all-cause mortality. ESRD inflammation also
induces intestinal permeability, which allows endotoxin (gram-negative bacterial toxin) to translocate from the gut and into the bloodstream.
Beyond fueling further inflammation, endotoxin is a potent activator of sepsis, which can lead to multiple organ failure and ultimately
death.
Sigyn
Therapy establishes a candidate strategy to improve the health and quality-of-life of ESRD patients. Beyond its potential to reduce endotoxin,
TNF-α, IL-1β, and IL-6 from human blood plasma, Sigyn Therapy can be administered in series with regularly scheduled dialysis
therapy.
We
are currently preparing an Investigational Device Exemption (IDE) for submission to the FDA
related to a human feasibility study of Sigyn Therapy in ESRD patients with endotoxemia and concurrent inflammation. As per the study
protocol, Sigyn Therapy will be administered in combination with the regularly scheduled dialysis treatments of enrolled subjects. The
primary study objective will be to evaluate the safety of Sigyn Therapy in health compromised ESRD patients. A secondary objective is
to quantify changes in circulating levels of endotoxin, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
and interleukin-6 (IL-6) before and after each Sigyn Therapy administration. Endotoxin and excess TNF-α, IL-1β, and IL-6 production
are commonly associated with each of our candidate treatment indications, including sepsis and community-acquired pneumonia.
Sepsis
Sepsis
is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. In January of 2020, a report
entitled; “Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease
Study,” was published in the Journal Lancet. The publication reported 48.9 million cases of sepsis and 11 million deaths in
2017. In that same year, an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5-years old.
The report included a reference that sepsis kills more people around the world than all forms of cancer combined. In the United States,
sepsis was reported to be the most common cause of hospital deaths with an annual financial burden that exceeds $24 billion.
To
date, more than 100 human studies have been conducted to evaluate the safety and efficacy of candidate drugs to treat sepsis. With one
brief exception (Xigris, Eli Lilly), none of these studies resulted in a market cleared therapy. As sepsis remains beyond the reach of
single-target drugs, there is an emerging interest in multi-mechanism therapies that can target both inflammatory and pathogen associated
targets. Sigyn Therapy addresses a broad-spectrum of pathogen sources and the resulting dysregulated cytokine production (the cytokine
storm) that is the hallmark of sepsis. Additionally, we believe that inflammatory cytokine cargos transported by CytoVesicles may represent
a novel, yet important therapeutic target.
Community
Acquired Pneumonia
Community
Acquired Pneumonia (“CAP”) represents a significant opportunity for Sigyn Therapy to reduce the occurrence of sepsis. CAP is a leading
cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately
50% of sepsis and septic shock cases.
In
the United States, more than 1.5 million individuals are hospitalized with CAP each year, resulting in an annual financial burden that
exceeds $10 billion.
Statistically,
a therapeutic strategy that reduced the incidence of CAP related sepsis and septic shock would save thousands of lives each year. In
a study of 4,222 patients, the all-cause mortality for adult patients with CAP was reported to be 6.5% during hospitalization. However,
the mortality of patients with CAP related sepsis and septic shock rose to 51% during hospitalization.
CAP
is further complicated by the fact that the pathogen sources of CAP are identified in only 38% of patients, based on a study of 2,259
subjects whose pneumonia diagnosis was confirmed by chest x-ray. Of the source pathogens identified in the study, ninety seven percent
(97%) were either viral or bacterial in origin.
To
reduce the occurrence of CAP related sepsis and septic shock, Sigyn Therapy offers a broad-spectrum mechanism to reduce the circulating
presence of viral pathogens and bacterial toxins before and if they are identified as the CAP pathogen source. Additionally, Sigyn Therapy
may help to control the excess production of inflammatory cytokines (the cytokine storm) that precipitate sepsis and septic shock.
Drug-Resistant
Bacterial Infections
According
to the U.S. Centers for Disease Control and Prevention (“CDC”), nearly three million individuals are infected with multi-drug resistant
bacterial infections in the U.S. each year, which results in more than 35,000 deaths. The United Nations reported approximately 5 million
deaths in 2019 were associated with antimicrobial drug resistance and projects the annual death toll could increase to 10 million by
2050 in the absence of new therapeutic advances. Based on its potential broad-spectrum mechanism to extract bacterial toxins from the
bloodstream, Sigyn Therapy may provide a novel strategy to address life-threatening drug-resistant bacterial infections.
Emerging
Pandemic Threats
Covid-19
affirmed the use of extracorporeal blood purification as a first-line countermeasure to treat an emerging pandemic threat not addressed
with an approved drug or vaccine at the outset of an outbreak. On March 24, 2020, the U.S. Department of Health and Human Services (“HHS”)
declared that the emergence of COVID-19 justified the Emergency-Use Authorization (“EUA”) of drugs, biological products, and medical devices
to combat the pandemic. Within a month of this HHS declaration, FDA awarded an EUA to blood purification therapies from Terumo BCT, ExThera
Medical Corporation, CytoSorbents, Inc., and Baxter Healthcare Corporation. In connection with these authorizations, FDA published a
statement that blood purification devices may be effective at treating patients with confirmed COVID-19 by reducing various pathogens,
cytokines, and other inflammatory mediators from the bloodstream.
Consistent
with FDA’s statement, small-scale versions of Sigyn Therapy have been quantified to reduce the presence of various pathogens, cytokines,
and other inflammatory mediators from human blood plasma during in vitro studies. As such, we believe that Sigyn Therapy could
provide a candidate strategy to treat future pandemic outbreaks, which are increasingly being fueled by a confluence of global warming,
urban crowding, and intercontinental travel.
Additionally,
as a majority of infectious human viruses are not addressed with a corresponding drug or vaccine, there may be an ongoing need for blood
purification technologies that offer to reduce the severity of infection and mitigate the excess production of inflammatory cytokines
(the cytokine storm) associated with high mortality in non-pandemic viral infections. In this regard, we believe Sigyn Therapy aligns
with HHS initiatives established through the Public Health Emergency Medical Countermeasure Enterprise (“PHEMCE”) that support the development
of broad-spectrum medical countermeasures that can mitigate the impact of an emerging pandemic or bioterror threat, yet also have viability
in established disease indications.
Our
Therapeutic Pipeline
Our
therapeutic pipeline is comprised of technologies that we have designed to improve the targeted delivery of cancer drug agents. ChemoPrepTM
and ChemoPureTM are components of a therapeutic system to improve the delivery of chemotherapy and reduce its toxicity.
ImmunePrepTM is a novel platform to enhance the potential efficacy of immunotherapeutic antibodies (including checkpoint inhibitors).
At present, we have no market approved medical products and there is no assurance that we will be able to commercialize any of our product
candidates.
ChemoPrepTM
and ChemoPureTM
On
October 6, 2022, we disclosed that a provisional patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY
AND REDUCE TOXICITY” had been filed with the USPTO. The provisional patent submission established the priority date for our
patent pending invention and provided us up to one year to submit a non-provisional patent application. On October 4, 2023, we subsequently
disclosed that a non-provisional Patent Cooperation Treaty (“PCT”) submission had been filed to support the continued advancement of this
patent. Related to these patent submissions, trademark applications to register ChemoPrep™ and ChemoPure™ have been filed
with the USPTO. However, there is no assurance that we will receive a registered trademark for either the ChemoPrep™ or ChemoPureTM
name, nor is there any assurance that patent submissions associated with ChemoPrep™ and ChemoPureTM will result
in an issued patent.
Chemotherapeutic
agents are the most commonly administered drug to treat cancer, which is the second leading cause of death in the United States. Despite
therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy. To
overcome these challenges, our patent submission describes a therapeutic device system whose primary objective is to enhance tumor site
delivery of chemotherapy and reduce its toxicity. A secondary objective of the system is to reduce treatment dosing without sacrificing
patient benefit.
Our
proposed chemotherapy enhancement system is comprised of two blood purification technologies. ChemoPrepTM, administered prior
to chemotherapy to optimize tumor site delivery with lower chemotherapy doses and ChemoPureTM, which is deployed post-chemotherapy
to further reduce toxicity through the extraction of circulating chemotherapeutic agents that were not delivered to the target tumor
site.
To
improve the delivery of chemotherapeutic agents, we designed ChemoPrepTM with an objective to reduce the bloodstream presence
of tumor-derived extracellular vesicles or exosomes (Tumor-EXs) that diminish the efficacy of chemotherapy. As compared to non-cancer
subjects, Tumor-EXs are highly concentrated in the bloodstream of those suffering from cancer. Tumor-EXs decoy and directly inhibit chemotherapeutic
agents from reaching tumor cell targets. Tumor-EXs have also been reported to export chemotherapeutic agents out of cancer cells. Based
on these factors, we believe the pre-chemo depletion of circulating Tumor-EXs could establish a novel, yet practical strategy to increase
tumor-site saturation of chemotherapy, which in turn may permit for lower doses of chemotherapy to be administered without diminishing
patient benefit.
ChemoPrepTM
may also improve the performance of ChemoPureTM as a reduced bloodstream presence of Tumor-EXs, which are competitive
binding and adsorption factors based on similar size and structural characteristics, would likely increase the efficiency of ChemoPureTM
to reduce the presence of off-target chemotherapeutic agents that remain circulating in the bloodstream.
Unlike
Sigyn TherapyTM, which is a candidate to treat life-threatening conditions that are not addressed with approved drug
therapies, the intent of the ChemoPrepTM and ChemoPureTM is to enhance the delivery of market-cleared
chemotherapeutic drugs and reduce their toxicity. Additionally, while Sigyn TherapyTM is a hollow-fiber based device
designed for use on dialysis and continuous renal replacement machines, ChemoPrepTM and ChemoPureTM do not
contain hollow-fibers and are intended for use on portable blood processing systems that can be located within the clinical sites
where chemotherapy is administered. During treatment, the functionality of the blood processing system allows for patient blood
plasma to flow through our devices, which contain formulations of adsorbent and binding components intended to deplete Tumor-EXs and
chemotherapeutic agents from the bloodstream.
In
an in vitro study conducted by researchers at Innovative Biotherapies, we obtained pre-clinical insight that liposomal nanoparticles,
commonly used to deliver chemotherapeutic agents, can be reduced from human blood plasma with a formulation of adsorbent components.
In the study, liposome concentrations in human blood plasma were reduced by 92.5% after a two-hour interaction with the adsorbent components.
Beyond providing initial support for our candidate strategy to remove liposomal drug agents, the study established the possibility that
Tumor-EXs may also be reduced from blood plasma as liposomes have previously served as a research model system for isolating extracellular
vesicles and exosomes based on a similarity of size and structural characteristics. However, we have yet to conduct other in vitro
studies to further validate the potential of either ChemoPrepTM or ChemoPureTM.
ImmunePrepTM
On
May 17, 2023, we disclosed that a provisional patent application entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC
ANTIBODIES” had been submitted to the USPTO. The provisional patent submission established the priority date of this patent
pending invention and provides us up to one year to submit a non-provisional patent application. Associated with this patent submission,
we further disclosed that a trademark application to register the name ImmunePrepTM had also been filed with the USPTO. However,
there is no assurance that we will receive a registered trademark for the ImmunePrepTM name, nor is there any assurance that
patent submissions associated with ImmunePrepTM will result in an issued patent.
We
intend for ImmunePrepTM to become a platform that allows for antibody-based immunotherapies to be incorporated within plasma
extraction devices to enhance the targeted delivery of therapeutic antibodies without increased drug toxicity.
Therapeutic
antibodies are market-cleared to treat a variety of indications, including cancer. However, patient response to these therapies is often
suboptimal as just a small portion of infused antibodies reach their intended therapeutic target. In many cases, infused antibodies are
bound by drug decoys that display the antibody’s antigen binding site on their surface. As a result, these decoys are empowered
to bind and sequester antibodies from being delivered to their intended therapeutic targets.
ImmunePrepTM
is designed to extract bloodstream decoys that would subsequently block the infused delivery of therapeutic antibodies. The mechanistic
objective of this pre-treatment strategy is to increase the availability of antibodies to interact with their intended therapeutic targets.
Conversely, the ability of therapeutic targets to evade antibody interactions would be diminished.
Unlike
Sigyn TherapyTM, which is a candidate to treat life-threatening conditions that are not addressed with approved drug therapies,
the intent of our ImmunePrepTM platform is to enhance the infused delivery of therapeutic antibodies. Additionally, while
Sigyn TherapyTM is a hollow-fiber based device designed for use on dialysis and continuous renal replacement machines, ImmunePrepTM
does not contain hollow-fibers and is intended for use on portable blood processing systems that can be located within the clinical
sites where therapeutic antibodies are administered. During treatment, the functionality of the blood processing system allows for patient
blood plasma to flow through ImmunePrepTM, which selectively extracts circulating drug decoys from the bloodstream prior to
antibody infusion.
Candidate
Pipeline Product
Beyond
our focus to clinically advance Sigyn Therapy, we intend to develop a pipeline of extracorporeal blood purification therapies. In this
regard, we have designed a therapeutic system to enhance the benefit of cancer chemotherapy. To support this endeavor, we disclosed on
October 6, 2022, that a patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY”
had been filed with the USPTO. On October 13, 2022, we subsequently disclosed that trademark applications to register ChemoPrepTM
and ChemoPureTM were filed with the USPTO.
Chemotherapeutic
agents are the most commonly administered drugs to treat cancer, which is the second leading cause of death in the United States. Despite
therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapy. To
overcome these challenges, our patent submission describes a therapeutic device system whose primary objective is to enhance tumor site
delivery of chemotherapy and reduce its toxicity. A secondary objective of the system is to reduce treatment dosing without sacrificing
patient benefit, or conversely increase chemotherapy dosing without added toxicity. In concert with these objectives, our candidate therapeutic
system offers to inhibit the spread of cancer metastasis that can be induced by the administration of chemotherapy.
Our
proposed chemotherapy enhancement system is comprised of two blood purification technologies. ChemoPrepTM, administered prior
to chemotherapy to optimize tumor site delivery and improve the benefit of ChemoPureTM, which is deployed post-chemotherapy
to reduce treatment toxicity and inhibit the potential spread of cancer metastasis.
To
improve the delivery of chemotherapeutic agents, we designed ChemoPrepTM with an objective to reduce the bloodstream presence
of tumor-derived extracellular vesicles or exosomes (Tumor-EXs) that diminish the efficacy of chemotherapy. As compared to non-cancer
subjects, Tumor-EXs are highly concentrated in the bloodstream of those suffering from cancer. Tumor-EXs decoy and directly inhibit chemotherapeutic
agents from reaching tumor cell targets. Tumor-EXs have also been reported to export chemotherapeutic agents out of cancer cells. Based
on these factors, we believe the pre-chemo depletion of circulating Tumor-EXs could establish a novel, yet practical strategy to increase
tumor-site saturation of chemotherapy, which in turn may permit for lower doses of chemotherapy to be administered without diminishing
patient benefit.
ChemoPrepTM
may also improve the performance of ChemoPureTM as a reduced bloodstream presence of Tumor-EXs, which are competitive
binding and adsorption factors based on similar size and structural characteristics, would likely increase the efficiency of ChemoPureTM
to reduce the presence of off-target chemotherapeutic agents that remain circulating in the bloodstream.
ChemoPureTM
was designed to perform two critical functions after chemotherapy administration. To reduce treatment toxicity by lowering the
bloodstream presence of chemotherapeutic agents that are not delivered to the target tumor site, and to reduce the circulating presence
of chemotherapy-induced Tumor-EXs that may promote the spread of cancer metastases.
Unlike
Sigyn TherapyTM, which is a candidate to treat life-threatening conditions that are not addressed with approved drug therapies,
the intent of the ChemoPrepTM and ChemoPureTM is to enhance the delivery of market-cleared chemotherapeutic drugs
and reduce their toxicity. Additionally, while Sigyn TherapyTM is a hollow-fiber based device designed for use on dialysis
and continuous renal replacement machines, ChemoPrepTM and ChemoPureTM do not contain hollow-fibers and are intended
for use on portable blood processing systems that can be located within the clinical sites where chemotherapy is administered. During
treatment, the functionality of the blood processing system allows for patient blood plasma to flow through our devices, which contain
formulations of adsorbent and binding components intended deplete Tumor-EXs and chemotherapeutic agents from the bloodstream.
In
an in vitro study conducted by researchers at Innovative Biotherapies, we obtained pre-clinical insight that liposomal nanoparticles,
commonly used to deliver chemotherapeutic agents, can be reduced from human blood plasma with a formulation of adsorbent components.
In the study, liposome concentrations in human blood plasma were reduced by 92.5% after a two-hour interaction with the adsorbent components.
Beyond providing initial support for our candidate strategy to remove liposomal drug agents, the study established the possibility that
Tumor-EXs may also be reduced from blood plasma as liposomes have previously served as a research model system for isolating extracellular
vesicles and exosomes based on a similarity of size and structural characteristics.
Recent
Corporate Developments
|
● |
December
2020 – Reported the first in vitro study results of Sigyn Therapy. The study reported the simultaneous reduction
of endotoxin, a gram-negative bacterial toxin, and relevant pro-inflammatory cytokines from human blood plasma. The cytokines evaluated
in the study were Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). |
|
|
|
|
● |
January
2021 - Reported the results of an in vitro study that modelled the potential of Sigyn Therapy adsorbent components to
reduce the presence of CytoVesicles (extracellular vesicles that transport inflammatory cargos in the bloodstream) from human blood
plasma. |
|
|
|
|
● |
January
2021 - Appointed industry veteran Eric Lynam as Head of Clinical Affairs, with a mandate to oversee clinical studies of Sigyn
Therapy. |
|
|
|
|
● |
April
2021 - Disclosed in vitro study observations that small-scale versions of Sigyn Therapy were quantified to reduce the
presence of viral pathogens, including SARS-CoV-2 (COVID-19) from human blood plasma. |
|
|
|
|
● |
April
2021 - Appointed former Aethlon Medical executive Charlene Owen as Director of Operations. |
|
|
|
|
● |
July
2021 - Disclosed the completion of in vitro studies that quantified the reduction of hepatic toxins (ammonia, bile acid
& bilirubin) from human blood plasma with small-scale versions of Sigyn Therapy. |
|
● |
July
2021 - Disclosed the completion of a first-in-mammal pilot animal study of Sigyn Therapy at the University of Michigan. |
|
|
|
|
● |
December
2021 - Reported that small-scale versions of Sigyn Therapy reduced the presence of gram-positive bacterial toxins from human
blood plasma. |
|
|
|
|
● |
February
2022 - Reported the subsequent completion of an in vivo animal study of Sigyn Therapy at the University of Michigan. |
|
|
|
|
● |
March
2022 - Announced the appointments of two internationally recognized clinician researchers, Alexander S. Yevzlin, MD, FASN and
H. David Humes, MD, to Sigyn Therapeutics’ Scientific Advisory Board. |
|
|
|
|
● |
March
2022 - Ajay Verma, MD, PhD, a recognized thought leader in the field of neurology joins the Scientific Advisory Board. |
|
|
|
|
● |
April
2022 - Donald J. Hillebrand, M.D., a recognized thought leader in the field of Hepatology and Liver Transplantation joins the
Scientific Advisory Board. |
|
|
|
|
● |
August
2022 – The Company’s common stock commences trading on the OTCQB Venture Market. |
|
|
|
|
● |
October
2022 – |
|
|
● |
Announced
the appointment of Richa Nand, B.S., J.D.; Jim Dorst, B.S., M.S.; and Christopher Wetzel, B.S., M.B.A. to our Board of Directors. |
|
|
|
|
|
|
● |
Patent
application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” is submitted to
the USPTO. |
|
|
|
|
|
|
● |
Trademark
applications to register ChemoPrepTM and ChemoPureTM are filed with the USPTO related to medical device products
to enhance cancer therapies. |
|
● |
December 2022 – Eric Stroup, a dialysis industry thought leader joins the Sigyn Therapeutics Science Advisory Board. |
|
|
|
|
● |
April 2023 - Annette Marleau, Ph.D. appointed as Chief Scientific Officer (CSO) of Sigyn Therapeutics. |
|
|
|
|
● |
May 2023 – Patent application entitled: “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” submitted to the USPTO. |
|
|
|
|
● |
May 2023 - Trademark application to register ImmunePrepTM is filed with the USPTO. |
|
|
|
|
● |
December
2023 - Appointed Gerald DeCiccio, CPA, as Chief Financial Officer. |
Marketing
and Sales
At
present, our primary focus is the clinical and regulatory advancement of Sigyn Therapy. As such, we do not market or sell any therapeutic
products at this time. However, we plan to forge relationships with organizations that have established distribution channels into markets
that may have a demand for Sigyn Therapy should it receive market clearance from FDA or other foreign regulatory agencies.
Intellectual
Property
We
own the intellectual property rights to pending royalty-free patents that have been assigned to us by our co-founders, James A. Joyce
and Craig P. Roberts. We have also received a “Notice of Allowance” from the USPTO related to the use of Sigyn Therapeutics,
Sigyn Therapy, and the protection of our corporate logo. We plan to continually expand our intellectual property portfolio and protect
trade secrets that are not the subject of patent submissions. However, there is no assurance that the claims of current pending and future
patent applications will result in issued patents. Pending changes in patent law, it is anticipated that each patent that becomes issued
will have an enforceable life that will extend for a period of 20 years from the initial patent filing date and will expire at the end
of such 20-year terms.
At
present, we own the rights to the following patents pending.
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - U.S. Application No.: 62/881,740; Filing
Date: 2019-08-01 - Inventors: Joyce and Roberts
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - International Patent Application No.: PCT/US2020/044223;
Filing Date: 2020-07-30 - Inventors: Joyce and Roberts
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - U.S. Patent Application No.: 16/943,436;
Filing Date: 2020-07-30 - Inventors: Joyce and Roberts
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - EP No.: 20757445; Filing Date: 2022-01-24
- Inventors: Joyce and Roberts
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - CA No.: 3148773; Filing Date: 2022-01-25
- Inventors: Joyce and Roberts
DEVICES,
SYSTEMS AND METHODS FOR THE BROAD-SPECTRUM REDUCTION OF PRO-INFLAMMATORY CYTOKINES IN BLOOD - JP No.: 2022-506670; Filing Date: 2022-01-31
- Inventors: Joyce and Roberts
EXTRA-LUMEN
ADSORPTION OF VIRAL PATHOGENS FROM BLOOD U.S. Patent Application No.: 63/177,520; Filing Date: 2021-04-21 Inventor: James A. Joyce
SYSTEM
AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY U.S. Patent Application No.: 63/410,764; Filing Date: 09/28/2022 Inventor:
James A. Joyce
DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES - Patent Application
No.: 63/465,360; Filing Date: 05/10/2023 Inventor: James A. Joyce and Annette M. Marleau
Government
Regulation
In
the United States, Sigyn Therapy is subject to regulation by the FDA. Should we seek to commercialize Sigyn Therapy outside the United
States, we expect to face comparable international regulatory oversight. The U.S. regulatory jurisdiction for extracorporeal blood purification
therapies is the Center for Devices and Radiological Health (“CDRH”), the FDA branch that oversees the market approval of
medical devices.
Based
on published CDRH guidance, we believe that Sigyn Therapy will be classified as a Class III medical device that is subject to a Pre-Market
Approval (“PMA”) submission pathway. A PMA pathway requires extensive data, including but not limited to technical documents,
preclinical studies, animal studies, human clinical trials, the establishment of Current Good Manufacturing Practices (“cGMPs”)
standards and labelling that fulfils FDA’s requirement to demonstrate reasonable evidence of safety and effectiveness of a medical
device product. However, as Sigyn Therapy does not emit electronic product radiation, it will not be subject to regulatory challenges
associated with medical devices that emit electronic radiation.
The
commercialization of medical devices in the United States requires either a prior 510(k) clearance, unless it is exempt, or a PMA from
the FDA. Generally, if a new device has a predicate that is already on the market under a 510(k) clearance, the FDA will allow that new
device to be marketed under a 510(k) clearance; otherwise, a premarket approval, or PMA, is required. Medical devices are classified
into one of three classes; Class I, Class II or Class III which are determined by the degree of risk associated with each medical device
and the extent of control needed to provide reasonable assurance of safety and effectiveness. Class I devices are deemed to be low risk
and are subject to the general controls of the Federal Food, Drug and Cosmetic Act, such as provisions that relate to: adulteration;
misbranding; registration and listing; notification, including repair, replacement, or refund; records and reports; and good manufacturing
practices. Most Class I devices are classified as exempt from pre-market notification under section 510(k) of the FD&C Act, and therefore
may be commercially distributed without obtaining 510(k) clearance from the FDA. Class II devices are subject to both general controls
and special controls to provide reasonable assurance of safety and effectiveness. Special controls include performance standards, post
market surveillance, patient registries and guidance documents. A manufacturer may be required to submit to the FDA a pre-market notification
requesting permission to commercially distribute some Class II devices. Devices deemed by the FDA to pose the greatest risk, such as
life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k)
device, are placed in Class III. A Class III device cannot be marketed in the United States unless the FDA approves the device after
submission of a PMA. We believe that Sigyn Therapy will be classified as a Class III device and as such will be subject to a PMA submission
and approval.
Should
Sigyn Therapy receive market clearance from FDA, we would need to comply with applicable laws and regulations that govern the development,
testing, manufacturing, labeling, marketing, storage, distribution, advertising and promotion, and post-marketing surveillance reporting
for medical devices. Failure to comply with these applicable requirements may subject a device and/or its manufacturer to a variety of
administrative sanctions, such as issuance of warning letters, import detentions, civil monetary penalties and/or judicial sanctions,
such as product seizures, injunctions and criminal prosecution. Our failure to comply with any of these laws and regulations could have
a material adverse effect on our operations.
The
Pre-market Approval Pathway
A
pre-market approval (“PMA”) application must be submitted to the FDA for Class III devices for which FDA requires a PMA. The PMA application
process is much more demanding than the 510(k)-pre-market notification process. A PMA application must be supported by extensive data,
including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA’s satisfaction
reasonable evidence of safety and effectiveness of the device.
After
a PMA application is submitted, the FDA has 45 days to determine whether the application is sufficiently complete to permit a substantive
review and thus whether the FDA will file the application for review. The FDA has 180 days to review a filed PMA application, although
the review of an application generally occurs over a significantly longer period of time and can take up to several years. During this
review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel
of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the
approvability of the device.
Although
the FDA is not bound by the advisory panel decision, the panel’s recommendations are important to the FDA decision making process.
In addition, the FDA may conduct a preapproval inspection of the manufacturing facility to ensure compliance with the Quality System
Regulation, or QSR. The agency also may inspect one or more clinical sites to assure compliance with FDA’s regulations.
Upon
completion of the PMA review, the FDA may: (i) approve the PMA which authorizes commercial marketing with specific prescribing
information for one or more indications, which can be more limited than those originally sought; (ii) issue an approvable letter
which indicates the FDA’s belief that the PMA is approvable and states what additional information the FDA requires, or the
post-approval commitments that must be agreed to prior to approval; (iii) issue a not approvable letter which outlines steps
required for approval, but which are typically more onerous than those in an approvable letter, and may require additional clinical
trials that are often expensive and time consuming and can delay approval for months or even years; or (iv) deny the application. If
the FDA issues an approvable or not approvable letter, the applicant has 180 days to respond, after which the FDA’s review
clock is reset.
Clinical
Trials
Clinical
trials are almost always required to support PMA market clearance and are sometimes required for 510(k) clearance. In the United States,
for significant risk Class III devices, these trials require submission of an Investigational Device Exemption (IDE) application to the
FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to
test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a
specific number of patients at specified study sites. During the trial, the sponsor must comply with the FDA’s IDE requirements
for investigator selection, trial monitoring, reporting and record keeping. The investigators must obtain patient informed consent, rigorously
follow the investigational plan and study protocol, control the disposition of investigational devices and comply with all reporting
and record keeping requirements. Clinical trials for Class III devices may not begin until the IDE application is approved by the FDA
and the appropriate institutional review boards, or IRBs, at the clinical trial sites. An IRB is an appropriately constituted group that
has been formally designated to review and monitor medical research involving subjects and which has the authority to approve, require
modifications in, or disapprove research to protect the rights, safety and welfare of human research subjects. The FDA or the IRB at
each site at which a clinical trial is being performed may withdraw approval of a clinical trial at any time for various reasons, including
a belief that the risks to study subjects outweigh the benefits or a failure to comply with FDA or IRB requirements. Even if a trial
is completed, there is no assurance that clinical testing will demonstrate the safety and effectiveness of Sigyn Therapy or other pipeline
devices.
Manufacturing
and Procurement
We
are advancing a manufacturing relationship with an FDA registered Contract Manufacturing Organization (CMO) to establish cGMPs compliant
manufacturing to support human clinical studies and potential commercialization should we receive clearance to market Sigyn Therapy.
We plan to establish manufacturing procedure specifications that define each stage of our manufacturing, inspection and testing processes
and the control parameters or acceptance criteria that apply to each activity that result in the production of our technology.
We
have also established relationships with industry vendors that provide components necessary to manufacture our device. Should the relationship
with an industry vendor be interrupted or discontinued, we believe that alternate component suppliers can be identified to support the
continued manufacturing of our product. However, delays related to interrupted or discontinued vendor relationships could adversely impact
our business.
Research
and Product Development
To
date, we have outsourced our research and product development activities, which include the performance of in vitro blood plasma
validation studies, animal studies, pre-cGMPs product assembly and manufacturing through third party organizations with experience in
advancing extracorporeal blood purification technologies. Our pre-clinical in vitro blood plasma studies we each performed under
an agreement with Innovative BioTherapies, Inc. (IBT) and our animal clinical studies were conducted by IBT team members through a contract
with the University of Michigan to utilize animal care, associated institutional review oversight, as well as surgical suite facilities
located within the North Campus Research Complex. While we maintain ownership rights to all study data collected by IBT, we do permit
for IBT to publish or present the results of our contracted studies. At present, we do not have plans to build and staff our own research
and product development facility.
Environmental
Laws and Regulations
At
present, our operations are not subject to any environmental laws or regulations.
Employees
As
of the date of this filing, we have 5 salaried employees, whose benefits include paid medical, dental, and vision coverage. We also provide
our employees with access to a 401(k) plan, and we anticipate the establishment of an employee equity-stock option plan during the 2024
calendar year. To maintain a manageable employee headcount, we utilize non-employee consultants to perform as-needed services and we
contract with third party research organizations to perform studies designed to support the potential clinical advancement of Sigyn Therapy.
Available
Information
We
file various reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form
8-K, which are available through the SEC’s electronic data gathering, analysis and retrieval system (“EDGAR”) by accessing
the SEC’s home page (http://www.sec.gov). The documents are also available to be read or copied at the SEC’s Public Reference
Room located at 100 F Street, NE, Washington, D.C., 20549. Information on the Public Reference Room may be obtained by calling the SEC
at 1-800-SEC-0330.
Item
1A. Risk Factors
This
item is not applicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.
Item
1B. Unresolved Staff Comments
Not
applicable.
Item
2. Properties
Our
corporate address is 2468 Historic Decatur Road, Suite 140, San Diego, California, 92106.
We
believe that our existing facilities are adequate for our current needs and that we will be able to lease suitable additional or alternative
space on commercially reasonable terms if and when we need it.
Item
3. Legal Proceedings
From
time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our
business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our
business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future.
To the best of our knowledge, none of our directors, officers or affiliates is involved in a legal proceeding adverse to our business
or has a material interest adverse to our business.
Item
4. Mine Safety Disclosures
Pursuant
to Section 1503(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, issuers that are operators, or that have a subsidiary
that is an operator, of a coal or other mine in the United States are required to disclose in their periodic reports filed with the SEC
information regarding specified health and safety violations, orders and citations, related assessments and legal actions, and mining-related
fatalities from the Federal Mine Safety and Health Administration, or MSHA, under the Federal Mine Safety and Health Act of 1977, or
the Mine Act. During the year ended December 31, 2023, we did not have any projects that were in production and as such, were not subject
to regulation by MSHA under the Mine Act.
PART
II
Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
(a)
Market Information
Our
stock is quoted on the OTC markets under the symbol “SIGY.” There are 1,224,315 shares outstanding as of February 16, 2024.
(b)
Transfer Agent
The
transfer agent and registrar for our common stock is VStock Transfer, LLC located at 18 Lafayette Place, Woodmere, New York.
(b)
Shareholders of Record
The
number of beneficial holders of record of our common stock as of the close of business on December 31, 2023 was 111.
(c)
Dividends
We
do not expect to pay cash dividends in the next term. We intend to retain future earnings, if any, to provide funds for operation of
our business. We currently have no restrictions affecting our ability to pay cash dividends.
(d)
Equity Compensation Plans
The
Company does not have an equity compensation plan.
Recent
Sales of Unregistered Securities
None.
Item
6. Selected Financial Data
Because
we are a smaller reporting company, this Item 6 is not applicable.
Item
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You
should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and related notes included elsewhere in this filing. This discussion and other parts of this filing contain forward-looking
statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, intentions, and beliefs. Our
actual results may differ materially from those discussed in these forward-looking statements as a result of various factors, including
those set forth under “Risk Factors” and in other parts of this filing, and you should not place undue certain on these forward-looking
statements, which apply only as of the date of this filing. See “Disclosure Regarding Forward-Looking Statements”.
We
are an emerging growth company as defined in Section 2(a) (19) of the Securities Act. Pursuant to Section 107 of the Jumpstart Our Business
Startups Act, we may take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying
with new or revised accounting standards, meaning that we can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have chosen to take advantage of the extended transition period for complying with new
or revised accounting standards applicable to public companies to delay adoption of such standards until such standards are made applicable
to private companies. Accordingly, our consolidated financial statements may not be comparable to the financial statements of public
companies that comply with such new or revised accounting standards.
OVERVIEW:
Historical
Development
Our
Company
Sigyn
Therapeutics, Inc. (“Sigyn”, the “Company”, “we,” “us,” or “our”) is a development-stage
company focused on creating therapeutic solutions that address unmet needs in global healthcare. Our corporate address is 2468 Historic Decatur
Road, Suite 140, San Diego, California, 92106.
Sigyn
Therapy™, our lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory
disorders that are not addressed with approved drug therapies. Candidate treatment indications include endotoxemia and inflammation in
end-stage renal disease (dialysis) patients, sepsis (a leading cause of hospital deaths), community acquired pneumonia (a leading cause
of death among infectious diseases), and emerging pandemic threats.
Our
development pipeline includes a cancer treatment system comprised of ChemoPrep™ to enhance the tumor site delivery of chemotherapy,
and ChemoPure™ to reduce treatment toxicity and inhibit the spread of cancer metastasis.
Reverse
Stock Split
Effective
January 19, 2024, Board of Directors declared a one-for-forty reverse stock split to shareholders of record on or before January 31,
2024 of the Company’s issued and outstanding shares of common stock, outstanding warrants and options, and the Series B
Convertible Preferred Stock. The number of shares of common stock and convertible preferred shares obtainable upon exercise or
conversion and the exercise prices and conversion rate have been equitably adjusted. As such, all
share and per share amounts have been retroactively adjusted to reflect the reverse stock split.
Financing
Transactions
Preferred
Stock
The
Company has 10,000,000 shares of par value $0.0001 preferred stock authorized, of which 32 and none shares preferred shares are issued
and outstanding at December, 31, 2023 and 2022, respectively.
During
fiscal 2023, holders of 161,684 shares of common stock elected to exchange these shares for an aggregate of 32 shares of Series B Convertible
Preferred Stock. Each Series B Convertible Preferred Share converts into 5,025.1 shares of the Company’s common stock, subject
to antidilution adjustments for any stock splits and recapitalizations, and for issuances of additional shares at an issue price of less
than the conversion ratio in the Warrant Exchange Agreement.
Common
Stock
The
Company has authorized 1,000,000,000 shares of par value $0.0001 common stock, of which 1,288,415 shares were outstanding as of December
31, 2023.
During
the year ended December 31, 2023, a total of 559,839 warrants were exchanged for 279,920 shares of the Company’s common stock.
On
June 2, 2023, a third-party investor elected to convert the aggregate principal amount of two Notes of $198,000, into 31,075 common shares.
On
November 23, 2022, an investor elected to convert the aggregate principal amount of the Note, $145,200, into 24,200 common shares.
Shares
Cancelled
On
January 9, 2024, the Company’s CTO agreed to surrender 64,100 common shares held by him and were cancelled by the Company.
Restricted
Stock Units
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Effective January 1, 2023, each Director shall receive an
annual grant of restricted stock units of $50,000. During the years ended December 31, 2023 and 2022, respectively, the Company recorded
stock-based compensation totaling $150,000 and $0, respectively, in the consolidated Statements of Operations.
Warrants
In
March 2023, the Company offered a short-term inducement to the Company’s third party warrant holders in which the Company will
issue one share of the Company’s common stock in exchange for each two warrants were exchanged for 279,920 shares of the Company’s
common stock through December 31, 2023. The Company recognized a gain of $352,965 due to the modification of the warrants in the year
ended December 31, 2023 as a result of the modification.
Current
Noteholders
2024 Convertible Notes
In
February 2024, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2024 Notes”) totaling
(i) $50,050 aggregate principal amount of Note (total of $45,500 cash was received) due in February 2025 based on $1.00 for each $0.90909
paid by the noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 8,343
shares of the Company’s Common Stock at an exercise price of $10.00 per share. The conversion
price for the principal in connection with voluntary conversions by the holders of the convertible notes is $6.00 per share.
Brio
– $44,000
On
January 8, 2024, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $44,000 aggregate principal
amount of Note due January 8, 2025 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 7,333 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $40,000 which was issued at
a $4,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
2023
Convertible Notes - $1,443,200
During
the year ended December 31, 2023, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2023
Notes”) with third party investors totaling (i) $1,443,200 aggregate principal amount of Note due on various dates from January
2024 through September 1, 2024 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase
Warrants (“Warrants”) to purchase up to an aggregate of 233,200 shares of the Company’s Common Stock at an exercise
price of $10.00 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance
of the Note and Warrants was $1312,000 which was issued at a $131,200 original issue discount from the face value of the Note. The conversion
price for the principal in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to
adjustment as provided therein, such as stock splits and stock dividends.
On
June 2, 2023, a third-party investor elected to convert $181,500 of principal of the Note into 30,250 common shares.
In
October 2023, the holders of $997,700 of Original Issue Discount Senior Convertible Debentures converted their debentures at a contractual
exercise price of $10.00 per share in exchange for the issuance of 166,284 shares of Common Stock to the holders.
Osher
– $110,000
On
December 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due December 22, 2023 based on $1.00 for each $0.90909 paid by Osher noteholder and (ii) five-year Common Stock Purchase
Warrants (“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise
price of $10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and
Warrants was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for
the principal in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment
as provided therein, such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $55,000
On
November 14, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due November 14, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 9,167 shares of the Company’s Common Stock at an exercise price of $10.00
per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,000
which was issued at a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection
with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as
stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Brio
– $92,400
On
November 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $82,500 aggregate principal
amount of Note due November 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $110,000
On
October 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due October 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $123,200
On
September 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due September 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Brio
– $92,400
On
September 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $82,500 aggregate principal
amount of Note due September 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants
was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $123,200
On
August 31, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due August 31, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Other
– $341,000
In
July 2022, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “July 2022 Notes”) totaling
(i) $341,000 aggregate principal amount of Note (total of $310,000 cash was received) due in various dates in July 2023 based on $1.00
for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate
of 16,923 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The conversion price for the principal
in connection with voluntary conversions by the holders of the convertible notes is $20.00 per share.
In
October 2023, the noteholders converted the remaining $324,500 in exchange for the issuance of 16,225 shares of Common Stock to the holders.
On
June 2, 2023, a third-party investor elected to convert $16,500 of principal of the Note into 825 common shares.
Osher
– $94,314
On
June 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $82,500 aggregate principal
amount of Note due June 22, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 4,125 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $11,814.
Osher
– $63,302
On
June 1, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due June 1, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 2,750 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,000 which was issued at
a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $8,302.
Brio
– $128,020
On
May 10, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due May 10, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $18,020.
Osher
– $127,979
On
April 28, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due April 28, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $17,979.
Osher
– $129,721
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is 20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $19,721.
Brio
– $129,964
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $19,964.
Osher
– $225,377
On
September 17, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $181,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due September
30, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to
purchase up to an aggregate of 206 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $165,000 which was issued at
a $16,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided
therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated September 17, 2020, for the number of warrant shares from 206 warrant shares to 11,634 warrant
shares at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
October 28, 2021, Osher elected to convert $16,714 of the aggregate principal amount of the Note of $199,650, into 1,071 common shares.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $42,441.
Osher
– $74,621
On
June 23, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due June 23,
2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase
up to an aggregate of 250 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate cash
subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at a $0
original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions
by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received
by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at an amended $4,995 original issue
discount from the face value of the Note. |
|
|
|
|
● |
The
parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 250 warrant shares to 3,526 warrant shares
at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows (see Note 12):
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $14,121.
Osher
– $564,138
On
January 28, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $385,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture due January 26, 2021, based on $1.00
for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants to purchase up to an aggregate of 2,005 shares of the
Company’s Common Stock at an exercise price of $280.00 per share. The aggregate cash subscription amount received by the Company
from Osher for the issuance of the note and warrants was $350,005 which was issued at a $34,995 original issue discount from the face
value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes
is $3.76 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated January 28, 2020, for the number of warrant shares from 2,005 warrant shares to 102,827 warrant
shares at an exercise price of $5.60 per share. |
|
|
|
|
● |
The
parties amended the Note to provide for interest at 8% per annum. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $106,758.
Previous
Noteholders
Other
– $145,200
On
November 21, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with a third-party
investor of (i) $145,200 aggregate principal amount of Note due November 21, 2023 based on $1.00 for each $0.90909 paid by the previous
noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 24,200 shares
of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate cash subscription amount received by the
Company from the previous noteholder for the issuance of the Note and Warrants was $132,000 which was issued at a $13,200 original issue
discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder
of the convertible notes is $0.15 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.
On
November 23, 2022, third party investor elected to convert the aggregate principal amount of the Note, $145,200, into 24,200 common shares.
All
other previous notes were detailed in our Form 10-K filed on March 31, 2022. No changes occurred related to these notes during the period
covered by this Form 10-Q.
Limited
Operating History; Need for Additional Capital
There
is limited historical financial information about us on which to base an evaluation of our performance. We cannot guarantee we will be
successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including
limited capital resources, and possible cost overruns due to increases in the cost of services. To become profitable and competitive,
we must receive additional capital. We have no assurance that future financing will materialize. If that financing is not available,
we may be unable to continue operations.
Overview
of Presentation
The
following Management’s Discussion and Analysis (“MD&A”) or Plan of Operations includes the following sections:
|
● |
Results
of Operations |
|
|
|
|
● |
Liquidity
and Capital Resources |
|
|
|
|
● |
Capital
Expenditures |
|
|
|
|
● |
Going
Concern |
|
|
|
|
● |
Critical
Accounting Policies |
|
|
|
|
● |
Off-Balance
Sheet Arrangements |
General
and administrative expenses consist primarily of personnel costs and professional fees required to support our operations and growth.
Depending
on the extent of our future growth, we may experience significant strain on our management, personnel, and information systems. We will
need to implement and improve operational, financial, and management information systems. In addition, we are implementing new information
systems that will provide better record-keeping, customer service and billing. However, there can be no assurance that our management
resources or information systems will be sufficient to manage any future growth in our business, and the failure to do so could have
a material adverse effect on our business, results of operations and financial condition.
Results
of Operations
Year
Ended December 31, 2023 Compared to Year Ended December 31, 2022
The
following discussion represents a comparison of our results of operations for the years ended December 31, 2023 and 2022. The results
of operations for the periods shown in our audited consolidated financial statements are not necessarily indicative of operating results
for the entire period. In the opinion of management, the audited consolidated financial statements recognize all adjustments of a normal
recurring nature considered necessary to fairly state our financial position, results of operations and cash flows for the periods presented.
| |
Year Ended December 31, 2023 | | |
Year Ended December 31, 2022 | |
| |
| | |
| |
Net revenues | |
$ | - | | |
$ | - | |
Cost of sales | |
| - | | |
| - | |
Gross Profit | |
| - | | |
| - | |
Operating expenses | |
| 2,455,317 | | |
| 2,147,265 | |
Other expense | |
| 1,690,619 | | |
| 782,552 | |
Net loss before income taxes | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
Net
Revenues
For
the years ended December 31, 2023 and 2022, we had no revenues.
Cost
of Sales
For
the years ended December 31, 2023 and 2022, we had no cost of sales.
Operating
expenses
Operating
expenses increased by $308,052, or 14.3%, to $2,455,317 for the year ended December 31, 2023 from $2,147,265 for the year ended December
31, 2022 primarily due to increases in research and development costs of $140,508, stock based compensation of $215,558, insurance costs
of $20,048, rent expenses of $1,537, and travel costs of $2,021, offset partially by professional fees of $35,141, compensation costs
of $9,109, consulting costs of $2,933, investor relations costs of $16,680, depreciation costs of $98, amortization costs of $1,500,
and general and administration costs of $6,159, as a result of administrative infrastructure for our anticipated business development.
In 2023, the Company incurred stock-based compensation as a result adding members to our board of directors, research and development
costs attributed to in house efforts while reducing professional fees, primarily investor relations.
For
the year ended December 31, 2023, we had marketing expenses of $392, research and development costs of $798,165, and general and administrative
expenses of $1,656,760 primarily due to professional fees of $174,245, compensation costs of $680,608, consulting costs of $203,892,
insurance costs of $235,752, stock based compensation of $215,558, rent of $78,305, depreciation costs of $6,756, amortization costs
of $2,100, investor relations costs of $36,528, travel costs of $2,170, and general and administration costs of $20,847, as a result
of administrative infrastructure for our anticipated business development. In 2023, the Company incurred stock-based compensation as
a result adding members to our board of directors, research and development costs attributed to in house efforts, and professional fees,
primarily investor relations.
For
the year ended December 31, 2022, we had marketing expenses of $457, research and development costs of $657,657, and general and administrative
expenses of $1,489,151 primarily due to professional fees of $209,386, compensation costs of $689,717, consulting costs of $206,825,
insurance costs of $215,704, rent of $76,768, depreciation costs of $6,854, amortization costs of $3,600, investor relations costs of
$53,208, and general and administration costs of $27,089, as a result of adding administrative infrastructure for our anticipated business
development. In 2022, the Company has incurred professional fees (primarily legal and audit fees), incurred compensation for its CEO
and CTO and hired a CFO, incurred consulting costs (primarily for public relations and brand awareness), had investor relations costs,
and had rent through the lease of office space. Research and development costs consist of $579,977 attributed to in house efforts and
$77,680 to third parties for developmental services and testing.
Other
Expense
Other
expense for the year ended December 31, 2023 totaled $1,690,619 primarily due interest expense of $2,041,182 in conjunction with accretion
of debt discount and original issuance discount, and interest expense of $2,402, and the modification of warrants of $352,965, compared
to other expense of $782,552 primarily due interest expense of $782,114 in conjunction with accretion of debt discount and original issuance
discount, and interest expense of $438 for the year ended December 31, 2022.
Net
loss before income taxes
Net
loss before income taxes for the year ended December 31, 2023 totaled $4,145,936 primarily due to increases/decreases in compensation
costs, professional fees, consulting costs, research and development costs, investor relations costs, insurance costs, stock based compensation,
rent, and general and administration costs compared to a loss of $2,929,817 primarily due to increases/decreases in compensation costs,
professional fees, consulting costs, research and development costs, investor relations costs, insurance costs, and general and administration
costs for the year ended December 31, 2022 primarily due to professional fees.
Assets
and Liabilities
Assets
were $321,806 as of December 31, 2023. Assets consisted primarily of cash of $11,690, inventories of $50,000, other current assets of
$56,373, equipment of $15,296, operating lease right-of-use assets of $167,736, and other assets of $20,711. Liabilities were $3,734,306
as of December 31, 2023. Liabilities consisted primarily of accounts payable of $524,146, accrued payroll and payroll taxes of $729,254,
advance from shareholder of $80,000, convertible notes of $2,210,299, net of $297,337 of unamortized debt discount, operating lease liabilities
of $187,425, and other current liabilities of $3,182.
Liquidity
and Capital Resources
Going
Concern
The
accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated
deficit of $11,341,512 at December 31, 2023, had a working capital deficit of $3,489,941 at December 31, 2023, had net losses of $4,145,936
and $2,929,817 for the years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $1,383,210
and $1,830,242 for the years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational
history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.
While
the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough
to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset
sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues
provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to
generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or
on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability
to further implement its business plan and generate revenues.
The
consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
General
– Overall, we had an increase in cash flows for the year ended December 31, 2023 of $3,334 resulting from cash provided
by financing activities of $1,386,544, offset partially by cash used in operating activities of $1,383,210.
The
following is a summary of our cash flows provided by (used in) operating, investing, and financing activities during the periods indicated:
| |
Year Ended December 31, 2023 | | |
Year Ended December 31, 2022 | |
| |
| | |
| |
Net cash provided by (used in): | |
| | | |
| | |
Operating activities | |
$ | (1,383,210 | ) | |
$ | (1,830,242 | ) |
Investing activities | |
| - | | |
| (860 | ) |
Financing activities | |
| 1,386,544 | | |
| 1,498,502 | |
| |
$ | 3,334 | | |
$ | (332,600 | ) |
Year
Ended December 31, 2023 Compared to Year Ended December 31, 2022
Cash
Flows from Operating Activities – For the year ended December 31, 2023, net cash used in operations was $1,383,210 compared
to net cash used in operations of $1,830,242 for the year ended December 31, 2022. Net cash used in operations was primarily due to a
net loss of $4,145,936 for year ended December 31, 2023 and the changes in operating assets and liabilities of $850,095, primarily due
to the increases in other current assets of $44,431, accounts payable of $134,129, and accrued payroll and payroll taxes of $761,630,
offset primarily by decreases in other current liabilities of $1,233. In addition, net cash used in operating activities includes adjustments
to reconcile net profit from depreciation expense of $6,756, amortization expense of $2,100, accretion of original issuance costs of
$285,187, the accretion of debt discount of $1,755,995, stock-based compensation of $215,558, and the modification of warrants of $352,965.
Net
cash used in operations was primarily due to a net loss of $2,929,817 for the year ended December 31, 2022 and the changes in operating
assets and liabilities of $307,007, primarily due to the increases in other current assets of $9,867, accounts payable of $287,843, and
accrued payroll and payroll taxes of $29,052, offset primarily by decreases in other current liabilities of $21. In addition, net cash
used in operating activities includes adjustments to reconcile net profit from depreciation expense of $6,854, amortization expense of
$3,600, accretion of original issuance costs of $135,812, and the accretion of debt discount of $646,302.
Cash
Flows from Investing Activities – For the year ended December 31, 2023, net cash used in investing was $0 compared to cash
flows from investing activities of $860 due to the purchase of property and equipment for the year ended December 31, 2022.
Cash
Flows from Financing Activities – For the year ended December 31, 2023, net cash provided by financing was $1,386,544 due
to proceeds from short term convertible notes of $1,312,000 net of fees associated with the filing of the Company’s Form S-1 of
$5,456 and advance from shareholder of $80,000. For the year ended December 31, 2022, net cash provided by financing was $1,498,502 due
to proceeds from short term convertible notes of $1,567,000 net of fees associated with the filing of the Company’s Form S-1 of
$68,498.
Financing
– We expect that our current working capital position, together with our expected future cash flows from operations will
be insufficient to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements
and other contractual obligations for at least the next twelve months. However, this belief is based upon many assumptions and is subject
to numerous risks, and there can be no assurance that we will not require additional funding in the future.
We
have no present agreements or commitments with respect to any material acquisitions of other businesses, products, product rights or
technologies or any other material capital expenditures. However, we will continue to evaluate acquisitions of and/or investments in
products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or
investments in the future. Accordingly, we may need to obtain additional sources of capital in the future to finance any such acquisitions
and/or investments. We may not be able to obtain such financing on commercially reasonable terms, if at all. Due to the ongoing global
economic crisis, we believe it may be difficult to obtain additional financing if needed. Even if we are able to obtain additional financing,
it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders,
in the case of equity financing.
Advance
from Shareholder
The
Company borrows funds from the Company’s CEO for working capital purposes from time to time. The Company has recorded the principal
balance due of $80,000 and $0 under Advance from Shareholder in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively.
The Company received advances of $80,000 and $0 and no repayments for the years ended December 31, 2023 and 2022. In January 2024, the
Company received an additional advance of $25,000 with a balance due of $105,000 as of the date of this filing. The advance from our
CEO was not made pursuant to any loan agreements or promissory notes, are non-interest bearing and due on demand.
Convertible
Notes Payable
In
October 2023, the holders of $997,700 of Original Issue Discount Senior Convertible Debentures converted their debentures at a contractual
exercise price of $10.00 per share in exchange for the issuance of 166,284 shares of Common Stock to the holders.
Capital
Expenditures
We
expect to purchase approximately $30,000 of equipment in connection with the expansion of our business during the next twelve months.
Fiscal
Year-End
Our
fiscal year end is December 31.
Critical
Accounting Policies
Refer
to Note 3 in the accompanying notes to the consolidated financial statements for critical accounting policies.
Recent
Accounting Pronouncements
Refer
to Note 3 in the accompanying notes to the consolidated financial statements.
Future
Contractual Obligations and Commitments
Refer
to Note 3 in the accompanying notes to the consolidated financial statements for future contractual obligations and commitments. Future
contractual obligations and commitments are based on the terms of the relevant agreements and appropriate classification of items under
GAAP as currently in effect. Future events could cause actual payments to differ from these amounts.
We
incur contractual obligations and financial commitments in the normal course of our operations and financing activities. Contractual
obligations include future cash payments required under existing contracts, such as debt and lease agreements. These obligations may
result from both general financing activities and from commercial arrangements that are directly supported by related operating activities.
Details on these obligations are set forth below.
Off-Balance
Sheet Arrangements
As
of December 31, 2023, we have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated
under which it has:
|
● |
a
retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit; |
|
|
|
|
● |
liquidity
or market risk support to such entity for such assets; |
|
|
|
|
● |
an
obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument; or |
|
|
|
|
● |
an
obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by, and
material to us, where such entity provides financing, liquidity, market risk or credit risk support to or engages in leasing, hedging,
or research and development services with us. |
Inflation
We
do not believe that inflation has had a material effect on our results of operations.
Item
7A. Quantitative and Qualitative Disclosure About Market Risk
We
are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information
under this item.
Item
8. Financial Statements and Supplementary Data
The
financial statements and supplementary financial information which are required to be filed under this item are presented under Item
15. Exhibits, Financial Statement Schedules and Reports on Form 10-K in this document, and are incorporated herein by reference.
Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item
9A. Controls and Procedures
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures (as defined in Rule 13a-l5(e) under the Exchange Act) that are designed to ensure that information
that would be required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time period
specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including
to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Our
management, under the supervision and with the participation of our CEO and Chief Financial Officer (“CFO”), has evaluated
the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period
covered by this report. Based on such evaluation, management identified deficiencies that were determined to be a material weakness.
Management’s
Report on Internal Controls over Financial Reporting
The
Company’s management is responsible for establishing and maintaining effective internal control over financial reporting (as defined
in Rule 13a-l5(f) of the Securities Exchange Act). Management assessed the effectiveness of the Company’s internal control over
financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”) (2013). Based on that assessment, management believes that, as of December
31, 2023, the Company’s internal control over financial reporting was ineffective based on the COSO criteria, due to the following
material weaknesses listed below.
The
specific material weaknesses identified by the company’s management as of end of the period covered by this report include the
following:
|
● |
we
have not performed a risk assessment and mapped our processes to control objectives; |
|
● |
we
have not implemented comprehensive entity-level internal controls; |
|
● |
we
have not implemented adequate system and manual controls; and |
|
● |
we
do not have sufficient segregation of duties. As such, the officers approve their own related business expense reimbursements |
Despite
the material weaknesses reported above, our management believes that our consolidated financial statements included in this report fairly
present in all material respects our financial condition, results of operations and cash flows for the periods presented and that this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
This
report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting.
Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the Commission
that permit us to provide only management’s report in this report.
Management’s
Remediation Plan
The
weaknesses and their related risks are not uncommon in a company of our size because of the limitations in the size and number of staff.
Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible.
However,
we plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by
this annual report on Form 10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses,
we plan to implement the following changes in the current fiscal year as resources allow:
|
(i) |
appoint
additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls
to address such inadequacies; |
|
(ii) |
hire
a new Big 4 CFO with experience working in publicly traded companies and hire a staff person to support the CFO, which was accomplished
in March 2022. |
The
remediation efforts set out herein will be implemented in the current 2024 fiscal year. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within our company have been detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because
of simple error or mistake.
Management
believes that despite our material weaknesses set forth above, our consolidated financial statements for the year ended December 31,
2023 are fairly stated, in all material respects, in accordance with GAAP.
Changes
in Internal Control over Financial Reporting
There
have been no changes in our internal control over financial reporting during the fiscal year ending December 31, 2023 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item
9B. Other Information
There
have been no events required to be reported under this Item.
PART
III
Item
10. Directors, Executive Officers and Corporate Governance
The
following table sets forth the names, ages, and biographical information of each of our current directors and executive officers and
the positions with the Company held by each person. Our executive officers are elected annually by the board of directors. The directors
serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation
or removal by the board of directors. Unless described below, there are no family relationships among any of the directors and officers.
Name |
|
Age |
|
Title |
Jim Joyce |
|
62 |
|
Chief Executive Officer and Chairman of the Board of Directors (“CEO”) |
Craig Roberts |
|
71 |
|
Chief Technology Officer and Director |
Gerald DeCiccio (3) |
|
66 |
|
Chief Financial Officer |
Richa Nand (2) |
|
50 |
|
Non-Employee Director |
Jim Dorst (2) |
|
69 |
|
Non-Employee Director |
Christopher Wetzel (2) |
|
48 |
|
Non-Employee Director |
Jeremy Ferrell (1) |
|
53 |
|
Chief Financial Officer |
(1) |
Mr.
Ferrell was hired as the Company’s Chief Financial Officer effective March 9, 2022 and terminated December 6, 2023 |
(2) |
Ms.
Nand, Mr. Dorst and Mr. Wetzel were appointed as Non-Executive Directors effective October 10, 2022. |
(3) |
Mr.
DeCiccio was hired as the Company’s Chief Financial Officer effective December 6, 2023. |
Executive
Officers
Jim
Joyce. Mr. Joyce is a Co-founder of Sigyn Therapeutics and has served as Chairman and CEO of the Company since it was founded
in 2019. He has 30+ years of diverse public market experience, which includes two decades of public company CEO and Corporate Board leadership
roles. Previously, Mr. Joyce was the founder of Exosome Sciences, Inc., where he served as Executive Chairman from 2011 to 2018. Mr.
Joyce is also the founder, former Chairman and CEO of Aethlon Medical, a therapeutic device company that he navigated from a single shareholder
start-up to Nasdaq-traded Company with 8000+ shareholders.
While
employed at Aethlon from 1999 to 2018, Mr. Joyce oversaw the development of the Aethlon Hemopurifier, the first therapeutic candidate
to receive two “Breakthrough Device” designations from the FDA. Under his leadership, the Hemopurifier received FDA “Emergency
Use Authorization” (EAU) approval to treat Ebola virus and additionally was cleared to treat Ebola by the German Government and
Health Canada. Time Magazine named the Hemopurifier one of the “11 Most Remarkable Advances in Healthcare” and designated
the device to its “Top 25 Best Inventions” award list.
During
Mr. Joyce’s tenure, Aethlon won multiple Department of Defense (DOD) contract awards, a National Cancer Institute (NCI) contract
award and grants from the National Institutes of Health (NIH). He also led the completion of approximately $100 million of equity financings
and originated preclinical and clinical collaborations with more than twenty government and non-government institutes and organizations.
We
believe Mr. Joyce’s service as our Chief Executive Officer, his extensive experience in therapeutic device technologies, his prior
board service and his extensive public company background qualifies him to serve on our board of directors.
Craig
Roberts. Mr. Roberts is an inventor of therapeutic device technologies, which includes a Percutaneous Adult Extracorporeal Membrane
Oxygenation (ECMO) system that was licensed and subsequently sold to C.R. Bard. During the ongoing pandemic, ECMO has been broadly deployed
to treat critically ill COVID-19 patients. Additionally, Mr. Roberts is the inventor of the IMPACT System, which received CE Mark clearance
in the European Union and was subsequently registered in 32 countries and successfully deployed to treat cytokine storm related conditions,
including sepsis, acute respiratory distress syndrome (ARDS), acute liver failure, severe pneumonia and H5N1 bird flu virus infection.
Mr.
Roberts is a Co-founder of Sigyn Therapeutics and has been our Chief Technical Officer since it was founded in 2019. Prior to joining
the Company, Mr. Roberts served as a consultant for Aethlon Medical, Inc. from 2016 to 2019. Prior to Aethlon, Mr. Roberts was a founder,
Chief Technology Officer and Board Member of Hemolife Medical, Inc. We believe Mr. Roberts’s service as our Chief Technology Officer,
his extensive experience with therapeutic device technologies and his previous service as board of medical device company qualifies him
to serve on our board of directors.
Gerald
DeCiccio. Mr. DeCiccio is an experienced finance professional with more than 40 years of professional experience that includes
serving in executive roles in publicly traded companies. Mr. DeCiccio is a licensed CPA in California and has been serving as a consultant
within his own firm for the past five years. Mr. DeCiccio has a Bachelor’s degree in Accounting and Business Administration from
Loma Linda University and an MBA from the University of Southern California.
Non-Employee
Directors
Richa
Nand. Ms. Nand is a senior legal executive with more than 20 years of experience as an intellectual property (“IP”)
attorney and strategic business advisor for biotechnology and medical device companies. Ms. Nand is the founder of Insight Patents, a
legal and consulting firm providing IP and transactional corporate services for the life sciences industry. Ms. Nand previously served
as Vice President of Corporate Development and Legal at Bird Rock Bio – a Johnson & Johnson-backed biopharmaceutical company
in San Diego – and Vice President of Intellectual Property and Licensing; Director of Business Development; and In-House Patent
Counsel at Cytori Therapeutics. Prior to law school, she was a biomedical researcher at Cedars Sinai Medical Center in Beverly Hills,
California. Ms. Nand received a Bachelor of Science degree in Microbiology and Molecular Genetics from the University of California,
Los Angeles, and a Juris Doctor degree from Boston University School of Law. We believe Ms. Nand’s experience in the healthcare
field makes her well suited to serve on our Board.
Jim
Dorst. Mr. Dorst has more than 30 years of senior management experience in finance, operations, planning and business transactions
at both private and public companies. He was most recently Director of Corporate Development at SYNNEX/Concentrix, where he was primarily
responsible for mergers and acquisitions. Mr. Dorst was previously Chief Operating Officer (“COO”) and Chief Financial Officer
(“CFO”) at SpectraScience, Inc.; CFO of Aethlon Medical, Inc. and Vice President of Finance and Operations for Verdisoft
Corporation. In addition, he previously served as Senior Vice President of Finance and Administration at SeeCommerce; CFO and COO of
Omnis Technology Corp; and CFO and Senior Vice President of Information Technology at Savoir Technology Group, Inc. Mr. Dorst practiced
as a Certified Public Accountant with Coopers & Lybrand (now PricewaterhouseCoopers LLP); and holds a Master of Science degree in
Accounting and a Bachelor of Science degree in Finance from the University of Oregon. We believe Mr. Dorst’s public company experience
makes him well suited to sit on our Board.
Christopher
Wetzel. Mr. Wetzel has more than 25 years of leadership experience in various aspects of the healthcare delivery system and since
2004, has served as Chief Executive Officer for the Surgery Center at Hamilton in New Jersey. His career has focused on building organizations,
increasing operational efficiency, increasing profitability, maximizing revenue, and managing change in the complex and high-growth healthcare
environment. Mr. Wetzel applied his broad background in strategy, finance, and operations to guide various entities starting new ventures,
entering new markets, and reengineering business processes. He is a long-term investor in the extracorporeal therapy space. Mr. Wetzel
received a Master of Business Administration degree in Healthcare Management and a Bachelor of Science degree in Nursing from Thomas
Jefferson University (formerly Philadelphia University). Mr. Wetzel’s experience in the health care field well serves him to sit
on our Board.
Conflicts
of Interest
Certain
potential conflicts of interest are inherent in the relationships between our officers and directors and us.
From
time to time, one or more of our affiliates may form or hold an ownership interest in and/or manage other businesses both related and
unrelated to the type of business that we own and operate. These persons expect to continue to form, hold an ownership interest in and/or
manage additional other businesses which may compete with our business with respect to operations, including financing and marketing,
management time and services and potential customers. These activities may give rise to conflicts between or among the interests of us
and other businesses with which our affiliates are associated. Our affiliates are in no way prohibited from undertaking such activities,
and neither we nor our shareholders will have any right to require participation in such other activities.
We
may transact business with some of our officers, directors and affiliates, as well as with firms in which some of our officers, directors
or affiliates have a material interest, potential conflicts may arise between the respective interests of us and these related persons
or entities. We believe that such transactions will be effected on terms at least as favorable to us as those available from unrelated
third parties. As of this filing, we have not transacted business with any officer, director, or affiliate.
With
respect to transactions involving real or apparent conflicts of interest, we have adopted policies and procedures which require that:
(i) the fact of the relationship or interest giving rise to the potential conflict be disclosed or known to the directors who authorize
or approve the transaction prior to such authorization or approval, (ii) the transaction be approved by a majority of our disinterested
outside directors, and (iii) the transaction be fair and reasonable to us at the time it is authorized or approved by our directors.
Our
policies and procedures regarding transactions involving potential conflicts of interest are not in writing. We understand that it will
be difficult to enforce our policies and procedures and will rely and trust our officers and directors to follow our policies and procedures.
We will implement our policies and procedures by requiring the officer or director who is not in compliance with our policies and procedures
to remove himself and the other officers and directors will decide how to implement the policies and procedures, accordingly.
Corporate
Governance
The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in
other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules and regulations.
Director
Independence
Our
board of directors consists of five members, with three independent directors (all of our Non-Employee Directors are independent) in
accordance with NASDAQ listing rule 5605(a)(2). Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence”
of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director”
is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the
company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of
a director. The NASDAQ listing rules provide that a director cannot be considered independent if:
|
● |
the
director is, or at any time during the past three years was, an employee of the company; |
|
● |
the
director or a family member of the director accepted any compensation from the company in excess of $120,000 during any period of
12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including,
among other things, compensation for board or board committee service); |
|
● |
a
family member of the director is, or at any time during the past three years was, an executive officer of the company; |
|
● |
the
director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to
which the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed
5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions); |
|
● |
the
director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three
years, any of the executive officers of the company served on the compensation committee of such other entity; or |
|
● |
the
director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during the
past three years was a partner or employee of the Company’s outside auditor, and who worked on the company’s audit. |
Board
Composition
Our
business and affairs are managed under the direction of our board of directors, which consists of five members. Directors serve for a
term of one year and until their successors have been duly elected and qualified.
Committees
of the Board
On
October 26, 2023, the Company established an audit, nominating, and compensation committee.
Our
Audit Committee is primarily responsible for overseeing our risk management processes on behalf of our Board of Directors. The Audit
Committee receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding
our company’s assessment of risks. In addition, the Audit Committee reports regularly to the full Board of Directors, which also
considers our risk profile. The Audit Committee and the full Board of Directors focus on the most significant risks facing our Company
and our Company’s general risk management strategy, and also ensure that risks undertaken by our Company are consistent with the
Board’s appetite for risk. While the Board oversees our company’s risk management, management is responsible for day-to-day
risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing
our company and that our Board leadership structure supports this approach.
The
Company maintains a Scientific Advisory Board (“SAB”) to assist our Board of Directors by reviewing and evaluating our clinical
development programs. We intend for our SAB members to receive per meeting fees and also be eligible to receive stock option compensation.
However, a formal SAB compensation plan has not yet been approved by our Board of Directors.
Audit
Committee Financial Expert
Mr.
Dorst qualifies as an “audit committee financial expert” as defined in Item 407(D)(5) of Regulation S-K, and our three new
directors qualify as “independent” as the term is used in Item 7(d)(3)(iv)(B) of Schedule 14A under the Securities Exchange
Act of 1934, as amended, and as defined by Rule 4200(a)(14) of the FINRA Rules.
We
believe that our directors are capable of analyzing and evaluating our consolidated financial statements and understanding internal controls
and procedures for financial reporting. The directors of our Company do not believe that it is necessary to have an audit committee because
management believes that the board of directors can adequately perform the functions of an audit committee.
Involvement
in Certain Legal Proceedings
Our
directors and our executive officers have not been involved in or a party in any of the following events or actions during the past ten
years:
|
1. |
any
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the
time of the bankruptcy or within two years prior to that time; |
|
|
|
|
2. |
any
conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor
offenses); |
|
|
|
|
3. |
being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities
or banking activities; or |
|
|
|
|
4. |
being
found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have
violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated. |
|
|
|
|
5. |
Such
person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State
securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended,
or vacated; |
|
|
|
|
6. |
Such
person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not
been subsequently reversed, suspended or vacated; |
|
|
|
|
7. |
Such
person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not
subsequently reversed, suspended or vacated, relating to an alleged violation of: (I) Any Federal or State securities or commodities
law or regulation; or (ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited
to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist
order, or removal or prohibition order; or (iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with
any business entity; or |
|
|
|
|
8. |
Such
person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section
1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that
has disciplinary authority over its members or persons associated with a member. |
Code
of Ethics
On October 25,2023, we adopted a Code of Ethics for our principal executive
officers and senior management. The Code is designed to deter wrongdoing and promote honest and ethical conduct; full and fair disclosure
in reports and documents submitted to the SEC; compliance with applicable governmental laws, rules and regulations; and the prompt internal
reporting of violations of the code to appropriate persons by our senior management. A copy of our Code of Ethics can be accessed at https://www.sigyntherapeutics.com/investors/corporate-governance/governance-documents.
Role
of Board of Directors in Risk Oversight
Our
board of directors oversees an enterprise-wide approach to risk management, designed to support the achievement of business objectives,
including organizational and strategic objectives, to improve long-term organizational performance and enhance stockholder value. The
involvement of our board of directors in setting our business strategy is a key part of its assessment of management’s plans for
risk management and its determination of what constitutes an appropriate level of risk for our company. The participation of our board
of directors in our risk oversight process includes receiving regular reports from members of senior management on areas of material
risk to our company, including operational, financial, legal and regulatory, and strategic and reputational risks.
While
our board of directors has the ultimate responsibility for the risk management process, senior management and various committees of our
board of directors, when formed, will also have responsibility for certain areas of risk management. Our senior management team is responsible
for day-to-day risk management and regularly reports on risks to our full board of directors or a relevant committee. Our finance and
regulatory personnel serve as the primary monitoring and evaluation function for company-wide policies and procedures, and manage the
day-to-day oversight of the risk management strategy for our ongoing business. This oversight includes identifying, evaluating, and addressing
potential risks that may exist at the enterprise, strategic, financial, operational, compliance and reporting levels.
Director
Compensation
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Each Director shall receive an annual retainer of $30,000
paid in equal quarterly amounts at the end of each quarter. In addition, each Director shall receive a grant of restricted stock units
of $50,000, or at the discretion of the Board of Directors, options to acquire shares of common stock. Restricted stock units will be
valued based on the average of the five trading days preceding and including the date of grant and will vest at a rate determined by
the Board of Directors over one year. If options are granted, the options will be valued at the exercise price based on the average of
the five trading days preceding and including the date of grant, have a ten-year term, and will vest at a rate determined by the Board
of Directors.
Limitation
on Liability and Indemnification Matters
Our
Certificate of Incorporation and Bylaws provide that we will indemnify our directors and officers, and may indemnify our employees and
other agents, to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our Certificate of Incorporation
from limiting the liability of our directors for the following:
|
● |
any
breach of the director’s duty of loyalty to the corporation or its shareholders; |
|
|
|
|
● |
any
act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
|
|
|
|
● |
unlawful
payments of dividends or unlawful stock repurchases or redemptions; or |
|
|
|
|
● |
any
transaction from which the director derived an improper personal benefit. |
If
Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the
liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our Certificate
of Incorporation does not eliminate a director’s duty of care and in appropriate circumstances, equitable remedies, such as injunctive
or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a director’s responsibilities
under any other laws, such as the federal securities laws or other state or federal laws. Under our bylaws, we will also be empowered
to purchase insurance on behalf of any person whom we are required or permitted to indemnify.
The
limitation of liability and indemnification provisions in our Certificate of Incorporation and bylaws may discourage shareholders from
bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation
against directors and officers, even though an action, if successful, might benefit us and our shareholders. A shareholder’s investment
may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions. Insofar as we may provide indemnification for liabilities arising under the Securities Act to our directors, officers, and
controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding
naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation
that may result in claims for indemnification by any director or officer.
Item
11. Executive Compensation
The
following is a discussion and analysis of compensation arrangements of our named executive officers, or NEOs. This discussion contains
forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation
programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion.
As an “emerging growth company” as defined in the JOBS Act, we are not required to include a Compensation Discussion and
Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.
Summary
Compensation Table
The
particulars of the compensation paid to the following persons: (1) our principal executive officer; and (2) each of our two most highly
compensated executive officers who were serving as executive officers at the end of the fiscal year ended December 31, 2023, who we will
collectively refer to as the “named executive officers” of the Company, are set out in the following summary compensation
table:
SUMMARY
COMPENSATION TABLE
| |
| | |
| | |
| | |
| | |
| | |
| | |
Change in | | |
| | |
| |
| |
| | |
| | |
| | |
| | |
| | |
| | |
Pension | | |
| | |
| |
| |
| | |
| | |
| | |
| | |
| | |
| | |
Value and | | |
| | |
| |
| |
| | |
| | |
| | |
| | |
| | |
Non-Equity | | |
Nonqualified | | |
| | |
| |
| |
| | |
| | |
| | |
Stock | | |
Option | | |
Incentive Plan | | |
Deferred | | |
All Other | | |
| |
Name and | |
| | |
Salary | | |
Bonus | | |
Awards | | |
Awards | | |
Compensation | | |
Compensation | | |
Compensation | | |
Total | |
Principal Position | |
Year | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | | |
Earnings ($) | | |
($)(1) | | |
($) | |
Jim Joyce | |
| 2023 | | |
| 455,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 31,037 | | |
$ | 486,037 | |
Chief Executive Officer (2) | |
| 2022 | | |
| 453,067 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 48,811 | | |
$ | 501,878 | |
| |
| 2021 | | |
| 473,375 | | |
| 22,750 | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 31,126 | | |
$ | 527,251 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Craig Roberts | |
| 2023 | | |
| 240,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 16,460 | | |
$ | 256,460 | |
Chief Technology Officer (3) | |
| 2022 | | |
| 233,678 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 25,312 | | |
$ | 258,990 | |
| |
| 2021 | | |
| 247,000 | | |
| 12,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 21,704 | | |
$ | 280,704 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Gerald DeCiccio | |
| 2023 | | |
| 9,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | - | | |
$ | 9,000 | |
Chief Financial Officer (4) | |
| 2022 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | - | | |
$ | - | |
| |
| 2021 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Jeremy Ferrell | |
| 2023 | | |
| 57,288 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 4,263 | | |
$ | 61,551 | |
Chief Financial Officer (5) | |
| 2022 | | |
| 177,083 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | 23,205 | | |
$ | 200,288 | |
| |
| 2021 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
$ | - | | |
$ | - | |
|
(1) |
Amounts
include health insurance and employer matched 401(k) costs. |
|
(2) |
Mr.
Joyce’s 2023 salary includes $284,375 of accrued salary. |
|
(3) |
Mr.
Roberts 2023 salary includes $160,000 of accrued salary. |
|
(4) |
Mr.
DeCiccio was hired as the Company’s Chief Financial Officer effective December 6, 2023. Mr. DeCiccio’s 2023 salary includes
$9,000 of accrued salary. |
|
(5) |
Mr.
Ferrell was hired as the Company’s Chief Financial Officer effective March 9, 2022. Mr. Ferrell receives an annual base salary
of $250,000, amended to $62,500 on December 1, 2022. Mr. Ferrell’s employment was terminated on December 6, 2023. Mr. Ferrell’s
2023 salary includes $24,479 of accrued salary. |
Other
than as disclosed below, there are no compensatory plans or arrangements with respect to our executive officers resulting from their
resignation, retirement or other termination of employment or from a change of control.
Grants
of Plan-Based Awards Table
None
of our named executive officers received any grants of stock, option awards or other plan-based awards during the years ended December
31, 2023 and 2022, except as described below in “Equity Compensation Plans and Other Benefit Plans” below.
Options
Exercised and Stock Vested Table
None
of our named executive officers exercised any stock options or restricted stock units during the years ended December 31, 2023 and 2022.
Outstanding
Equity Awards at 2023 Year End
Except
as described below in “Equity Compensation Plans and Other Benefit Plans”, the Company has not issued any awards to its named
executive officers. The Company and its board of directors may grant awards as it sees fit to its employees as well as key consultants.
See the discussion of “Equity Compensation Plans and Other Benefit Plans” below.
Agreements
with Executive Officers
Jim
Joyce
Mr.
Joyce receives an annual base salary of $455,000, plus bonus compensation not to exceed 50% of salary. Mr. Joyce’s employment also
provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due
to a change in control. Additionally, the Company has agreed to maintain a beneficial ownership target of 9% for Mr. Joyce. There is
no written employment agreement for Mr. Joyce at this time.
Gerald
DeCiccio
Mr.
DeCiccio was hired December 6, 2023 as the Company’s Chief Financial Officer. Mr. DeCiccio receives an annual base salary of $250,000,
plus discretionary bonus compensation not to exceed 40% of salary. Mr. DeCiccio’s employment also provides for medical insurance,
disability benefits and three months of severance pay if his employment is terminated without cause or due to a change in control. Additionally,
Mr. DeCiccio was granted up to 17,500 options to purchase 17,500 of the Company’s common shares.
Craig
Roberts
Mr.
Roberts, the Company’s Chief Technology Officer (CTO) receives an annual base salary of $240,000 as well as medical insurance and
related benefits. Mr. Roberts is eligible to receive bonus compensation at the discretion of the Sigyn Therapeutics, Inc. Board of Directors.
Equity
Compensation Plans and Other Benefit Plans
The
Company does not currently have any equity compensation plans and there are no arrangements or plans in which we provide pension, retirement
or similar benefits for directors or executive officers. We have no material bonus or profit-sharing plans.
Indebtedness
of Directors, Senior Officers, Executive Officers and Other Management
None
of our directors or executive officers or any associate or affiliate of the Company during the last two fiscal years, is or has been
indebted to the Company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently
outstanding.
Outstanding
Equity Awards at Fiscal Year-End Table
The
following table sets forth certain information concerning outstanding stock awards held by the Named Executive Officers for our year
ended December 31, 2023:
| |
Option
Awards | | |
Stock
Awards | |
Name | |
Number
of Securities Underlying Unexercised Options (#) Exercisable | | |
Number
of Securities Underlying Unexercised Options (#) Unexercisable | | |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | | |
Option
Exercise Price ($) | | |
Option
Expiration Date | | |
Number
of Shares or Units of Stock That Have Not Vested (#) | | |
Market
Value of Shares or Units of Stock That Have Not Vested ($) | | |
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | | |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
None.
| |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | | |
| -0- | |
Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The
following table sets forth information relating to the beneficial ownership our common stock as of February 16, 2024 by (i) each person
known to be the beneficial owner of more than 5% of the outstanding shares of common stock and (ii) each of our directors and executive
officers. Unless otherwise noted below, we believe that all persons named in the table have sole voting and investment power with respect
to all shares of common stock beneficially owned by them. For purposes hereof, a person is deemed to be the beneficial owner of securities
that can be acquired by such person within 60 days from the date hereof upon the exercise of warrants or options or the conversion of
convertible securities. Each beneficial owner’s percentage ownership is determined by assuming that any warrants, options or convertible
securities that are held by such person (but not those held by any other person) and which are exercisable within 60 days from the date
hereof, have been exercised.
Name and Address (2) | |
Amount of Beneficial Ownership | | |
Percent of Class (1) | |
| |
| | |
| |
Jim Joyce (3) | |
| 320,500 | | |
| 26.2 | % |
Craig Roberts (4) | |
| 256,400 | | |
| 20.9 | % |
Gerald DeCiccio (5) | |
| - | | |
| - | % |
Jeremy Ferrell (9) | |
| - | | |
| - | % |
Chris Wetzel (8) | |
| 3,192 | | |
| 0.3 | % |
| |
| | | |
| | |
All Officers and Directors as a Group (2 Persons) | |
| 580,092 | | |
| 47.4 | % |
| |
| | | |
| | |
Brio Capital Master Fund Ltd. (6) | |
| 93,146 | | |
| 7.6 | % |
| |
| | | |
| | |
Osher Capital Partners LLC (7) | |
| 76,266 | | |
| 6.2 | % |
(1)
|
Based
on 1,224,315 shares of common stock issued and outstanding. |
(2)
|
Unless
otherwise noted, the address of each beneficial owner is c/o Sigyn Therapeutics, Inc., 2468 Historic Decatur Road, Suite 140, San
Diego, CA 92106. |
(3)
|
Mr.
Joyce is the Company’s CEO. |
(4)
|
Mr.
Roberts is the Company’s CTO. |
(5)
|
Mr.
DeCiccio is the Company’s CFO effective December 6, 2023. |
(6)
|
Consists
of 93,146 common shares as of the date of this filing. Brio Capital Master Fund Ltd (“Brio”) is contractually limited
to beneficial ownership of our common stock not to exceed 9.99%. The stockholder of record by the stockholder is held by Shaye Hirsch
who is a director of Brio. The business address of Brio is 100 Merrick Road, Suite 401W, Rockville Center, NY 11570. |
(7)
|
Consists
of 96,266 common shares as of the date of this filing. Osher Capital Partners LLC (“Osher”) is contractually limited
to beneficial ownership of our common stock not to exceed 9.99%. The Stockholder has advised us that voting and dispositive power
of all the common shares of the Company owned of record by the stockholder is held by Ari Kluger, who is President of Osher. The
business address of Osher is 23 Tammy Lane, Spring Valley NY 10977. |
(8) |
Mr.
Wetzel is a director of the Company. |
(9) |
Mr.
Ferrell was the Company’s previous CFO and terminated December 6, 2023. |
We
are not aware of any person who owns of record, or is known to own beneficially, five percent or more of our outstanding securities of
any class, other than as set forth above. We do not have an investment advisor. There are no current arrangements which will result in
a change in control.
Equity
Compensation Plans
The
following represents a summary of the Equity Compensation grants and options awards outstanding at December 31, 2023 and 2022 and changes
during the years then ended:
2023 and 2022 |
Plan category | |
Number of securities to be issued upon exercise of outstanding options, warrants and rights | | |
Weighted-average exercise price of outstanding options, warrants and rights | | |
Number of securities remaining available for future issuance under equity compensation plan (excluding securities reflected in column (a)) | |
| |
(a) | | |
(b) | | |
(c) | |
Equity compensation plans approved by security holders | |
| -0- | | |
$ | -0- | | |
| -0- | |
Equity compensation plans not approved by security holders | |
| -0- | | |
$ | -0- | | |
| -0- | |
Total | |
| -0- | | |
$ | -0- | | |
| -0- | |
Item
13. Certain Relationships and Related Transactions, and Director Independence
Other
than compensation arrangements, we describe below transactions and series of similar transactions, since January 1, 2020 (i.e., the last
two completed fiscal years), to which we were a party or will be a party, in which the amounts involved exceeded or will exceed the lesser
of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and any of our directors,
executive officers, or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons,
had or will have a direct or indirect material interest. Compensation arrangements, including employment agreements, for our directors
and named executive officers are described elsewhere in “Executive Compensation - Agreements with Executive Officers.”
Employment
Agreements
Mr.
Joyce receives an annual base salary of $455,000, plus bonus compensation not to exceed 50% of salary. Mr. Joyce’s employment also
provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due
to a change in control. Additionally, the Company has agreed to maintain a beneficial ownership target of 9% for Mr. Joyce. The Company
incurred compensation expense of $455,000 (including accrued compensation of $284,375) and $453,067 for the years ended December 31,
2023 and 2022, respectively.
Sigyn
had no employment agreement with its CTO but Sigyn still incurred compensation on behalf of the CTO. The Company incurred compensation
expense of $225,000 and $233,678 for the years ended December 31, 2023 and 2022, respectively.
Mr.
DeCiccio was hired December 6, 2023 as the Company’s Chief Financial Officer. Mr. DeCiccio receives an annual base salary of $250,000plus
discretionary bonus compensation not to exceed 40% of salary. Mr. DeCiccio’s employment also provides for medical insurance, disability
benefits and three months of severance pay if his employment is terminated without cause or due to a change in control. Additionally,
Mr. DeCiccio will be granted up to 17,500 options to purchase 17,500 of the Company’s common shares.
On
April 1, 2023, the Company entered into an Employment Agreement with Dr. Annette Marleau whereby Dr. Marleau became the Company’s
Chief Scientific Officer. Dr. Marleau receives an annual base salary of $300,000, with automatic 3% annual increases plus bonus compensation
not to exceed 40% of salary. Dr. Marleau’s employment also provides for medical insurance, disability benefits and up to six months
of severance pay if her employment is terminated by the Company. The Company incurred compensation expense of $225,000 (including accrued
compensation of $100,000) and $0 for the years ended December 31, 2023 and 2022, respectively.
Indemnification
Agreements
We
have entered or intend to enter into indemnification agreements with each of our directors and executive officers. These agreements,
among other things, will require us to indemnify each individual to the fullest extent permitted by Delaware law, including indemnification
of expenses such as attorneys’ fees, judgments, fines and settlement amounts incurred by the individual in any action or proceeding,
including any action or proceeding by or in right of us, arising out of the person’s services as a director, officer or other employee.
Policies
and Procedures for Related Party Transactions
Given
our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification
of transactions with our executive officer(s), director(s) and significant shareholders. We rely on our board to review related party
transactions on an ongoing basis to prevent conflicts of interest. Our board reviews a transaction in light of the affiliations of the
director, officer or employee and the affiliations of such person’s immediate family. Transactions are presented to our board for
approval before they are entered into or, if this is not possible, for ratification after the transaction has occurred. If our board
finds that a conflict of interest exists, then it will determine the appropriate remedial action, if any. Our board approves or ratifies
a transaction if it determines that the transaction is consistent with the best interests of the Company. We intend to establish formal
policies and procedures in the future, once we have sufficient resources and have appointed additional directors, so that such transactions
will be subject to the review, approval or ratification of our board of directors, or an appropriate committee thereof.
Item
14. Principal Accounting Fees and Services
The
aggregate fees billed for the most recently completed fiscal period for the audit of our annual financial statements and services normally
provided by the independent registered public accounting firm for this fiscal period were as follows:
| |
FY 2023 | | |
FY 2022 | |
Audit Fees | |
$ | 46,350 | | |
$ | 36,850 | |
Total Fees | |
$ | 46,350 | | |
$ | 36,850 | |
In
the above table, “audit fees” are fees billed by our external auditor for services provided in auditing our annual financial
statements for the subject year. The fees set forth on the foregoing table relate to the audit as of and for the years ended December
31, 2023 and 2022 which were performed by Kreit & Chiu CPA LLP (formerly Paris, Kreit & Chiu CPA LLP). All of the services described
above were approved in advance by the Board of Directors or the Company’s Audit Committee.
PART
IV
Item
15. Exhibits, Financial Statement Schedules.
(a) |
The
following documents are filed as a part of this Annual Report: |
1. |
Financial
Statements. The following consolidated financial statements of the Company are included below: |
Report of Independent Registered Public Accounting Firm.
Consolidated Balance Sheets as of December 31, 2023 and 2022.
Consolidated Statement of Operations for the Years ended December 31, 2023 and 2022.
Consolidated Statements of Shareholders’ Deficit for the Years ended December 31, 2023 and 2022.
Consolidated Statements of Cash Flows for the Years ended December 31, 2023 and 2022.
Notes to Consolidated Financial Statements.
2. |
Financial
Statement Schedule(s): |
All
schedules are omitted for the reason that the information is included in the consolidated financial statements or the notes thereto or
that they are not required or are not applicable.
Exhibit |
|
|
Number |
|
Description |
1.1 |
|
Form
of Underwriting Agreement** |
|
|
|
3.1* |
|
Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware |
|
|
|
3.2* |
|
Bylaws of the Registrant, as currently in effect (Filed as Exhibit 3.2 to the Registration Statement on Form S-1 filed by the Registrant on May 27, 2015, and incorporated herein by reference). |
|
|
|
10.1 |
|
Share Exchange Agreement dated August 25, 2020 (Filed as Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on August 31, 2020 and incorporated herein by reference)* |
|
|
|
10.2 |
|
Operating Lease* |
|
|
|
10.3 |
|
Employment Agreement for Jeremy Ferrell (Filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Registrant on March 9, 2022 and incorporated herein by reference)* |
|
|
|
10.4 |
|
January 2020 Financing Documents and Extensions* |
|
|
|
10.5 |
|
June 23, 2020 Financing Documents* |
|
|
|
10.6 |
|
September 17, 2020 Financing Documents* |
|
|
|
10.7 |
|
Senior Convertible Debenture dated May 10, 2022* |
|
|
|
10.8 |
|
Warrant dated May 10, 2022* |
|
|
|
10.9 |
|
Warrant dated October 18, 2021* |
|
|
|
10.10 |
|
Senior Convertible Debenture dated March 23, 2022* |
10.11 |
|
Warrant dated March 23, 2022* |
|
|
|
10.12 |
|
Senior Convertible Debenture dated March 23, 2022* |
|
|
|
10.13 |
|
Warrant dated March 23, 2022* |
|
|
|
10.14 |
|
Senior Convertible Debenture dated April 28, 2022* |
|
|
|
10.15 |
|
Warrant dated April 28, 2022* |
|
|
|
10.16 |
|
June 1, 2022 Financing Documents* |
|
|
|
10.17 |
|
June 22, 2022 Financing Documents* |
|
|
|
10.18 |
|
Set of Form Documents for July 2022 Financing* |
|
|
|
10.19 |
|
August 31, 2022 Financing Documents* |
|
|
|
10.20 |
|
September 9, 2022 Financing Documents* |
|
|
|
10.21 |
|
October 20, 2022 Financing Documents* |
|
|
|
10.22 |
|
November 9, 2022 Financing Documents* |
|
|
|
10.23 |
|
November 14, 2022 Financing Documents* |
|
|
|
10.24 |
|
November 21, 2022 Financing Documents* |
|
|
|
21.1 |
|
Subsidiaries of the Registrant* |
|
|
|
31.1 |
|
Certification by Principal Executive Officer pursuant to Rule 13a-14(a) |
|
|
|
31.2 |
|
Certification by Principal Financial and Accounting Officer pursuant to Rule 13a-14(a) |
* |
|
Previously
filed. |
|
|
|
** |
|
To
be filed by amendment |
|
|
|
*** |
|
Filed
herewith |
All
references to Registrant’s Forms 8-K, 10-K and 10-Q include reference to File No. 000-55575
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Sigyn
Therapeutics, Inc. |
|
a
Delaware corporation |
|
|
|
Dated:
February 20, 2024 |
By: |
/s/
James Joyce |
|
|
James
Joyce |
|
|
Chief
Executive Officer and Director |
|
|
(Principal
Executive Officer) |
|
|
|
Dated:
February 20, 2024 |
By: |
/s/
Gerald DeCiccio |
|
|
Gerald
DeCiccio |
|
|
Chief
Financial Officer |
|
|
(Principal
Financial and Accounting Officer) |
Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/
Mr. James Joyce |
|
Chief
Executive Officer and Director |
|
February
20, 2024 |
Mr.
James Joyce |
|
|
|
|
|
|
|
|
|
/s/
Mr. Craig Roberts |
|
Chief
Technology Officer and Director |
|
February
20, 2024 |
Mr.
Craig Roberts |
|
|
|
|
|
|
|
|
|
/s/
Mr. Gerald DeCiccio |
|
Chief
Financial Officer |
|
February
20, 2024 |
Mr.
Gerald DeCiccio |
|
|
|
|
|
|
|
|
|
/s/
Richa Nand |
|
Director |
|
February
20, 2024 |
Richa
Nand |
|
|
|
|
|
|
|
|
|
/s/
Jim Dorst |
|
Director |
|
February
20, 2024 |
Jim
Dorst |
|
|
|
|
|
|
|
|
|
/s/
Chris Wetzel |
|
Director |
|
February
20, 2024 |
Chris
Wetzel |
|
|
|
|
SIGYN
THERAPEUTICS, INC.
Index
to Financial Statements
CONTENTS
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Stockholders
of
Sigyn Therapeutics, Inc.
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Sigyn Therapeutics, Inc. (the “Company”) as of December 31,
2023 and 2022, and the related consolidated statements of operations, changes in shareholders’ equity, and cash flows for each
of the two years ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023,
in conformity with accounting principles generally accepted in the United States of America.
Going
Concern
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a net capital deficiency, and negative
cash flows from operating activities, therefore, the Company has stated that substantial doubt exists about its ability to continue as
a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.
/s/ Kreit & Chiu CPA LLP
We
have served as the Company’s auditor since 2021.
New
York, New York
February
20, 2024
SIGYN
THERAPEUTICS, INC.
CONSOLIDATED
BALANCE SHEETS
| |
2023 | | |
2022 | |
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash | |
$ | 11,690 | | |
$ | 8,356 | |
Inventories | |
| 50,000 | | |
| 50,000 | |
Other current assets | |
| 56,373 | | |
| 11,942 | |
Total current assets | |
| 118,063 | | |
| 70,298 | |
| |
| | | |
| | |
Property and equipment, net | |
| 15,296 | | |
| 22,052 | |
Intangible assets, net | |
| - | | |
| 2,100 | |
Operating lease right-of-use assets, net | |
| 167,736 | | |
| 217,718 | |
Other assets | |
| 20,711 | | |
| 20,711 | |
Total assets | |
$ | 321,806 | | |
$ | 332,879 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 461,646 | | |
$ | 327,517 | |
Accrued payroll and payroll taxes | |
| 791,754 | | |
| 30,124 | |
Advance from shareholder | |
| 80,000 | | |
| - | |
Short-term convertible notes payable, less unamortized debt issuance costs of $297,337 and $642,660, respectively | |
| 2,210,299 | | |
| 1,636,656 | |
Current portion of operating lease liabilities | |
| 61,123 | | |
| 53,200 | |
Other current liabilities | |
| 3,182 | | |
| 1,197 | |
Total current liabilities | |
| 3,608,004 | | |
| 2,048,694 | |
Long-term liabilities: | |
| | | |
| | |
Operating lease liabilities, net of current portion | |
| 126,302 | | |
| 187,425 | |
Total long-term liabilities | |
| 126,302 | | |
| 187,425 | |
Total liabilities | |
| 3,734,306 | | |
| 2,236,119 | |
| |
| | | |
| | |
Stockholders’ deficit: | |
| | | |
| | |
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 32 and no shares issued and outstanding at December 31, 2023 and 2022, respectively | |
| - | | |
| - | |
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 1,288,415 and 956,595 shares issued and outstanding at December 31, 2023 and 2022, respectively | |
| 129 | | |
| 96 | |
Additional paid-in capital | |
| 7,928,883 | | |
| 5,292,240 | |
Accumulated deficit | |
| (11,341,512 | ) | |
| (7,195,576 | ) |
Total stockholders’ deficit | |
| (3,412,500 | ) | |
| (1,903,240 | ) |
Total liabilities and stockholders’ deficit | |
$ | 321,806 | | |
$ | 332,879 | |
See
accompanying notes to consolidated financial statements
SIGYN
THERAPEUTICS, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Net revenues | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Gross Profit | |
| - | | |
| - | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Marketing expenses | |
| 392 | | |
| 457 | |
Research and development | |
| 798,165 | | |
| 657,657 | |
General and administrative | |
| 1,656,760 | | |
| 1,489,151 | |
Total operating expenses | |
| 2,455,317 | | |
| 2,147,265 | |
Loss from operations | |
| (2,455,317 | ) | |
| (2,147,265 | ) |
| |
| | | |
| | |
Other expense (income): | |
| | | |
| | |
Modification of warrants | |
| (352,965 | ) | |
| - | |
Interest expense | |
| 2,402 | | |
| 438 | |
Interest expense - debt discount | |
| 1,755,995 | | |
| 646,302 | |
Interest expense - original issuance costs | |
| 285,187 | | |
| 135,812 | |
Total other expense | |
| 1,690,619 | | |
| 782,552 | |
| |
| | | |
| | |
Income taxes | |
| - | | |
| - | |
| |
| | | |
| | |
Net loss | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
| |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (3.77 | ) | |
$ | (3.13 | ) |
| |
| | | |
| | |
Weighted average number of shares outstanding | |
| | | |
| | |
Basic and diluted | |
| 1,100,372 | | |
| 934,915 | |
See
accompanying notes to consolidated financial statements
SIGYN
THERAPEUTICS, INC.
CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Paid-in Capital | | |
Deficit | | |
Deficit | |
| |
Preferred Stock | | |
Common Stock | | |
Additional | | |
Accumulated | | |
Total Stockholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Paid-in Capital | | |
Deficit | | |
Deficit | |
Balance as of December 31, 2021 | |
| - | | |
$ | - | | |
| 932,395 | | |
$ | 93 | | |
$ | 4,001,082 | | |
$ | (4,265,759 | ) | |
$ | (264,584 | ) |
Warrants issued to third parties in conjunction with debt issuance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 793,039 | | |
| - | | |
| 793,039 | |
Beneficial conversion feature in conjunction with debt issuance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 273,700 | | |
| - | | |
| 273,700 | |
Amortization of warrants issued in connection with a debt modification | |
| - | | |
| - | | |
| - | | |
| - | | |
| 147,720 | | |
| - | | |
| 147,720 | |
Common stock issued to third parties in conjunction with conversion of debt | |
| - | | |
| - | | |
| 24,200 | | |
| 3 | | |
| 145,197 | | |
| - | | |
| 145,200 | |
Fees associated with filing of Form S-1 | |
| - | | |
| - | | |
| - | | |
| - | | |
| (68,498 | ) | |
| - | | |
| (68,498 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,929,817 | ) | |
| (2,929,817 | ) |
Balance as of December 31, 2022 | |
| - | | |
$ | - | | |
| 956,595 | | |
$ | 96 | | |
$ | 5,292,240 | | |
$ | (7,195,576 | ) | |
$ | (1,903,240 | ) |
Beginning balance, value | |
| - | | |
$ | - | | |
| 956,595 | | |
$ | 96 | | |
$ | 5,292,240 | | |
$ | (7,195,576 | ) | |
$ | (1,903,240 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Warrants issued to third parties in conjunction with debt issuance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 858,276 | | |
| - | | |
| 858,276 | |
Beneficial conversion feature in conjunction with debt issuance | |
| - | | |
| - | | |
| - | | |
| - | | |
| 401,063 | | |
| - | | |
| 401,063 | |
Stock-based compensation | |
| - | | |
| - | | |
| - | | |
| - | | |
| 215,558 | | |
| - | | |
| 215,558 | |
Common stock issued to third parties in conjunction with conversion of debt | |
| - | | |
| - | | |
| 213,584 | | |
| 21 | | |
| 1,520,179 | | |
| | | |
| 1,520,200 | |
Modification of warrants | |
| - | | |
| - | | |
| 279,920 | | |
| 28 | | |
| (352,993 | ) | |
| - | | |
| (352,965 | ) |
Conversion of common stock for Series A preferred stock | |
| 32 | | |
| - | | |
| (161,684 | ) | |
| (16 | ) | |
| 16 | | |
| | | |
| - | |
Fees associated with filing of Form S-1 | |
| - | | |
| - | | |
| - | | |
| - | | |
| (5,456 | ) | |
| - | | |
| (5,456 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (4,145,936 | ) | |
| (4,145,936 | ) |
Balance as of December 31, 2023 | |
| 32 | | |
$ | - | | |
| 1,288,415 | | |
$ | 129 | | |
$ | 7,928,883 | | |
$ | (11,341,512 | ) | |
$ | (3,412,500 | ) |
Ending
balance, value | |
| 32 | | |
$ | - | | |
| 1,288,415 | | |
$ | 129 | | |
$ | 7,928,883 | | |
$ | (11,341,512 | ) | |
$ | (3,412,500 | ) |
See
accompanying notes to consolidated financial statements
SIGYN
THERAPEUTICS, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Cash flows from operating activities: | |
| | | |
| | |
Net loss | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation expense | |
| 6,756 | | |
| 6,854 | |
Amortization expense | |
| 2,100 | | |
| 3,600 | |
Stock based compensation | |
| 215,558 | | |
| - | |
Accretion of debt discount | |
| 1,755,995 | | |
| 646,302 | |
Accretion of original issuance costs | |
| 285,187 | | |
| 135,812 | |
Modification of warrants | |
| (352,965 | ) | |
| - | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Other current assets | |
| (44,431 | ) | |
| (9,867 | ) |
Accounts payable | |
| 196,629 | | |
| 287,843 | |
Accrued payroll and payroll taxes | |
| 699,130 | | |
| 29,052 | |
Other current liabilities | |
| (1,233 | ) | |
| (21 | ) |
Net cash used in operating activities | |
| (1,383,210 | ) | |
| (1,830,242 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchase of property and equipment | |
| - | | |
| (860 | ) |
Net cash used in investing activities | |
| - | | |
| (860 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from short-term convertible notes | |
| 1,312,000 | | |
| 1,567,000 | |
Advance from shareholder | |
| 80,000 | | |
| - | |
Fees associated with filing of Form S-1 | |
| (5,456 | ) | |
| (68,498 | ) |
Net cash provided by financing activities | |
| 1,386,544 | | |
| 1,498,502 | |
| |
| | | |
| | |
Net (decrease) increase in cash | |
| 3,334 | | |
| (332,600 | |
| |
| | | |
| | |
Cash at beginning of period | |
$ | 8,356 | | |
$ | 340,956 | |
Cash at end of period | |
$ | 11,690 | | |
$ | 8,356 | |
| |
| | | |
| | |
Supplemental disclosures of cash flow information: | |
| | | |
| | |
Cash paid during the period for: | |
| | | |
| | |
Interest | |
$ | - | | |
$ | - | |
Income taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
Non-cash investing and financing activities: | |
| | | |
| | |
Beneficial conversion feature in conjunction with debt issuance | |
$ | 401,063 | | |
$ | 273,700 | |
Amortization of warrants issued in connection with a debt modification | |
$ | - | | |
$ | 147,720 | |
Warrants issued to third parties in conjunction with debt issuance | |
$ | 858,276 | | |
$ | 793,039 | |
Original issue discount issued in conjunction with debt | |
$ | 131,200 | | |
$ | 156,700 | |
Original issue discount issued in conjunction with extension of debt | |
$ | 305,320 | | |
$ | - | |
Common stock issued to third parties in conjunction with conversion of debt | |
$ | 1,520,200 | | |
$ | 145,200 | |
Conversion of common stock for Series A preferred stock | |
| 16 | | |
| - | |
See
accompanying notes to consolidated financial statements
SIGYN
THERAPEUTICS, INC.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR
THE YEARS ENDED DECEMBER 31, 2023 AND 2022
NOTE
1 – ORGANIZATION AND PRINCIPAL ACTIVITIES
Corporate
History and Background
Sigyn
Therapeutics, Inc. (“Sigyn”, the “Company” “we,” “us,” or “our”) is a development-stage
company that creates blood purification technologies to overcome clearly defined limitations in healthcare.
Sigyn
Therapy™, our lead product candidate, is being advanced to treat life-threatening conditions that are not addressed with market-cleared
drug agents. Candidate treatment indications include endotoxemia, sepsis (a leading cause of hospital deaths), community acquired pneumonia
(a leading cause of infectious disease deaths), drug-resistant bacterial infections, and emerging pandemic viral threats.
Our
therapeutic pipeline is comprised of technologies that we have designed to improve the targeted delivery of cancer drug agents. ChemoPrepTM
and ChemoPureTM are components of a therapeutic system to improve the delivery of chemotherapy and reduce its toxicity.
ImmunePrepTM is a novel platform to enhance the potential efficacy of immunotherapeutic antibodies (including checkpoint inhibitors).
At present, we have no market approved medical products and there is no assurance that we will be able to commercialize any of our product
candidates.
Merger
Transaction
On
October 19, 2020, Sigyn Therapeutics, Inc, a Delaware corporation (the “Registrant”) formerly known as Reign Resources Corporation,
completed a Share Exchange Agreement (the “Agreement”) with Sigyn Therapeutics, Inc., a private entity incorporated in the
State of Delaware on October 19, 2019.
In
the Share Exchange Agreement, we acquired 100% of the issued and outstanding shares of privately held Sigyn Therapeutics common stock
in exchange for 75% of the fully paid and nonassessable shares of our common stock outstanding (the “Acquisition”). In conjunction
with the transaction, we changed our name from Reign Resources Corporation to Sigyn Therapeutics, Inc. pursuant to an amendment to our
articles of incorporation that was filed with the State of Delaware. Subsequently, our trading symbol was changed to SIGY. The Acquisition
was treated by the Company as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(“GAAP”). For accounting purposes, Sigyn is considered to have acquired Reign Resources Corporation as the accounting acquirer
because: (i) Sigyn stockholders own 75% of the combined company, on an as-converted basis, immediately following the Closing Date, (ii)
Sigyn directors hold a majority of board seats in the combined company and (iii) Sigyn management held all key positions in the management
of the combined company. Accordingly, Sigyn’s historical results of operations will replace Reign Resources Corporation’s
historical results of operations for all periods prior to the Acquisition and, for all periods following the Acquisition, the results
of operations of the combined company will be included in the Company’s financial statements. The Acquisition was treated as a
“tax-free exchange” under Section 368 of the Internal Revenue Code of 1986 and resulted in the private Sigyn Therapeutics
corporate entity (established on October 29, 2019) to become a wholly owned subsidiary of Reign Resources Corporation. Among the conditions
for closing the acquisition, the Reign Resources Corporation extinguished all previously reported liabilities, its preferred class of
shares, and all stock purchase options. As a result, the reported liabilities totaling $3,429,516 were converted into a total of 7,907,351
common shares. Additionally, assets held on the books of Reign Resources Corporation, such as Gem inventory, was kept in the Company
and therefore recorded as assets on the Share Exchange date. Upon the closing of the Acquisition, we appointed James A. Joyce and Craig
P. Roberts to serve as members of our Board of Directors.
Effective
January 19, 2024, Board of Directors declared a one-for-forty reverse stock split to shareholders of record on or before January 31,
2024 of the Company’s issued and outstanding shares of common stock, outstanding warrants and options, and the Series B
Convertible Preferred Stock. The number of shares of common stock and convertible preferred shares obtainable upon exercise or
conversion and the exercise prices and conversion rate have been equitably adjusted. As such, all
share and per share amounts have been retroactively adjusted to reflect the reverse stock split.
As
of February 16, 2024, we have a total of 1,224,315
shares issued and outstanding, of which 647,415
shares are held by non-affiliate stockholders.
NOTE
2 – BASIS OF PRESENTATION
The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America and include all adjustments necessary for the fair presentation of the Company’s financial position and results of operations
for the periods presented.
The
Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business.
A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the
entire business. The Company does not currently operate any separate lines of businesses or separate business entities.
Going
Concern
The
accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated
deficit of $11,341,512 at December 31, 2023, had a working capital deficit of $3,489,941 at December 31, 2023, had net losses of $4,145,936
and $2,929,817 for the years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $1,383,210
and $1,830,242 for the years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational
history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.
While
the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough
to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset
sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues
provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to
generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or
on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability
to further implement its business plan and generate revenues.
The
financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
This
summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements.
The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and
objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements.
Use
of Estimates
The
preparation of these financial statements in accordance with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and
expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the
financial statements. The more significant estimates and assumptions by management include among others: warrant valuation. The
Company calculates the fair value of warrants using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method
requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest
rate and the fair value of the underlying common stock on the date of grant. The current economic environment has increased the
degree of uncertainty inherent in these estimates and assumptions.
Cash
The
Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC)
up to $250,000. The Company has not experienced any cash losses.
Income
Taxes
Income
taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences
between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance
with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its
deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation
allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated
Statements of Operations.
ASC
740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and
prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to
be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized
at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation
of ASC 740-10 and currently, the Company does not have a liability for unrecognized income tax benefits.
Advertising
and Marketing Costs
Advertising
expenses are recorded as general and administrative expenses when they are incurred. The Company had $392 of advertising expenses for
the year ended December 31, 2023 and had $457 of advertising expenses for the year ended December 31, 2022.
Research
and Development
All
research and development costs are expensed as incurred. The Company incurred research and development expense of $798,165 and $657,657
for the years ended December 31, 2023 and 2022, respectively.
Inventories
In
conjunction with the October 19, 2020 Share Exchange Agreement, the Company kept the gem inventory of Reign Resources Corporation. Inventories
are stated at the lower of cost or market (net realizable value) on a lot basis each quarter. A lot is determined by the cut, clarity,
size, and weight of the sapphires. Inventory consists of sapphire jewels that meet rigorous grading criteria and are of cuts and sizes
most commonly used in the jewelry industry. As of December 31, 2023 and 2022, the Company carried primarily loose sapphire jewels, jewelry
for sale, and jewelry held as samples. Samples are used to show potential customers what the jewelry would look like. Promotional items
given to customers that are not expected to be returned will be removed from inventory and expensed. There have been no promotional items
given to customers as of December 31, 2023. The Company performs its own in-house assessment based on gem guide and the current market
price for metals to value its inventory on an annual basis or if circumstances dictate sooner to determine if the estimated fair value
is greater or less than cost. In addition, the inventory is reviewed each quarter by the Company against industry prices from gem-guide
and if there is a potential impairment, the Company would appraise the inventory. The estimated fair value is subject to significant
change due to changes in popularity of cut, perceived grade of the clarity of the sapphires, the number, type and size of inclusions,
the availability of other similar quality and size sapphires, and other factors. As a result, the internal assessed value of the sapphires
could be significantly lower from the current estimated fair value. Loose sapphire jewels do not degrade in quality over time.
Property
and Equipment
Property
and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally
five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets
are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are
included in income in the year of disposition.
Intangible
Assets
Intangible
assets consist primarily of website development costs. Our intangible assets are being amortized on a straight-line basis over a period
of three years.
Impairment
of Long-lived Assets
We
periodically evaluate whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate
the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted
cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment
loss is measured as the excess of the asset’s carrying value over its fair value.
Our
impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting
useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent
in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted
techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash
flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to
new information, we may be exposed to an impairment charge in the future. As of December 31, 2023 and 2022, the Company had not experienced
impairment losses on its long-lived assets.
Fair
Value of Financial Instruments
The
provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines
fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing
parties. As of December 31, 2023 and 2022, the fair value of cash, accounts payable, accrued expenses, advance from shareholder, and
notes payable approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which
fluctuate with market rates.
Fair
Value Measurements
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
as follows:
|
● |
Level
1 – Quoted prices in active markets for identical assets or liabilities. |
|
|
|
|
● |
Level
2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets
or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities. |
|
|
|
|
● |
Level
3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the
fair value of the assets or liabilities |
The
carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial
assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There
were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and
liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There
have been no transfers between levels.
Debt
The
Company issues debt that may have separate warrants, conversion features, or no equity-linked attributes.
Embedded
Conversion Features
The
Company evaluates embedded conversion features within convertible debt under ASC 815, Derivatives and Hedging, to determine whether
the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with
changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument
is evaluated under ASC 470-20, Debt with Conversion and Other Options, for consideration of any beneficial conversion feature.
Derivative
Financial Instruments
The
Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported as charges or credits to income.
For
option-based simple derivative financial instruments, the Company uses the Monte Carlo simulations to value the derivative instruments
at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. There were no derivative financial instruments
as of December 31, 2023 and 2022 and no charges or credits to income for the years ended December 31, 2023 and 2022.
Debt
Issue Costs and Debt Discount
The
Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs
may be paid in the form of cash or equity (such as warrants). These costs are amortized to interest expense through the maturity of the
debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized debt issue costs and debt discount are presented net of the related debt on the consolidated balance sheets.
Original
Issue Discount
For
certain convertible debt issued, the Company may provide the debt holder with an original issue discount. The original issue discount
would be recorded to debt discount, reducing the face amount of the note and is amortized to interest expense through the maturity of
the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized original issue discounts are presented net of the related debt on the consolidated balance sheets.
If
the conversion feature does not qualify for either the derivative treatment or as a beneficial conversion feature (“BCF”),
the convertible debt is treated as traditional debt.
Basic
and diluted earnings per share
Basic
net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period,
without consideration for common stock equivalents. Diluted earnings (loss) per share are computed on the basis of the weighted average
number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting
period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents,
because their inclusion would be anti-dilutive.
Basic
and diluted earnings (loss) per share are the same since net losses for all periods presented and including the additional potential
common shares would have an anti-dilutive effect.
Stock
Based Compensation
In
accordance with ASC No. 718, Compensation – Stock Compensation (“ASC 718”), we measure the compensation costs
of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over
the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted
share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.
Non-Employee
Stock-Based Compensation
In
accordance with ASC 505, Equity Based Payments to Non-Employees, issuances of the Company’s common stock or warrants for
acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants
or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached
(a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive
for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may
be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on
the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the
date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the
instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement
of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial
reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is
measured at the then-current fair values at each of those interim financial reporting dates.
Concentrations,
Risks, and Uncertainties
Business
Risk
Substantial
business risks and uncertainties are inherent to an entity, including the potential risk of business failure.
The
Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can
be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on
the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is
subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general
economic conditions, price of components, competition, and governmental and political conditions.
Interest
rate risk
Financial
assets and liabilities do not have material interest rate risk.
Credit
risk
The
Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are
recognized financial institutions.
Seasonality
The
business is not subject to substantial seasonal fluctuations.
Major
Suppliers
Sigyn
Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on a
third-party organization to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the
marketplace.
Should
the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed
that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement
of Sigyn Therapy.
Recent
Accounting Pronouncements
There
are no recently issued accounting updates that are expected to have a material impact on the Company’s consolidated financial statements.
NOTE
4 – PROPERTY AND EQUIPMENT
Property
and equipment consisted of the following as of:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
Estimated Life | |
December 31, 2023 | | |
December 31, 2022 | |
| |
| |
| | |
| |
Office equipment | |
5 years | |
$ | 29,041 | | |
$ | 29,041 | |
Computer equipment | |
3 years | |
| 3,157 | | |
| 3,157 | |
Property and equipment, gross | |
3 years | |
| 3,157 | | |
| 3,157 | |
Accumulated depreciation | |
| |
| (16,902 | ) | |
| (10,146 | ) |
Property and equipment, net | |
| |
$ | 15,296 | | |
$ | 22,052 | |
Depreciation
expense was $6,756 and $6,854 for the years ended December 31, 2023 and 2022, respectively, and is classified in general and administrative
expenses in the Consolidated Statements of Operations.
NOTE
5 – INTANGIBLE ASSETS
Intangible
assets consisted of the following as of:
SCHEDULE OF INTANGIBLE ASSETS
| |
Estimated life | |
December
31, 2023 | | |
December
31, 2022 | |
Website | |
3 years | |
$ | 10,799 | | |
$ | 10,799 | |
Accumulated amortization | |
| |
| (10,799 | ) | |
| (8,699 | ) |
Intangible assets, net | |
| |
$ | - | | |
$ | 2,100 | |
The
Company had amortization expense of $2,100 and $3,600 for the years ended December 31, 2023 and 2022, respectively.
NOTE
6 – CONVERTIBLE PROMISSORY DEBENTURES
Convertible
notes payable consisted of the following:
SCHEDULE OF CONVERTIBLE NOTES PAYABLE
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
June 23, 2020 ($74,621) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 2”) | |
| 74,621 | | |
| 60,500 | |
September 17, 2020 ($225,377) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 3”). | |
| 225,377 | | |
| 182,936 | |
March 23, 2022 ($259,685) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 4”) | |
| 259,685 | | |
| 220,000 | |
April 28, 2022 ($127,979) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 5”) | |
| 127,979 | | |
| 110,000 | |
May 10, 2022 ($128,020) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 6”) | |
| 128,020 | | |
| 110,000 | |
June 1, 2022 ($63,301) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 7”) | |
| 63,302 | | |
| 55,000 | |
June 22, 2022 ($94,314) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 8”) | |
| 94,314 | | |
| 82,500 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $341,000 of principal of the Note into 17,050 common shares (“Note 9”) | |
| - | | |
| 341,000 | |
August 31, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 10”) | |
| 123,200 | | |
| 110,000 | |
September 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024 (“Note 11”) | |
| 92,400 | | |
| 82,500 | |
September 20, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 12”) | |
| 123,200 | | |
| 110,000 | |
October 20, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due October 20, 2023 (“Note 13”) | |
| 110,000 | | |
| 110,000 | |
November 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 14”) | |
| 92,400 | | |
| 82,500 | |
November 14, 2022 ($55,000) – 0% interest per annum outstanding principal and interest due November 14, 2023 (“Note 15”) | |
| 55,000 | | |
| 55,000 | |
December 22, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due December 22, 2023 (“Note 16”) | |
| 110,000 | | |
| 110,000 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $1,179,200 of principal of the Note into 196,534 common shares (“Note 17”) | |
| 264,000 | | |
| - | |
| |
| | | |
| | |
Total convertible notes payable | |
| 2,507,636 | | |
| 2,279,316 | |
Original issue discount | |
| (225,835 | ) | |
| (74,502 | ) |
Beneficial conversion feature | |
| (22,013 | ) | |
| (175,275 | ) |
Debt discount | |
| (49,489 | ) | |
| (392,883 | ) |
| |
| | | |
| | |
Total convertible notes payable | |
$ | 2,210,299 | | |
$ | 1,636,656 | |
Principal
payments on convertible promissory debentures are due as follows:
SCHEDULE OF PRINCIPAL PAYMENTS DUE ON CONVERTIBLE PROMISSORY DEBENTURES
Year ending December 31, | |
| |
2024 | |
$ | 2,507,636 | |
Long-Term Debt | |
$ | 2,507,636 | |
Changes
in convertible notes were as follows:
SCHEDULE OF CHANGES IN CONVERTIBLE NOTES
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Convertible notes payable, net, as of December 31, 2021 | |
| 457,380 | | |
| 60,500 | | |
| 182,936 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 700,816 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2022 | |
| - | | |
| - | | |
| - | | |
| 220,000 | | |
| 110,000 | | |
| 110,000 | | |
| 55,000 | | |
| 82,500 | | |
| 341,000 | | |
| 110,000 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,578,500 | |
Convertible notes payable as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
Convertible notes payable, Begining balance | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Convertible notes payable issued | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Conversion of debt for common stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (341,000 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,179,200 | ) | |
| - | | |
| (1,520,200 | ) |
Convertible notes payable as of December 31, 2023 | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
Convertible notes payable, Ending balance | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
Changes
in note discounts were as follows:
SCHEDULE OF CHANGES IN NOTE DISCOUNTS
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Note discounts as of December 31, 2021 | |
| 34,176 | | |
| 4,521 | | |
| 14,917 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 53,614 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2022 | |
| - | | |
| - | | |
| - | | |
| 113,418 | | |
| 44,786 | | |
| 44,787 | | |
| 22,794 | | |
| 34,861 | | |
| 140,289 | | |
| 64,104 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,015,039 | |
2022 accretion of note discounts | |
| (34,176 | ) | |
| (4,521 | ) | |
| (14,917 | ) | |
| (87,938 | ) | |
| (30,308 | ) | |
| (28,836 | ) | |
| (13,301 | ) | |
| (18,336 | ) | |
| (70,720 | ) | |
| (32,316 | ) | |
| (39,994 | ) | |
| (49,874 | ) | |
| (23,671 | ) | |
| (12,822 | ) | |
| (7,726 | ) | |
| (6,537 | ) | |
| - | | |
| 50,000 | | |
| (425,993 | ) |
Note discounts as of December 31, 2022 | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
Note discounts, Begining balance | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
Note discounts issued in conjunction with debt | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
2023 accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Note discounts as of December 31, 2023 | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
Note discounts, Ending balance | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable, net, as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 194,520 | | |
$ | 95,522 | | |
$ | 94,049 | | |
$ | 45,507 | | |
$ | 65,975 | | |
$ | 271,431 | | |
$ | 78,212 | | |
$ | 39,994 | | |
$ | 49,874 | | |
$ | 23,671 | | |
$ | 12,822 | | |
$ | 7,726 | | |
$ | 6,537 | | |
$ | - | | |
$ | (50,000 | ) | |
$ | 1,636,656 | |
Convertible notes payable, net, as of December 31, 2023 | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
Convertible notes payable, net | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
2022 Effective interest rate | |
| 7 | % | |
| 7 | % | |
| 8 | % | |
| 40 | % | |
| 28 | % | |
| 26 | % | |
| 24 | % | |
| 22 | % | |
| 21 | % | |
| 29 | % | |
| 48 | % | |
| 45 | % | |
| 22 | % | |
| 16 | % | |
| 14 | % | |
| 6 | % | |
| -% | | |
| -% | | |
| 19 | % |
2023 Effective interest rate | |
| 6 | % | |
| 6 | % | |
| 6 | % | |
| 14 | % | |
| 15 | % | |
| 17 | % | |
| 19 | % | |
| 21 | % | |
| - | % | |
| 29 | % | |
| 49 | % | |
| 52 | % | |
| 78 | % | |
| 78 | % | |
| 86 | % | |
| 94 | % | |
| 496 | % | |
| -% | | |
| 81 | % |
Current
Noteholders
2023
Notes – $1,443,200 (Note 17)
During
the year ended December 31, 2023, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2023
Notes”) with third party investors totaling (i) $1,443,200 aggregate principal amount of Note due on various dates from January
2024 through December 7, 2024 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase
Warrants (“Warrants”) to purchase up to an aggregate of 233,200 shares of the Company’s Common Stock at an exercise
price of $10.00 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance
of the Note and Warrants was $1,312,000 which was issued at a $131,200 original issue discount from the face value of the Note. The conversion
price for the principal in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to
adjustment as provided therein, such as stock splits and stock dividends.
On
June 2, 2023, a third-party investor elected to convert $181,500 of principal of the Note into 30,250 common shares.
In
October 2023, the holders of $997,700 of Original Issue Discount Senior Convertible Debentures converted their debentures at a contractual
exercise price of $10.00 per share in exchange for the issuance of 166,284 shares of Common Stock to the holders.
Osher
– $110,000 (Note 16)
On
December 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due December 22, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $55,000 (Note 15)
On
November 14, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due November 14, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 9,167 shares of the Company’s Common Stock at an exercise price of $10.00
per share. The aggregate cash subscription amount received by the Company from Osher noteholder for the issuance of the Note and Warrants
was $50,000 which was issued at a $5,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Brio
– $92,400 (Note 14)
On
November 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $82,500 aggregate principal
amount of Note due November 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $110,000 (Note 13)
On
October 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due October 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $123,200 (Note 12)
On
September 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due September 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Brio
– $92,400 (Note 11)
On
September 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $82,500 aggregate principal
amount of Note due September 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants
was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $123,200 (Note 10)
On
August 31, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due August 31, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Other
– $341,000 (Note 9)
In
July 2022, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “July 2022 Notes”) totaling
(i) $341,000 aggregate principal amount of Note (total of $310,000 cash was received) due in various dates in July 2023 based on $1.00
for each $0.90909 paid by the noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to
an aggregate of 16,923 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The conversion price for
the principal in connection with voluntary conversions by the holders of the convertible notes is $20.00 per share.
In
October 2023, the noteholders converted the remaining $324,500 in exchange for the issuance of 16,225 shares of Common Stock to the holders.
On
June 2, 2023, a third-party investor elected to convert $16,500 of principal of the Note into 825 common shares.
Osher
– $94,314 (Note 8)
On
June 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $82,500 aggregate principal
amount of Note due June 22, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 4,125 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $11,814.
Osher
– $63,302 (Note 7)
On
June 1, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due June 1, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 2,750 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,000 which was issued at
a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $8,302.
Brio
– $128,020 (Note 6)
On
May 10, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due May 10, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $18,020.
Osher
– $127,979 (Note 5)
On
April 28, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due April 28, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $17,979.
Osher
– $129,721 (Note 4)
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $19,721.
Brio
– $129,964 (Note 4)
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $19,964.
Osher
– $225,377 (Note 3)
On
September 17, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $181,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due September
30, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to
purchase up to an aggregate of 206 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $165,000 which was issued at
a $16,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided
therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated September 17, 2020, for the number of warrant shares from 206 warrant shares to 11,634 warrant
shares at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
October 28, 2021, Osher elected to convert $16,714 of the aggregate principal amount of the Note of $199,650, into 1,071 common shares.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $42,441.
Osher
– $74,621 (Note 2)
On
June 23, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due June 23,
2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase
up to an aggregate of 250 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate cash
subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at a $0
original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions
by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received
by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at an amended $4,995 original issue
discount from the face value of the Note. |
|
|
|
|
● |
The
parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 250 warrant shares to 3,526 warrant shares
at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows (see Note 12):
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $14,121.
Osher
– $564,138 (Note 1)
On
January 28, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $385,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture due January 26, 2021, based on $1.00
for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants to purchase up to an aggregate of 2,005 shares of the
Company’s Common Stock at an exercise price of $280.00 per share. The aggregate cash subscription amount received by the Company
from Osher for the issuance of the note and warrants was $350,005 which was issued at a $34,995 original issue discount from the face
value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes
is $3.76 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated January 28, 2020, for the number of warrant shares from 2,005 warrant shares to 102,827 warrant
shares at an exercise price of $5.60 per share. |
|
|
|
|
● |
The
parties amended the Note to provide for interest at 8% per annum. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $106,758.
Previous
Noteholders
Other
– $145,200
On
November 21, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with a third-party
investor of (i) $145,200 aggregate principal amount of Note due November 21, 2023 based on $1.00 for each $0.90909 paid by the previous
noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 24,200 shares
of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate cash subscription amount received by the
Company from the previous noteholder for the issuance of the Note and Warrants was $132,000 which was issued at a $13,200 original issue
discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder
of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.
On
November 23, 2022, third party investor elected to convert the aggregate principal amount of the Note, $145,200, into 24,200 common shares.
All
other previous notes were detailed in our Form 10-K filed on March 31, 2023. No changes occurred related to these notes during the period
covered by this Form 10-K.
NOTE
7 – ADVANCE FROM SHAREHOLDER
The
Company borrows funds from the Company’s CEO for working capital purposes from time to time. The Company has recorded the principal
balance due of $80,000 and $0 under Advance From Shareholder in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively.
The Company received advances of $80,000 and $0 and had no repayments for the years ended December 31, 2023 and 2022, respectively. The
advance from our CEO was not made pursuant to any loan agreements or promissory notes, is non-interest bearing and due on demand.
NOTE
8 – STOCKHOLDERS’ DEFICIT
Preferred
Stock
The
Company authorized 10,000,000 shares of par value $0.0001 preferred stock, of which 32 and none shares are issued and outstanding at
December 31, 2023 and 2022, respectively.
During
fiscal 2023, holders of 161,684 shares of common stock elected to exchange these shares for an aggregate of 32 shares of Series B Convertible
Preferred Stock. Each Series B Convertible Preferred Share converts into 5,025.1 shares of the Company’s common stock, subject
to antidilution adjustments for any stock splits and recapitalizations, and for issuances of additional shares at an issue price of less
than the conversion ratio in the Warrant Exchange Agreement.
Rights
and Privileges - The holders of Series B preferred stock have various rights and preferences as follows:
Rights
- The holders of the Series B preferred stock have the same rights as the Common Stock, on an “as-if” converted
basis, with respect to any dividends, distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization,
merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily.
Voting
Rights - Shares of Series B preferred stock have no voting rights except on matters adversely affecting the rights of the
holders of the Preferred Stock.
Rank
- With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Corporation,
whether voluntary or involuntary, the Series B Preferred Stock shall rank equal to the Common Stock on an as converted basis.
Conversion
Rights - The holders of the preferred stock have certain conversion rights of such preferred stock into shares of common stock
of the Company. Each share of preferred stock is convertible at the option of the holder at any time into the number of shares of common
stock at the quotient of the stated value divided by the conversion price, subject to customary adjustments to protect against dilution.
Redemption
Rights – The Series B preferred stock is not subject to any redemption rights.
Common
Stock
The
Company has authorized 1,000,000,000 shares of par value $0.0001 common stock, of which 1,288,415 and 956,595 shares are outstanding
as of December 31, 2023 and 2022, respectively.
During
the year ended December 31, 2023, a total of 559,839 warrants were exchanged for 279,920 shares of the Company’s common stock.
On
June 2, 2023, a third-party investor elected to convert the aggregate principal amount of two Notes of $198,000, into 31,075 common shares.
Restricted
Stock Units
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Effective January 1, 2023, each Director shall receive an
annual grant of restricted stock units of $50,000. During the years ended December 31, 2023 and 2022, respectively, the Company recorded
stock-based compensation totaling $150,000 and $0, respectively, in the consolidated Statements of Operations (see Note 13).
Reverse
Stock Split
Effective
January 19, 2024, Board of Directors declared a one-for-forty
reverse stock split to shareholders of record on or before January 31, 2024 of the Company’s issued and outstanding
shares of common stock, outstanding warrants and options, and the Series B Convertible Preferred Stock. The number of shares of
common stock and convertible preferred shares obtainable upon exercise or conversion and the exercise prices and conversion rate
have been equitably adjusted. As such, all share and per share amounts have been retroactively
adjusted to reflect the reverse stock split.
Warrants
In
accordance with ASC 718-20, Compensation – Stock Compensation, a modification of a stock award is treated as an exchange
of the original award for a new award incurring additional compensation cost for any incremental value resulting from the modification.
Incremental compensation cost shall be measured as the excess of the fair value of the modified award over the fair value of the original
award immediately before its terms are modified and recognized over the vesting period. A short-term inducement shall be accounted for
as a modification of the terms of only those that accept the inducement.
In
March 2023, the Company offered a short-term inducement to the Company’s third party warrant holders in which the Company will
issue one share of the Company’s common stock in exchange for each two warrants were exchanged for 279,920 shares of the Company’s
common stock through December 31, 2023. The Company recognized a gain of $352,965 due to the modification of the warrants in the year
ended December 31, 2023, as a result of the modification.
On
October 22, 2021, the Company and Osher amended convertible debt agreements for the maturity date from October 20, 2021 to October 20,
2022. In exchange for the extension of the Note, the Company issued Osher 11,250 warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock, valued at $197,501 (based on the Black Scholes valuation model on the date of grant). The warrants
are exercisable for a period of five years at $40.00 per share in whole or in part, as either a cash exercise or as a cashless exercise,
and fully vest at grant date. The Company accreted the value of the warrants ratably through October 20, 2022, recorded $0 and $147,720
for the years ended December 31, 2023 and 2022, respectively, and is classified in other expenses in the consolidated Statements of Operations.
See Note 6 for further warrant discussions.
NOTE
9 – OPERATING LEASES
On
May 27, 2021, the Company entered into a sixty-three month lease for its corporate office at $5,955 per month commencing June 15, 2021
maturing September 30, 2026. The Company accounts for this lease in accordance with ASC 842. Adoption of the standard resulted in the
initial recognition of operating lease ROU asset of $290,827 and operating lease liability of $290,827 as of June 15, 2021.
Operating
lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent
our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily
determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s
incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease
ROU asset includes any lease payments made and excludes lease incentives. Our variable lease payments primarily consist of maintenance
and other operating expenses from our real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities
and are recognized in the period in which the obligation for those payments is incurred. Our lease terms may include options to extend
or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized
on a straight-line basis over the lease term.
We
have lease agreements with lease and non-lease components. We have elected to account for these lease and non-lease components as a single
lease component. We are also electing not to apply the recognition requirements to short-term leases of twelve months or less and instead
will recognize lease payments as expense on a straight-line basis over the lease term.
The
components of lease expense and supplemental cash flow information related to leases for the period are as follows:
In
accordance with ASC 842, the components of lease expense were as follows:
SCHEDULE OF OPERATING LEASE COST AND SUPPLEMENTAL CASH FLOW INFORMATION
| |
2023 | | |
2022 | |
| |
Years ended December 31, | |
| |
2023 | | |
2022 | |
Operating lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
Short term lease cost | |
$ | - | | |
$ | - | |
Total lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
In
accordance with ASC 842, other information related to leases was as follows:
Years ended December 31, | |
2023 | | |
2022 | |
Operating cash flows from operating leases | |
$ | 54,263 | | |
$ | 72,714 | |
Cash paid for amounts included in the measurement of lease liabilities | |
$ | 54,263 | | |
$ | 72,714 | |
| |
| | | |
| | |
Weighted-average remaining lease term—operating leases | |
| 2.67 years | | |
| 3.67 years | |
Weighted-average discount rate—operating leases | |
| 10 | % | |
| 10 | % |
In
accordance with ASC 842, maturities of operating lease liabilities as of December 31, 2023 were as follows:
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating | |
Year ending: | |
Lease | |
2024 | |
$ | 77,142 | |
2026 | |
| 79,456 | |
2027 | |
| 54,225 | |
Total undiscounted cash flows | |
$ | 210,823 | |
| |
| | |
Reconciliation of lease liabilities: | |
| | |
Weighted-average remaining lease terms | |
| 2.67
years | |
Weighted-average discount rate | |
| 10 | % |
Present values | |
$ | 187,425 | |
| |
| | |
Lease liabilities—current | |
| 61,123 | |
Lease liabilities—long-term | |
| 126,302 | |
Lease liabilities—total | |
$ | 187,425 | |
| |
| | |
Difference between undiscounted and discounted cash flows | |
$ | 23,398 | |
Operating
lease cost was $71,676 and $71,676 for the years ended December 31, 2023 and 2022, respectively.
NOTE
10 – RELATED PARTY TRANSACTIONS
Other
than as set forth below, and as disclosed in Notes 7, 8, 13 and 14, there have not been any transaction entered into or been a participant
in which a related person had or will have a direct or indirect material interest.
Employment
Agreements
Mr.
Joyce receives an annual base salary of $455,000, plus bonus compensation not to exceed 50% of salary. Mr. Joyce’s employment also
provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due
to a change in control. Additionally, the Company has agreed to maintain a beneficial ownership target of 9% for Mr. Joyce. The Company
incurred compensation expense of $455,000 (including accrued compensation of $284,375) and $453,067 for the years ended December 31,
2023 and 2022, respectively.
Mr.
DeCiccio was hired December 6, 2023 as the Company’s Chief Financial Officer (“CFO”). Mr. DeCiccio receives an annual
base salary of $250,000, plus discretionary bonus compensation not to exceed 40% of salary. Mr. DeCiccio’s employment also provides
for medical insurance, disability benefits and three months of severance pay if his employment is terminated without cause or due to
a change in control. Additionally, Mr. DeCiccio was granted up to 17,500 options to purchase 17,500 of the Company’s common shares.
The Company incurred compensation expense of $9,000 (recorded as accrued compensation) for the year ended December 31, 2023. Prior to
Mr. DeCiccio hired as the CFO, he was a consultant to the Company. The Company has recorded a balance due to Mr. DeCiccio of $35,242
and $0 under Accounts Payable in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively, for services rendered.
On
April 1, 2023, the Company entered into an Employment Agreement with Dr. Annette Marleau whereby Dr. Marleau became the Company’s
Chief Scientific Officer. Dr. Marleau receives an annual base salary of $300,000, with automatic 3% annual increases plus bonus compensation
not to exceed 40% of salary. Dr. Marleau’s employment also provides for medical insurance, disability benefits and up to six months
of severance pay if her employment is terminated by the Company. The Company incurred compensation expense of $225,000 (including accrued
compensation of $100,000) and $0 for the years ended December 31, 2023 and 2022, respectively.
Sigyn
had no employment agreement with its CTO but still incurred compensation on behalf of the CTO. The Company incurred compensation expense
of $240,000 (including accrued compensation of $160,000) and $233,678 for the years ended December 31, 2023 and 2022, respectively.
NOTE
11 – INCOME TAXES
At
December 31, 2023, net operating loss carry forwards for Federal and state income tax purposes totaling approximately $2,782,000 available
to reduce future income which under the Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards
limited to 80% of each subsequent year’s net income. There is no income tax affect due to the recognition of a full valuation allowance
on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets.
A
reconciliation of the statutory income tax rates and the effective tax rate is as follows:
SCHEDULE
OF RECONCILIATION OF STATUTORY INCOME TAX RATES AND EFFECTIVE TAX RATE
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Statutory U.S. federal rate | |
| 21.0 | % | |
| 21.0 | % |
State income tax, net of federal benefit | |
| 7.0 | % | |
| 7.0 | % |
Permanent differences | |
| - | % | |
| (7.5 | )% |
Valuation allowance | |
| (28.0 | )% | |
| (20.5 | )% |
| |
| | | |
| | |
Provision for income taxes | |
| 0.0 | % | |
| 0.0 | % |
The
tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:
SCHEDULE
OF DEFERRED TAX ASSETS
| |
2023 | | |
2022 | |
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Deferred tax assets: | |
| | | |
| | |
Net operating loss carry forwards | |
$ | 2,781,577 | | |
$ | 1,674,531 | |
Accrued payroll | |
| 203,771 | | |
| - | |
Stock-based compensation | |
| 60,321 | | |
| - | |
Depreciation and amortization | |
| (21,911 | ) | |
| - | |
Valuation allowance | |
| (3,023,758 | ) | |
| (1,674,531 | ) |
| |
| | | |
| | |
Total | |
$ | - | | |
$ | - | |
Major
tax jurisdictions are the United States and California. All of the tax years will remain open three and four years for examination by
the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. There are no tax audits
pending.
NOTE
12 – EARNINGS PER SHARE
FASB
ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings
(loss) per share (EPS) computations.
Basic
earnings (loss) per share are computed by dividing net earnings available to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the
denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number
of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
Convertible notes payable | |
| 365,274 | | |
| 293,174 | |
Restricted stock units | |
| 17,178 | | |
| - | |
Warrants to purchase shares of common stock | |
| 78,000 | | |
| 379,812 | |
Total potentially dilutive shares | |
| 460,452 | | |
| 672,986 | |
The
following table sets forth the computation of basic and diluted net income per share:
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Net loss attributable to the common stockholders | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
| |
| | | |
| | |
Basic weighted average outstanding shares of common stock | |
| 1,100,372 | | |
| 934,915 | |
Dilutive effect of options and warrants | |
| - | | |
| - | |
Diluted weighted average common stock and common stock equivalents | |
| 1,100,372 | | |
| 934,915 | |
| |
| | | |
| | |
Loss per share: | |
| | | |
| | |
Basic and diluted | |
$ | (3.77 | ) | |
$ | (3.13 | ) |
NOTE
13 – COMMITMENTS AND CONTINGENCIES
Legal
From
time to time, various lawsuits and legal proceedings may arise in the ordinary course of business. However, litigation is subject to
inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are
currently not aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial
condition or operating results.
Board
of Directors Compensation
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Each Director shall receive an annual retainer of $30,000
paid in equal quarterly amounts at the end of each quarter. In addition, each Director shall receive a grant of restricted stock units
of $50,000, or at the discretion of the Board of Directors, options to acquire shares of common stock. Restricted stock units will be
valued based on the average of the five trading days preceding and including the date of grant and will vest at a rate determined by
the Board of Directors over one year. If options are granted, the options will be valued at the exercise price based on the average of
the five trading days preceding and including the date of grant, have a ten-year term, and will vest at a rate determined by the Board
of Directors.
NOTE
14 – SUBSEQUENT EVENTS
The
Company evaluated all events or transactions that occurred after December 31, 2023 up through the date the financial statements were
available to be issued. During this period, the Company did not have any material recognizable subsequent events required to be disclosed
as of and for the period ended December 31, 2023, except for the following:
Brio
– $44,000
On
January 8, 2024, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $44,000 aggregate principal
amount of Note due January 8, 2025 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 7,333 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $40,000 which was issued at
a $4,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
Shares
Cancelled
On
January 9, 2024, the Company’s CTO agreed to surrender 64,100 common shares held by him and were cancelled by the Company.
Reverse
Stock Split
Effective
January 19, 2024, Board of Directors declared a one-for-forty reverse stock split to shareholders of record on or before January 31,
2024 of the Company’s issued and outstanding shares of common stock, outstanding warrants and options, and the Series B Convertible
Preferred Stock. The number of shares of common stock obtainable upon exercise or conversion and the exercise prices and conversion rate
have been equitably adjusted, and convertible preferred shares. As such, all share and per share amounts have been retroactively adjusted
to reflect the reverse stock split.
Advance
from Shareholder
In
January 2024, the Company received an additional advance of $25,000 from the Company’s CEO for working capital purposes with a
balance due of $105,000 as of February 15, 2024.
2024 Convertible Notes
In
February 2024, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2024 Notes”) totaling
(i) $50,050 aggregate principal amount of Note (total of $45,500 cash was received) due in February 2025 based on $1.00 for each $0.90909
paid by the noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 8,343
shares of the Company’s Common Stock at an exercise price of $10.00 per share. The conversion
price for the principal in connection with voluntary conversions by the holders of the convertible notes is $6.00 per share.
EXHIBIT
31.1
SECTION
302 CERTIFICATION
I,
James Joyce, certify that:
1.
I have reviewed this annual report on Form 10-K of Sigyn Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date:
February 20, 2024
/s/
James Joyce |
|
James
Joyce |
|
Chief
Executive Officer (Principal Executive Officer) |
|
EXHIBIT
31.2
SECTION
302 CERTIFICATION
I,
Gerald DeCiccio, certify that:
1.
I have reviewed this annual report on Form 10-K of Sigyn Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date:
February 20, 2024
/s/
Gerald DeCiccio |
|
Gerald
DeCiccio |
|
Chief
Financial Officer (Principal Financial and Accounting Officer) |
|
EXHIBIT
32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Annual Report of Sigyn Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31,
2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Joyce, Chief Executive
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, to the best of my knowledge, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the dates and periods covered by the Report.
This
certificate is being made for the exclusive purpose of compliance by the Chief Executive Officer of the Company with the requirements
of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other
than as specifically required by law.
/s/
James Joyce |
|
James
Joyce |
|
Chief
Executive Officer (Principal Executive Officer) |
|
|
|
February
20, 2024 |
|
EXHIBIT
32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT
TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Annual Report of Sigyn Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31,
2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gerald DeCiccio, Chief Financial
Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, to the best of my knowledge, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company for the dates and periods covered by the Report.
This
certificate is being made for the exclusive purpose of compliance by the Chief Financial Officer of the Company with the requirements
of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other
than as specifically required by law.
/s/
Gerald DeCiccio |
|
Gerald
DeCiccio |
|
Chief
Financial Officer (Principal Financial and Accounting Officer) |
|
|
|
February
20, 2024 |
|
v3.24.0.1
Cover - USD ($)
|
12 Months Ended |
|
|
Dec. 31, 2023 |
Feb. 16, 2024 |
Jun. 30, 2023 |
Cover [Abstract] |
|
|
|
Document Type |
10-K
|
|
|
Amendment Flag |
false
|
|
|
Document Annual Report |
true
|
|
|
Document Transition Report |
false
|
|
|
Document Period End Date |
Dec. 31, 2023
|
|
|
Document Fiscal Period Focus |
FY
|
|
|
Document Fiscal Year Focus |
2023
|
|
|
Current Fiscal Year End Date |
--12-31
|
|
|
Entity File Number |
000-55575
|
|
|
Entity Registrant Name |
SIGYN
THERAPEUTICS, INC.
|
|
|
Entity Central Index Key |
0001642159
|
|
|
Entity Tax Identification Number |
84-4210559
|
|
|
Entity Incorporation, State or Country Code |
DE
|
|
|
Entity Address, Address Line One |
2468
Historic Decatur Road Ste.
|
|
|
Entity Address, Address Line Two |
140
|
|
|
Entity Address, City or Town |
San Diego
|
|
|
Entity Address, State or Province |
CA
|
|
|
Entity Address, Postal Zip Code |
92106
|
|
|
City Area Code |
(619)
|
|
|
Local Phone Number |
353-0800
|
|
|
Title of 12(g) Security |
Common
Stock, $0.0001 Par Value
|
|
|
Entity Well-known Seasoned Issuer |
No
|
|
|
Entity Voluntary Filers |
No
|
|
|
Entity Current Reporting Status |
Yes
|
|
|
Entity Interactive Data Current |
Yes
|
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
|
Entity Small Business |
true
|
|
|
Entity Emerging Growth Company |
true
|
|
|
Elected Not To Use the Extended Transition Period |
true
|
|
|
Entity Shell Company |
false
|
|
|
Entity Public Float |
|
|
$ 1,859,140
|
Entity Common Stock, Shares Outstanding |
|
1,224,315
|
|
ICFR Auditor Attestation Flag |
false
|
|
|
Document Financial Statement Error Correction [Flag] |
false
|
|
|
Auditor Firm ID |
6651
|
|
|
Auditor Name |
Kreit & Chiu CPA LLP
|
|
|
Auditor Location |
New
York, New York
|
|
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPCAOB issued Audit Firm Identifier
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorFirmId |
Namespace Prefix: |
dei_ |
Data Type: |
dei:nonemptySequenceNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorLocation |
Namespace Prefix: |
dei_ |
Data Type: |
dei:internationalNameItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_AuditorName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:internationalNameItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an annual report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_DocumentAnnualReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection w
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_DocumentFinStmtErrorCorrectionFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
+ Details
Name: |
dei_EntityPublicFloat |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
+ Details
Name: |
dei_EntityVoluntaryFilers |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 405
+ Details
Name: |
dei_EntityWellKnownSeasonedIssuer |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection f
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f
+ Details
Name: |
dei_IcfrAuditorAttestationFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(g) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection g
+ Details
Name: |
dei_Security12gTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
Consolidated Balance Sheets - USD ($)
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Current assets: |
|
|
Cash |
$ 11,690
|
$ 8,356
|
Inventories |
50,000
|
50,000
|
Other current assets |
56,373
|
11,942
|
Total current assets |
118,063
|
70,298
|
Property and equipment, net |
15,296
|
22,052
|
Intangible assets, net |
|
2,100
|
Operating lease right-of-use assets, net |
167,736
|
217,718
|
Other assets |
20,711
|
20,711
|
Total assets |
321,806
|
332,879
|
Current liabilities: |
|
|
Accounts payable |
461,646
|
327,517
|
Accrued payroll and payroll taxes |
791,754
|
30,124
|
Advance from shareholder |
80,000
|
|
Short-term convertible notes payable, less unamortized debt issuance costs of $297,337 and $642,660, respectively |
2,210,299
|
1,636,656
|
Current portion of operating lease liabilities |
61,123
|
53,200
|
Other current liabilities |
3,182
|
1,197
|
Total current liabilities |
3,608,004
|
2,048,694
|
Long-term liabilities: |
|
|
Operating lease liabilities, net of current portion |
126,302
|
187,425
|
Total long-term liabilities |
126,302
|
187,425
|
Total liabilities |
3,734,306
|
2,236,119
|
Stockholders’ deficit: |
|
|
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 32 and no shares issued and outstanding at December 31, 2023 and 2022, respectively |
|
|
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 1,288,415 and 956,595 shares issued and outstanding at December 31, 2023 and 2022, respectively |
129
|
96
|
Additional paid-in capital |
7,928,883
|
5,292,240
|
Accumulated deficit |
(11,341,512)
|
(7,195,576)
|
Total stockholders’ deficit |
(3,412,500)
|
(1,903,240)
|
Total liabilities and stockholders’ deficit |
$ 321,806
|
$ 332,879
|
X |
- DefinitionAdvance from shareholder.
+ References
+ Details
Name: |
SIGYD_AdvanceFromShareholder |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedPayrollTaxesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 201.5-02(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Unamortized debt issuance costs |
$ 297,337
|
$ 642,660
|
Preferred stock, par value |
$ 0.0001
|
$ 0.0001
|
Preferred stock, shares authorized |
10,000,000
|
10,000,000
|
Preferred stock, shares issued |
32
|
0
|
Preferred stock, shares outstanding |
32
|
0
|
Common stock, par value |
$ 0.0001
|
$ 0.0001
|
Common stock, shares authorized |
1,000,000,000
|
1,000,000,000
|
Common stock, shares issued |
1,288,415
|
956,595
|
Common stock, shares outstanding |
1,288,415
|
956,595
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
+ Details
Name: |
us-gaap_DeferredFinanceCostsCurrentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
Consolidated Statements of Operations - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Income Statement [Abstract] |
|
|
Net revenues |
|
|
Gross Profit |
|
|
Operating expenses: |
|
|
Marketing expenses |
392
|
457
|
Research and development |
798,165
|
657,657
|
General and administrative |
1,656,760
|
1,489,151
|
Total operating expenses |
2,455,317
|
2,147,265
|
Loss from operations |
(2,455,317)
|
(2,147,265)
|
Other expense (income): |
|
|
Modification of warrants |
(352,965)
|
|
Interest expense |
2,402
|
438
|
Interest expense - debt discount |
1,755,995
|
646,302
|
Interest expense - original issuance costs |
285,187
|
135,812
|
Total other expense |
1,690,619
|
782,552
|
Loss before income taxes |
(4,145,936)
|
(2,929,817)
|
Income taxes |
|
|
Net loss |
$ (4,145,936)
|
$ (2,929,817)
|
Net loss per share, basic |
$ (3.77)
|
$ (3.13)
|
Net loss per share, diluted |
$ (3.77)
|
$ (3.13)
|
Weighted average number of shares outstanding, basic |
1,100,372
|
934,915
|
Weighted average number of shares outstanding, diluted |
1,100,372
|
934,915
|
X |
- DefinitionInterest expense debt discount.
+ References
+ Details
Name: |
SIGYD_InterestExpenseDebtDiscount |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest expense classified as other.
+ References
+ Details
Name: |
us-gaap_InterestExpenseOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExpenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_MarketingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
|
Preferred Stock [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Beginning balance, value at Dec. 31, 2021 |
|
$ 93
|
$ 4,001,082
|
$ (4,265,759)
|
$ (264,584)
|
Beginning balance, shares at Dec. 31, 2021 |
|
932,395
|
|
|
|
Warrants issued to third parties in conjunction with debt issuance |
|
|
793,039
|
|
793,039
|
Beneficial conversion feature in conjunction with debt issuance |
|
|
273,700
|
|
273,700
|
Amortization of warrants issued in connection with a debt modification |
|
|
147,720
|
|
147,720
|
Common stock issued to third parties in conjunction with conversion of debt |
|
$ 3
|
145,197
|
|
145,200
|
Common stock issued to third parties in conjunction with conversion of debt, shares |
|
24,200
|
|
|
|
Fees associated with filing of Form S-1 |
|
|
(68,498)
|
|
(68,498)
|
Net loss |
|
|
|
(2,929,817)
|
(2,929,817)
|
Ending balance, value at Dec. 31, 2022 |
|
$ 96
|
5,292,240
|
(7,195,576)
|
(1,903,240)
|
Ending balance, shares at Dec. 31, 2022 |
|
956,595
|
|
|
|
Warrants issued to third parties in conjunction with debt issuance |
|
|
858,276
|
|
858,276
|
Beneficial conversion feature in conjunction with debt issuance |
|
|
401,063
|
|
401,063
|
Common stock issued to third parties in conjunction with conversion of debt |
|
$ 21
|
1,520,179
|
|
1,520,200
|
Common stock issued to third parties in conjunction with conversion of debt, shares |
|
213,584
|
|
|
|
Fees associated with filing of Form S-1 |
|
|
(5,456)
|
|
(5,456)
|
Net loss |
|
|
|
(4,145,936)
|
(4,145,936)
|
Stock-based compensation |
|
|
215,558
|
|
215,558
|
Modification of warrants |
|
$ 28
|
(352,993)
|
|
(352,965)
|
Modification of warrants, shares |
|
279,920
|
|
|
|
Conversion of common stock for Series A preferred stock |
|
$ (16)
|
16
|
|
|
Conversion of common stock for Series A preferred stock, shares |
32
|
(161,684)
|
|
|
|
Ending balance, value at Dec. 31, 2023 |
|
$ 129
|
$ 7,928,883
|
$ (11,341,512)
|
$ (3,412,500)
|
Ending balance, shares at Dec. 31, 2023 |
32
|
1,288,415
|
|
|
|
X |
- DefinitionAdjustments to additional paid in capital amortization of warrants issued in connection with debt modification.
+ References
+ Details
Name: |
SIGYD_AdjustmentsToAdditionalPaidInCapitalAmortizationOfWarrantsIssuedInConnectionWithDebtModification |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares modification of warrants.
+ References
+ Details
Name: |
SIGYD_StockIssuedDuringPeriodSharesModificationOfWarrants |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value modification of warrants.
+ References
+ Details
Name: |
SIGYD_StockIssuedDuringPeriodValueModificationOfWarrants |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482663/740-10-55-51
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Cash flows from operating activities: |
|
|
Net loss |
$ (4,145,936)
|
$ (2,929,817)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
Depreciation expense |
6,756
|
6,854
|
Amortization expense |
2,100
|
3,600
|
Stock based compensation |
215,558
|
|
Accretion of debt discount |
1,755,995
|
646,302
|
Accretion of original issuance costs |
285,187
|
135,812
|
Modification of warrants |
(352,965)
|
|
Changes in operating assets and liabilities: |
|
|
Other current assets |
(44,431)
|
(9,867)
|
Accounts payable |
196,629
|
287,843
|
Accrued payroll and payroll taxes |
699,130
|
29,052
|
Other current liabilities |
(1,233)
|
(21)
|
Net cash used in operating activities |
(1,383,210)
|
(1,830,242)
|
Cash flows from investing activities: |
|
|
Purchase of property and equipment |
|
(860)
|
Net cash used in investing activities |
|
(860)
|
Cash flows from financing activities: |
|
|
Proceeds from short-term convertible notes |
1,312,000
|
1,567,000
|
Advance from shareholder |
80,000
|
|
Fees associated with filing of Form S-1 |
(5,456)
|
(68,498)
|
Net cash provided by financing activities |
1,386,544
|
1,498,502
|
Net (decrease) increase in cash |
3,334
|
(332,600)
|
Cash at beginning of period |
8,356
|
340,956
|
Cash at end of period |
11,690
|
8,356
|
Cash paid during the period for: |
|
|
Interest |
|
|
Income taxes |
|
|
Non-cash investing and financing activities: |
|
|
Beneficial conversion feature in conjunction with debt issuance |
401,063
|
273,700
|
Amortization of warrants issued in connection with a debt modification |
|
147,720
|
Warrants issued to third parties in conjunction with debt issuance |
858,276
|
793,039
|
Original issue discount issued in conjunction with debt |
131,200
|
156,700
|
Original issue discount issued in conjunction with extension of debt |
305,320
|
|
Common stock issued to third parties in conjunction with conversion of debt |
1,520,200
|
145,200
|
Conversion of common stock for Series A preferred stock |
$ 16
|
|
X |
- DefinitionAccretion of debt discount.
+ References
+ Details
Name: |
SIGYD_AccretionOfDebtDiscount |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAccretion of original issuance costs.
+ References
+ Details
Name: |
SIGYD_AccretionOfOriginalIssuanceCosts |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmortization of warrants issued in connection with a debt.
+ References
+ Details
Name: |
SIGYD_AmortizationOfWarrantsIssuedInConnectionWithADebt |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionBeneficial conversion feature in conjunction with debt issuance.
+ References
+ Details
Name: |
SIGYD_BeneficialConversionFeatureInConjunctionWithDebtIssuance |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCash paid during the period for abstract.
+ References
+ Details
Name: |
SIGYD_CashPaidDuringPeriodForAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionOriginal issue discount issued in conjunction with extension of debt
+ References
+ Details
Name: |
SIGYD_OriginalIssueDiscountIssuedInConjunctionWithExtensionOfDebt |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWarrants issued to third parties in conjunction with debt issuance.
+ References
+ Details
Name: |
SIGYD_WarrantsIssuedToThirdPartiesInConjunctionWithDebtIssuance |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AdjustmentForAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockAmountConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedTaxesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current liabilities classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of notes issued in noncash investing and financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_NotesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromShortTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.0.1
ORGANIZATION AND PRINCIPAL ACTIVITIES
|
12 Months Ended |
Dec. 31, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
ORGANIZATION AND PRINCIPAL ACTIVITIES |
NOTE
1 – ORGANIZATION AND PRINCIPAL ACTIVITIES
Corporate
History and Background
Sigyn
Therapeutics, Inc. (“Sigyn”, the “Company” “we,” “us,” or “our”) is a development-stage
company that creates blood purification technologies to overcome clearly defined limitations in healthcare.
Sigyn
Therapy™, our lead product candidate, is being advanced to treat life-threatening conditions that are not addressed with market-cleared
drug agents. Candidate treatment indications include endotoxemia, sepsis (a leading cause of hospital deaths), community acquired pneumonia
(a leading cause of infectious disease deaths), drug-resistant bacterial infections, and emerging pandemic viral threats.
Our
therapeutic pipeline is comprised of technologies that we have designed to improve the targeted delivery of cancer drug agents. ChemoPrepTM
and ChemoPureTM are components of a therapeutic system to improve the delivery of chemotherapy and reduce its toxicity.
ImmunePrepTM is a novel platform to enhance the potential efficacy of immunotherapeutic antibodies (including checkpoint inhibitors).
At present, we have no market approved medical products and there is no assurance that we will be able to commercialize any of our product
candidates.
Merger
Transaction
On
October 19, 2020, Sigyn Therapeutics, Inc, a Delaware corporation (the “Registrant”) formerly known as Reign Resources Corporation,
completed a Share Exchange Agreement (the “Agreement”) with Sigyn Therapeutics, Inc., a private entity incorporated in the
State of Delaware on October 19, 2019.
In
the Share Exchange Agreement, we acquired 100% of the issued and outstanding shares of privately held Sigyn Therapeutics common stock
in exchange for 75% of the fully paid and nonassessable shares of our common stock outstanding (the “Acquisition”). In conjunction
with the transaction, we changed our name from Reign Resources Corporation to Sigyn Therapeutics, Inc. pursuant to an amendment to our
articles of incorporation that was filed with the State of Delaware. Subsequently, our trading symbol was changed to SIGY. The Acquisition
was treated by the Company as a reverse merger in accordance with accounting principles generally accepted in the United States of America
(“GAAP”). For accounting purposes, Sigyn is considered to have acquired Reign Resources Corporation as the accounting acquirer
because: (i) Sigyn stockholders own 75% of the combined company, on an as-converted basis, immediately following the Closing Date, (ii)
Sigyn directors hold a majority of board seats in the combined company and (iii) Sigyn management held all key positions in the management
of the combined company. Accordingly, Sigyn’s historical results of operations will replace Reign Resources Corporation’s
historical results of operations for all periods prior to the Acquisition and, for all periods following the Acquisition, the results
of operations of the combined company will be included in the Company’s financial statements. The Acquisition was treated as a
“tax-free exchange” under Section 368 of the Internal Revenue Code of 1986 and resulted in the private Sigyn Therapeutics
corporate entity (established on October 29, 2019) to become a wholly owned subsidiary of Reign Resources Corporation. Among the conditions
for closing the acquisition, the Reign Resources Corporation extinguished all previously reported liabilities, its preferred class of
shares, and all stock purchase options. As a result, the reported liabilities totaling $3,429,516 were converted into a total of 7,907,351
common shares. Additionally, assets held on the books of Reign Resources Corporation, such as Gem inventory, was kept in the Company
and therefore recorded as assets on the Share Exchange date. Upon the closing of the Acquisition, we appointed James A. Joyce and Craig
P. Roberts to serve as members of our Board of Directors.
Effective
January 19, 2024, Board of Directors declared a one-for-forty reverse stock split to shareholders of record on or before January 31,
2024 of the Company’s issued and outstanding shares of common stock, outstanding warrants and options, and the Series B
Convertible Preferred Stock. The number of shares of common stock and convertible preferred shares obtainable upon exercise or
conversion and the exercise prices and conversion rate have been equitably adjusted. As such, all
share and per share amounts have been retroactively adjusted to reflect the reverse stock split.
As
of February 16, 2024, we have a total of 1,224,315
shares issued and outstanding, of which 647,415
shares are held by non-affiliate stockholders.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
BASIS OF PRESENTATION
|
12 Months Ended |
Dec. 31, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
BASIS OF PRESENTATION |
NOTE
2 – BASIS OF PRESENTATION
The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America and include all adjustments necessary for the fair presentation of the Company’s financial position and results of operations
for the periods presented.
The
Company currently operates in one business segment. The Company is not organized by market and is managed and operated as one business.
A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the
entire business. The Company does not currently operate any separate lines of businesses or separate business entities.
Going
Concern
The
accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated
deficit of $11,341,512 at December 31, 2023, had a working capital deficit of $3,489,941 at December 31, 2023, had net losses of $4,145,936
and $2,929,817 for the years ended December 31, 2023 and 2022, respectively, and net cash used in operating activities of $1,383,210
and $1,830,242 for the years ended December 31, 2023 and 2022, respectively, with no revenue earned since inception, and a lack of operational
history. These matters raise substantial doubt about the Company’s ability to continue as a going concern.
While
the Company is attempting to expand operations and increase revenues, the Company’s cash position may not be significant enough
to support the Company’s daily operations. Management intends to raise additional funds by way of a public offering or an asset
sale transaction. Management believes that the actions presently being taken to further implement its business plan and generate revenues
provide the opportunity for the Company to continue as a going concern. While management believes in the viability of its strategy to
generate revenues and in its ability to raise additional funds or transact an asset sale, there can be no assurances to that effect or
on terms acceptable to the Company. The ability of the Company to continue as a going concern is dependent upon the Company’s ability
to further implement its business plan and generate revenues.
The
financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
|
X |
- DefinitionThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfAccounting |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
12 Months Ended |
Dec. 31, 2023 |
Accounting Policies [Abstract] |
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
NOTE
3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
This
summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements.
The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and
objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements.
Use
of Estimates
The
preparation of these financial statements in accordance with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and
expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the
financial statements. The more significant estimates and assumptions by management include among others: warrant valuation. The
Company calculates the fair value of warrants using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method
requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest
rate and the fair value of the underlying common stock on the date of grant. The current economic environment has increased the
degree of uncertainty inherent in these estimates and assumptions.
Cash
The
Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC)
up to $250,000. The Company has not experienced any cash losses.
Income
Taxes
Income
taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences
between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance
with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its
deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation
allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated
Statements of Operations.
ASC
740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and
prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to
be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized
at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation
of ASC 740-10 and currently, the Company does not have a liability for unrecognized income tax benefits.
Advertising
and Marketing Costs
Advertising
expenses are recorded as general and administrative expenses when they are incurred. The Company had $392 of advertising expenses for
the year ended December 31, 2023 and had $457 of advertising expenses for the year ended December 31, 2022.
Research
and Development
All
research and development costs are expensed as incurred. The Company incurred research and development expense of $798,165 and $657,657
for the years ended December 31, 2023 and 2022, respectively.
Inventories
In
conjunction with the October 19, 2020 Share Exchange Agreement, the Company kept the gem inventory of Reign Resources Corporation. Inventories
are stated at the lower of cost or market (net realizable value) on a lot basis each quarter. A lot is determined by the cut, clarity,
size, and weight of the sapphires. Inventory consists of sapphire jewels that meet rigorous grading criteria and are of cuts and sizes
most commonly used in the jewelry industry. As of December 31, 2023 and 2022, the Company carried primarily loose sapphire jewels, jewelry
for sale, and jewelry held as samples. Samples are used to show potential customers what the jewelry would look like. Promotional items
given to customers that are not expected to be returned will be removed from inventory and expensed. There have been no promotional items
given to customers as of December 31, 2023. The Company performs its own in-house assessment based on gem guide and the current market
price for metals to value its inventory on an annual basis or if circumstances dictate sooner to determine if the estimated fair value
is greater or less than cost. In addition, the inventory is reviewed each quarter by the Company against industry prices from gem-guide
and if there is a potential impairment, the Company would appraise the inventory. The estimated fair value is subject to significant
change due to changes in popularity of cut, perceived grade of the clarity of the sapphires, the number, type and size of inclusions,
the availability of other similar quality and size sapphires, and other factors. As a result, the internal assessed value of the sapphires
could be significantly lower from the current estimated fair value. Loose sapphire jewels do not degrade in quality over time.
Property
and Equipment
Property
and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally
five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets
are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are
included in income in the year of disposition.
Intangible
Assets
Intangible
assets consist primarily of website development costs. Our intangible assets are being amortized on a straight-line basis over a period
of three years.
Impairment
of Long-lived Assets
We
periodically evaluate whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate
the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted
cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment
loss is measured as the excess of the asset’s carrying value over its fair value.
Our
impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting
useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent
in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted
techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash
flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to
new information, we may be exposed to an impairment charge in the future. As of December 31, 2023 and 2022, the Company had not experienced
impairment losses on its long-lived assets.
Fair
Value of Financial Instruments
The
provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines
fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing
parties. As of December 31, 2023 and 2022, the fair value of cash, accounts payable, accrued expenses, advance from shareholder, and
notes payable approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which
fluctuate with market rates.
Fair
Value Measurements
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
as follows:
|
● |
Level
1 – Quoted prices in active markets for identical assets or liabilities. |
|
|
|
|
● |
Level
2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets
or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities. |
|
|
|
|
● |
Level
3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the
fair value of the assets or liabilities |
The
carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial
assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There
were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and
liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There
have been no transfers between levels.
Debt
The
Company issues debt that may have separate warrants, conversion features, or no equity-linked attributes.
Embedded
Conversion Features
The
Company evaluates embedded conversion features within convertible debt under ASC 815, Derivatives and Hedging, to determine whether
the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with
changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument
is evaluated under ASC 470-20, Debt with Conversion and Other Options, for consideration of any beneficial conversion feature.
Derivative
Financial Instruments
The
Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported as charges or credits to income.
For
option-based simple derivative financial instruments, the Company uses the Monte Carlo simulations to value the derivative instruments
at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. There were no derivative financial instruments
as of December 31, 2023 and 2022 and no charges or credits to income for the years ended December 31, 2023 and 2022.
Debt
Issue Costs and Debt Discount
The
Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs
may be paid in the form of cash or equity (such as warrants). These costs are amortized to interest expense through the maturity of the
debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized debt issue costs and debt discount are presented net of the related debt on the consolidated balance sheets.
Original
Issue Discount
For
certain convertible debt issued, the Company may provide the debt holder with an original issue discount. The original issue discount
would be recorded to debt discount, reducing the face amount of the note and is amortized to interest expense through the maturity of
the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized original issue discounts are presented net of the related debt on the consolidated balance sheets.
If
the conversion feature does not qualify for either the derivative treatment or as a beneficial conversion feature (“BCF”),
the convertible debt is treated as traditional debt.
Basic
and diluted earnings per share
Basic
net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period,
without consideration for common stock equivalents. Diluted earnings (loss) per share are computed on the basis of the weighted average
number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting
period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents,
because their inclusion would be anti-dilutive.
Basic
and diluted earnings (loss) per share are the same since net losses for all periods presented and including the additional potential
common shares would have an anti-dilutive effect.
Stock
Based Compensation
In
accordance with ASC No. 718, Compensation – Stock Compensation (“ASC 718”), we measure the compensation costs
of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over
the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted
share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.
Non-Employee
Stock-Based Compensation
In
accordance with ASC 505, Equity Based Payments to Non-Employees, issuances of the Company’s common stock or warrants for
acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants
or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached
(a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive
for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may
be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on
the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the
date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the
instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement
of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial
reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is
measured at the then-current fair values at each of those interim financial reporting dates.
Concentrations,
Risks, and Uncertainties
Business
Risk
Substantial
business risks and uncertainties are inherent to an entity, including the potential risk of business failure.
The
Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can
be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on
the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is
subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general
economic conditions, price of components, competition, and governmental and political conditions.
Interest
rate risk
Financial
assets and liabilities do not have material interest rate risk.
Credit
risk
The
Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are
recognized financial institutions.
Seasonality
The
business is not subject to substantial seasonal fluctuations.
Major
Suppliers
Sigyn
Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on a
third-party organization to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the
marketplace.
Should
the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed
that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement
of Sigyn Therapy.
Recent
Accounting Pronouncements
There
are no recently issued accounting updates that are expected to have a material impact on the Company’s consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
PROPERTY AND EQUIPMENT
|
12 Months Ended |
Dec. 31, 2023 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT |
NOTE
4 – PROPERTY AND EQUIPMENT
Property
and equipment consisted of the following as of:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
Estimated Life | |
December 31, 2023 | | |
December 31, 2022 | |
| |
| |
| | |
| |
Office equipment | |
5 years | |
$ | 29,041 | | |
$ | 29,041 | |
Computer equipment | |
3 years | |
| 3,157 | | |
| 3,157 | |
Property and equipment, gross | |
3 years | |
| 3,157 | | |
| 3,157 | |
Accumulated depreciation | |
| |
| (16,902 | ) | |
| (10,146 | ) |
Property and equipment, net | |
| |
$ | 15,296 | | |
$ | 22,052 | |
Depreciation
expense was $6,756 and $6,854 for the years ended December 31, 2023 and 2022, respectively, and is classified in general and administrative
expenses in the Consolidated Statements of Operations.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
INTANGIBLE ASSETS
|
12 Months Ended |
Dec. 31, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
INTANGIBLE ASSETS |
NOTE
5 – INTANGIBLE ASSETS
Intangible
assets consisted of the following as of:
SCHEDULE OF INTANGIBLE ASSETS
| |
Estimated life | |
December
31, 2023 | | |
December
31, 2022 | |
Website | |
3 years | |
$ | 10,799 | | |
$ | 10,799 | |
Accumulated amortization | |
| |
| (10,799 | ) | |
| (8,699 | ) |
Intangible assets, net | |
| |
$ | - | | |
$ | 2,100 | |
The
Company had amortization expense of $2,100 and $3,600 for the years ended December 31, 2023 and 2022, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all or part of the information related to intangible assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent
+ Details
Name: |
us-gaap_IntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
CONVERTIBLE PROMISSORY DEBENTURES
|
12 Months Ended |
Dec. 31, 2023 |
Debt Disclosure [Abstract] |
|
CONVERTIBLE PROMISSORY DEBENTURES |
NOTE
6 – CONVERTIBLE PROMISSORY DEBENTURES
Convertible
notes payable consisted of the following:
SCHEDULE OF CONVERTIBLE NOTES PAYABLE
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
June 23, 2020 ($74,621) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 2”) | |
| 74,621 | | |
| 60,500 | |
September 17, 2020 ($225,377) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 3”). | |
| 225,377 | | |
| 182,936 | |
March 23, 2022 ($259,685) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 4”) | |
| 259,685 | | |
| 220,000 | |
April 28, 2022 ($127,979) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 5”) | |
| 127,979 | | |
| 110,000 | |
May 10, 2022 ($128,020) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 6”) | |
| 128,020 | | |
| 110,000 | |
June 1, 2022 ($63,301) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 7”) | |
| 63,302 | | |
| 55,000 | |
June 22, 2022 ($94,314) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 8”) | |
| 94,314 | | |
| 82,500 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $341,000 of principal of the Note into 17,050 common shares (“Note 9”) | |
| - | | |
| 341,000 | |
August 31, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 10”) | |
| 123,200 | | |
| 110,000 | |
September 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024 (“Note 11”) | |
| 92,400 | | |
| 82,500 | |
September 20, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 12”) | |
| 123,200 | | |
| 110,000 | |
October 20, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due October 20, 2023 (“Note 13”) | |
| 110,000 | | |
| 110,000 | |
November 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 14”) | |
| 92,400 | | |
| 82,500 | |
November 14, 2022 ($55,000) – 0% interest per annum outstanding principal and interest due November 14, 2023 (“Note 15”) | |
| 55,000 | | |
| 55,000 | |
December 22, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due December 22, 2023 (“Note 16”) | |
| 110,000 | | |
| 110,000 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $1,179,200 of principal of the Note into 196,534 common shares (“Note 17”) | |
| 264,000 | | |
| - | |
| |
| | | |
| | |
Total convertible notes payable | |
| 2,507,636 | | |
| 2,279,316 | |
Original issue discount | |
| (225,835 | ) | |
| (74,502 | ) |
Beneficial conversion feature | |
| (22,013 | ) | |
| (175,275 | ) |
Debt discount | |
| (49,489 | ) | |
| (392,883 | ) |
| |
| | | |
| | |
Total convertible notes payable | |
$ | 2,210,299 | | |
$ | 1,636,656 | |
Principal
payments on convertible promissory debentures are due as follows:
SCHEDULE OF PRINCIPAL PAYMENTS DUE ON CONVERTIBLE PROMISSORY DEBENTURES
Year ending December 31, | |
| |
2024 | |
$ | 2,507,636 | |
Long-Term Debt | |
$ | 2,507,636 | |
Changes
in convertible notes were as follows:
SCHEDULE OF CHANGES IN CONVERTIBLE NOTES
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Convertible notes payable, net, as of December 31, 2021 | |
| 457,380 | | |
| 60,500 | | |
| 182,936 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 700,816 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2022 | |
| - | | |
| - | | |
| - | | |
| 220,000 | | |
| 110,000 | | |
| 110,000 | | |
| 55,000 | | |
| 82,500 | | |
| 341,000 | | |
| 110,000 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,578,500 | |
Convertible notes payable as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
Convertible notes payable, Begining balance | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Convertible notes payable issued | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Conversion of debt for common stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (341,000 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,179,200 | ) | |
| - | | |
| (1,520,200 | ) |
Convertible notes payable as of December 31, 2023 | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
Convertible notes payable, Ending balance | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
Changes
in note discounts were as follows:
SCHEDULE OF CHANGES IN NOTE DISCOUNTS
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Note discounts as of December 31, 2021 | |
| 34,176 | | |
| 4,521 | | |
| 14,917 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 53,614 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2022 | |
| - | | |
| - | | |
| - | | |
| 113,418 | | |
| 44,786 | | |
| 44,787 | | |
| 22,794 | | |
| 34,861 | | |
| 140,289 | | |
| 64,104 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,015,039 | |
2022 accretion of note discounts | |
| (34,176 | ) | |
| (4,521 | ) | |
| (14,917 | ) | |
| (87,938 | ) | |
| (30,308 | ) | |
| (28,836 | ) | |
| (13,301 | ) | |
| (18,336 | ) | |
| (70,720 | ) | |
| (32,316 | ) | |
| (39,994 | ) | |
| (49,874 | ) | |
| (23,671 | ) | |
| (12,822 | ) | |
| (7,726 | ) | |
| (6,537 | ) | |
| - | | |
| 50,000 | | |
| (425,993 | ) |
Note discounts as of December 31, 2022 | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
Note discounts, Begining balance | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
Note discounts issued in conjunction with debt | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
2023 accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Note discounts as of December 31, 2023 | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
Note discounts, Ending balance | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable, net, as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 194,520 | | |
$ | 95,522 | | |
$ | 94,049 | | |
$ | 45,507 | | |
$ | 65,975 | | |
$ | 271,431 | | |
$ | 78,212 | | |
$ | 39,994 | | |
$ | 49,874 | | |
$ | 23,671 | | |
$ | 12,822 | | |
$ | 7,726 | | |
$ | 6,537 | | |
$ | - | | |
$ | (50,000 | ) | |
$ | 1,636,656 | |
Convertible notes payable, net, as of December 31, 2023 | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
Convertible notes payable, net | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
2022 Effective interest rate | |
| 7 | % | |
| 7 | % | |
| 8 | % | |
| 40 | % | |
| 28 | % | |
| 26 | % | |
| 24 | % | |
| 22 | % | |
| 21 | % | |
| 29 | % | |
| 48 | % | |
| 45 | % | |
| 22 | % | |
| 16 | % | |
| 14 | % | |
| 6 | % | |
| -% | | |
| -% | | |
| 19 | % |
2023 Effective interest rate | |
| 6 | % | |
| 6 | % | |
| 6 | % | |
| 14 | % | |
| 15 | % | |
| 17 | % | |
| 19 | % | |
| 21 | % | |
| - | % | |
| 29 | % | |
| 49 | % | |
| 52 | % | |
| 78 | % | |
| 78 | % | |
| 86 | % | |
| 94 | % | |
| 496 | % | |
| -% | | |
| 81 | % |
Current
Noteholders
2023
Notes – $1,443,200 (Note 17)
During
the year ended December 31, 2023, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2023
Notes”) with third party investors totaling (i) $1,443,200 aggregate principal amount of Note due on various dates from January
2024 through December 7, 2024 based on $1.00 for each $0.90909 paid by the previous noteholder and (ii) five-year Common Stock Purchase
Warrants (“Warrants”) to purchase up to an aggregate of 233,200 shares of the Company’s Common Stock at an exercise
price of $10.00 per share. The aggregate cash subscription amount received by the Company from the previous noteholder for the issuance
of the Note and Warrants was $1,312,000 which was issued at a $131,200 original issue discount from the face value of the Note. The conversion
price for the principal in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to
adjustment as provided therein, such as stock splits and stock dividends.
On
June 2, 2023, a third-party investor elected to convert $181,500 of principal of the Note into 30,250 common shares.
In
October 2023, the holders of $997,700 of Original Issue Discount Senior Convertible Debentures converted their debentures at a contractual
exercise price of $10.00 per share in exchange for the issuance of 166,284 shares of Common Stock to the holders.
Osher
– $110,000 (Note 16)
On
December 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due December 22, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $55,000 (Note 15)
On
November 14, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due November 14, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 9,167 shares of the Company’s Common Stock at an exercise price of $10.00
per share. The aggregate cash subscription amount received by the Company from Osher noteholder for the issuance of the Note and Warrants
was $50,000 which was issued at a $5,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Brio
– $92,400 (Note 14)
On
November 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $82,500 aggregate principal
amount of Note due November 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $110,000 (Note 13)
On
October 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due October 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company has not repaid this convertible note and the convertible note is now in default. The Company is currently in discussions to convert
or restructure the terms of the note.
Osher
– $123,200 (Note 12)
On
September 20, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due September 20, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants
was $100,000 which was issued at a $10,000 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Brio
– $92,400 (Note 11)
On
September 9, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $82,500 aggregate principal
amount of Note due September 9, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants
(“Warrants”) to purchase up to an aggregate of 13,750 shares of the Company’s Common Stock at an exercise price of
$10.00 per share. The aggregate cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants
was $75,000 which was issued at a $7,500 original issue discount from the face value of the Note. The conversion price for the principal
in connection with voluntary conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein,
such as stock splits and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $9,900.
Osher
– $123,200 (Note 10)
On
August 31, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due August 31, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 18,334 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $13,200.
Other
– $341,000 (Note 9)
In
July 2022, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “July 2022 Notes”) totaling
(i) $341,000 aggregate principal amount of Note (total of $310,000 cash was received) due in various dates in July 2023 based on $1.00
for each $0.90909 paid by the noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to
an aggregate of 16,923 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The conversion price for
the principal in connection with voluntary conversions by the holders of the convertible notes is $20.00 per share.
In
October 2023, the noteholders converted the remaining $324,500 in exchange for the issuance of 16,225 shares of Common Stock to the holders.
On
June 2, 2023, a third-party investor elected to convert $16,500 of principal of the Note into 825 common shares.
Osher
– $94,314 (Note 8)
On
June 22, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $82,500 aggregate principal
amount of Note due June 22, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 4,125 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $75,000 which was issued at
a $7,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $11,814.
Osher
– $63,302 (Note 7)
On
June 1, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $55,000 aggregate principal
amount of Note due June 1, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 2,750 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,000 which was issued at
a $5,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $8,302.
Brio
– $128,020 (Note 6)
On
May 10, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due May 10, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $18,020.
Osher
– $127,979 (Note 5)
On
April 28, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due April 28, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $17,979.
Osher
– $129,721 (Note 4)
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $19,721.
Brio
– $129,964 (Note 4)
On
March 23, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd. (“Brio”) of (i) $110,000 aggregate principal
amount of Note due March 23, 2023 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 5,500 shares of the Company’s Common Stock at an exercise price of $20.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $100,000 which was issued at
a $10,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $20.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
On
September 14, 2023, Brio agreed to extend the note to August 30, 2024 for original issue discount of $19,964.
Osher
– $225,377 (Note 3)
On
September 17, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $181,500 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due September
30, 2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to
purchase up to an aggregate of 206 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate
cash subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $165,000 which was issued at
a $16,500 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided
therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated September 17, 2020, for the number of warrant shares from 206 warrant shares to 11,634 warrant
shares at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from September 30, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
October 28, 2021, Osher elected to convert $16,714 of the aggregate principal amount of the Note of $199,650, into 1,071 common shares.
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $42,441.
Osher
– $74,621 (Note 2)
On
June 23, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $50,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture (the “Note”) due June 23,
2021, based on $1.00 for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase
up to an aggregate of 250 shares of the Company’s Common Stock at an exercise price of $1,200.00 per share. The aggregate cash
subscription amount received by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at a $0
original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions
by a holder of the convertible notes is $15.60 per share, as amended on October 20, 2020, subject to adjustment as provided therein,
such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Note for the aggregate principal amount from $50,000 to $55,000. The aggregate cash subscription amount received
by the Company from Osher for the issuance of the Note and Warrants was $50,005 which was issued at an amended $4,995 original issue
discount from the face value of the Note. |
|
|
|
|
● |
The
parties amended the Warrants dated June 23, 2020, for the number of warrant shares from 250 warrant shares to 3,526 warrant shares
at an exercise price of $23.60 per share. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows (see Note 12):
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $14,121.
Osher
– $564,138 (Note 1)
On
January 28, 2020 (the “Original Issue Date”), the Company entered into a Securities Purchase Agreement (the “Purchase
Agreement”) with respect to the sale and issuance to institutional investor Osher Capital Partners LLC (“Osher”) of
(i) $385,000 aggregate principal amount of Original Issue Discount Senior Convertible Debenture due January 26, 2021, based on $1.00
for each $0.90909 paid by Osher and (ii) five-year Common Stock Purchase Warrants to purchase up to an aggregate of 2,005 shares of the
Company’s Common Stock at an exercise price of $280.00 per share. The aggregate cash subscription amount received by the Company
from Osher for the issuance of the note and warrants was $350,005 which was issued at a $34,995 original issue discount from the face
value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder of the convertible notes
is $3.76 per share, as amended on October 20, 2020, subject to adjustment as provided therein, such as stock splits and stock dividends.
The
Company and Osher amended the convertible debt agreement as follows on October 20, 2020:
|
● |
The
parties amended the Warrants dated January 28, 2020, for the number of warrant shares from 2,005 warrant shares to 102,827 warrant
shares at an exercise price of $5.60 per share. |
|
|
|
|
● |
The
parties amended the Note to provide for interest at 8% per annum. |
|
|
|
|
● |
The
parties amended the Note for the maturity date from June 23, 2021 to October 20, 2021. |
On
October 22, 2021, the Company and Osher amended convertible debt agreements as follows:
|
● |
The
parties amended the October 20, 2020 Notes for the maturity date from October 20, 2021 to October 20, 2022. |
|
|
|
|
● |
The
parties amended the October 20, 2020 Notes for the aggregate principal amount and accrued interest from $652,300 to $717,530 which
is issued at a $65,230 original issue discount from the face value of the October 20, 2020 Notes now due October 20, 2022. |
|
|
|
|
● |
In
exchange for the extension of the Note, the Company issued Osher five-year warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock at an exercise price of $40.00 per share. |
On
September 14, 2023, Osher agreed to extend the note to August 30, 2024 for original issue discount of $106,758.
Previous
Noteholders
Other
– $145,200
On
November 21, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with a third-party
investor of (i) $145,200 aggregate principal amount of Note due November 21, 2023 based on $1.00 for each $0.90909 paid by the previous
noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 24,200 shares
of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate cash subscription amount received by the
Company from the previous noteholder for the issuance of the Note and Warrants was $132,000 which was issued at a $13,200 original issue
discount from the face value of the Note. The conversion price for the principal in connection with voluntary conversions by a holder
of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits and stock dividends.
On
November 23, 2022, third party investor elected to convert the aggregate principal amount of the Note, $145,200, into 24,200 common shares.
All
other previous notes were detailed in our Form 10-K filed on March 31, 2023. No changes occurred related to these notes during the period
covered by this Form 10-K.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
+ Details
Name: |
us-gaap_LongTermDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
ADVANCE FROM SHAREHOLDER
|
12 Months Ended |
Dec. 31, 2023 |
Advance From Shareholder |
|
ADVANCE FROM SHAREHOLDER |
NOTE
7 – ADVANCE FROM SHAREHOLDER
The
Company borrows funds from the Company’s CEO for working capital purposes from time to time. The Company has recorded the principal
balance due of $80,000 and $0 under Advance From Shareholder in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively.
The Company received advances of $80,000 and $0 and had no repayments for the years ended December 31, 2023 and 2022, respectively. The
advance from our CEO was not made pursuant to any loan agreements or promissory notes, is non-interest bearing and due on demand.
|
X |
- DefinitionAdvance from Shareholder [Text Block]
+ References
+ Details
Name: |
SIGYD_AdvanceFromShareholderTextBlock |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureAdvanceFromShareholderAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
STOCKHOLDERS’ DEFICIT
|
12 Months Ended |
Dec. 31, 2023 |
Equity [Abstract] |
|
STOCKHOLDERS’ DEFICIT |
NOTE
8 – STOCKHOLDERS’ DEFICIT
Preferred
Stock
The
Company authorized 10,000,000 shares of par value $0.0001 preferred stock, of which 32 and none shares are issued and outstanding at
December 31, 2023 and 2022, respectively.
During
fiscal 2023, holders of 161,684 shares of common stock elected to exchange these shares for an aggregate of 32 shares of Series B Convertible
Preferred Stock. Each Series B Convertible Preferred Share converts into 5,025.1 shares of the Company’s common stock, subject
to antidilution adjustments for any stock splits and recapitalizations, and for issuances of additional shares at an issue price of less
than the conversion ratio in the Warrant Exchange Agreement.
Rights
and Privileges - The holders of Series B preferred stock have various rights and preferences as follows:
Rights
- The holders of the Series B preferred stock have the same rights as the Common Stock, on an “as-if” converted
basis, with respect to any dividends, distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization,
merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily.
Voting
Rights - Shares of Series B preferred stock have no voting rights except on matters adversely affecting the rights of the
holders of the Preferred Stock.
Rank
- With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Corporation,
whether voluntary or involuntary, the Series B Preferred Stock shall rank equal to the Common Stock on an as converted basis.
Conversion
Rights - The holders of the preferred stock have certain conversion rights of such preferred stock into shares of common stock
of the Company. Each share of preferred stock is convertible at the option of the holder at any time into the number of shares of common
stock at the quotient of the stated value divided by the conversion price, subject to customary adjustments to protect against dilution.
Redemption
Rights – The Series B preferred stock is not subject to any redemption rights.
Common
Stock
The
Company has authorized 1,000,000,000 shares of par value $0.0001 common stock, of which 1,288,415 and 956,595 shares are outstanding
as of December 31, 2023 and 2022, respectively.
During
the year ended December 31, 2023, a total of 559,839 warrants were exchanged for 279,920 shares of the Company’s common stock.
On
June 2, 2023, a third-party investor elected to convert the aggregate principal amount of two Notes of $198,000, into 31,075 common shares.
Restricted
Stock Units
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Effective January 1, 2023, each Director shall receive an
annual grant of restricted stock units of $50,000. During the years ended December 31, 2023 and 2022, respectively, the Company recorded
stock-based compensation totaling $150,000 and $0, respectively, in the consolidated Statements of Operations (see Note 13).
Reverse
Stock Split
Effective
January 19, 2024, Board of Directors declared a one-for-forty
reverse stock split to shareholders of record on or before January 31, 2024 of the Company’s issued and outstanding
shares of common stock, outstanding warrants and options, and the Series B Convertible Preferred Stock. The number of shares of
common stock and convertible preferred shares obtainable upon exercise or conversion and the exercise prices and conversion rate
have been equitably adjusted. As such, all share and per share amounts have been retroactively
adjusted to reflect the reverse stock split.
Warrants
In
accordance with ASC 718-20, Compensation – Stock Compensation, a modification of a stock award is treated as an exchange
of the original award for a new award incurring additional compensation cost for any incremental value resulting from the modification.
Incremental compensation cost shall be measured as the excess of the fair value of the modified award over the fair value of the original
award immediately before its terms are modified and recognized over the vesting period. A short-term inducement shall be accounted for
as a modification of the terms of only those that accept the inducement.
In
March 2023, the Company offered a short-term inducement to the Company’s third party warrant holders in which the Company will
issue one share of the Company’s common stock in exchange for each two warrants were exchanged for 279,920 shares of the Company’s
common stock through December 31, 2023. The Company recognized a gain of $352,965 due to the modification of the warrants in the year
ended December 31, 2023, as a result of the modification.
On
October 22, 2021, the Company and Osher amended convertible debt agreements for the maturity date from October 20, 2021 to October 20,
2022. In exchange for the extension of the Note, the Company issued Osher 11,250 warrants to purchase an aggregate of 11,250 shares of
the Company’s common stock, valued at $197,501 (based on the Black Scholes valuation model on the date of grant). The warrants
are exercisable for a period of five years at $40.00 per share in whole or in part, as either a cash exercise or as a cashless exercise,
and fully vest at grant date. The Company accreted the value of the warrants ratably through October 20, 2022, recorded $0 and $147,720
for the years ended December 31, 2023 and 2022, respectively, and is classified in other expenses in the consolidated Statements of Operations.
See Note 6 for further warrant discussions.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
OPERATING LEASES
|
12 Months Ended |
Dec. 31, 2023 |
Operating Leases |
|
OPERATING LEASES |
NOTE
9 – OPERATING LEASES
On
May 27, 2021, the Company entered into a sixty-three month lease for its corporate office at $5,955 per month commencing June 15, 2021
maturing September 30, 2026. The Company accounts for this lease in accordance with ASC 842. Adoption of the standard resulted in the
initial recognition of operating lease ROU asset of $290,827 and operating lease liability of $290,827 as of June 15, 2021.
Operating
lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease
payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent
our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily
determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s
incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease
ROU asset includes any lease payments made and excludes lease incentives. Our variable lease payments primarily consist of maintenance
and other operating expenses from our real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities
and are recognized in the period in which the obligation for those payments is incurred. Our lease terms may include options to extend
or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized
on a straight-line basis over the lease term.
We
have lease agreements with lease and non-lease components. We have elected to account for these lease and non-lease components as a single
lease component. We are also electing not to apply the recognition requirements to short-term leases of twelve months or less and instead
will recognize lease payments as expense on a straight-line basis over the lease term.
The
components of lease expense and supplemental cash flow information related to leases for the period are as follows:
In
accordance with ASC 842, the components of lease expense were as follows:
SCHEDULE OF OPERATING LEASE COST AND SUPPLEMENTAL CASH FLOW INFORMATION
| |
2023 | | |
2022 | |
| |
Years ended December 31, | |
| |
2023 | | |
2022 | |
Operating lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
Short term lease cost | |
$ | - | | |
$ | - | |
Total lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
In
accordance with ASC 842, other information related to leases was as follows:
Years ended December 31, | |
2023 | | |
2022 | |
Operating cash flows from operating leases | |
$ | 54,263 | | |
$ | 72,714 | |
Cash paid for amounts included in the measurement of lease liabilities | |
$ | 54,263 | | |
$ | 72,714 | |
| |
| | | |
| | |
Weighted-average remaining lease term—operating leases | |
| 2.67 years | | |
| 3.67 years | |
Weighted-average discount rate—operating leases | |
| 10 | % | |
| 10 | % |
In
accordance with ASC 842, maturities of operating lease liabilities as of December 31, 2023 were as follows:
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating | |
Year ending: | |
Lease | |
2024 | |
$ | 77,142 | |
2026 | |
| 79,456 | |
2027 | |
| 54,225 | |
Total undiscounted cash flows | |
$ | 210,823 | |
| |
| | |
Reconciliation of lease liabilities: | |
| | |
Weighted-average remaining lease terms | |
| 2.67
years | |
Weighted-average discount rate | |
| 10 | % |
Present values | |
$ | 187,425 | |
| |
| | |
Lease liabilities—current | |
| 61,123 | |
Lease liabilities—long-term | |
| 126,302 | |
Lease liabilities—total | |
$ | 187,425 | |
| |
| | |
Difference between undiscounted and discounted cash flows | |
$ | 23,398 | |
Operating
lease cost was $71,676 and $71,676 for the years ended December 31, 2023 and 2022, respectively.
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
RELATED PARTY TRANSACTIONS
|
12 Months Ended |
Dec. 31, 2023 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
NOTE
10 – RELATED PARTY TRANSACTIONS
Other
than as set forth below, and as disclosed in Notes 7, 8, 13 and 14, there have not been any transaction entered into or been a participant
in which a related person had or will have a direct or indirect material interest.
Employment
Agreements
Mr.
Joyce receives an annual base salary of $455,000, plus bonus compensation not to exceed 50% of salary. Mr. Joyce’s employment also
provides for medical insurance, disability benefits and one year of severance pay if his employment is terminated without cause or due
to a change in control. Additionally, the Company has agreed to maintain a beneficial ownership target of 9% for Mr. Joyce. The Company
incurred compensation expense of $455,000 (including accrued compensation of $284,375) and $453,067 for the years ended December 31,
2023 and 2022, respectively.
Mr.
DeCiccio was hired December 6, 2023 as the Company’s Chief Financial Officer (“CFO”). Mr. DeCiccio receives an annual
base salary of $250,000, plus discretionary bonus compensation not to exceed 40% of salary. Mr. DeCiccio’s employment also provides
for medical insurance, disability benefits and three months of severance pay if his employment is terminated without cause or due to
a change in control. Additionally, Mr. DeCiccio was granted up to 17,500 options to purchase 17,500 of the Company’s common shares.
The Company incurred compensation expense of $9,000 (recorded as accrued compensation) for the year ended December 31, 2023. Prior to
Mr. DeCiccio hired as the CFO, he was a consultant to the Company. The Company has recorded a balance due to Mr. DeCiccio of $35,242
and $0 under Accounts Payable in the accompanying Balance Sheets at December 31, 2023 and 2022, respectively, for services rendered.
On
April 1, 2023, the Company entered into an Employment Agreement with Dr. Annette Marleau whereby Dr. Marleau became the Company’s
Chief Scientific Officer. Dr. Marleau receives an annual base salary of $300,000, with automatic 3% annual increases plus bonus compensation
not to exceed 40% of salary. Dr. Marleau’s employment also provides for medical insurance, disability benefits and up to six months
of severance pay if her employment is terminated by the Company. The Company incurred compensation expense of $225,000 (including accrued
compensation of $100,000) and $0 for the years ended December 31, 2023 and 2022, respectively.
Sigyn
had no employment agreement with its CTO but still incurred compensation on behalf of the CTO. The Company incurred compensation expense
of $240,000 (including accrued compensation of $160,000) and $233,678 for the years ended December 31, 2023 and 2022, respectively.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
INCOME TAXES
|
12 Months Ended |
Dec. 31, 2023 |
Income Tax Disclosure [Abstract] |
|
INCOME TAXES |
NOTE
11 – INCOME TAXES
At
December 31, 2023, net operating loss carry forwards for Federal and state income tax purposes totaling approximately $2,782,000 available
to reduce future income which under the Tax Cuts and Jobs Act of 2018, allows for an indefinite carryforward period, with carryforwards
limited to 80% of each subsequent year’s net income. There is no income tax affect due to the recognition of a full valuation allowance
on the expected tax benefits of future loss carry forwards based on uncertainty surrounding realization of such assets.
A
reconciliation of the statutory income tax rates and the effective tax rate is as follows:
SCHEDULE
OF RECONCILIATION OF STATUTORY INCOME TAX RATES AND EFFECTIVE TAX RATE
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Statutory U.S. federal rate | |
| 21.0 | % | |
| 21.0 | % |
State income tax, net of federal benefit | |
| 7.0 | % | |
| 7.0 | % |
Permanent differences | |
| - | % | |
| (7.5 | )% |
Valuation allowance | |
| (28.0 | )% | |
| (20.5 | )% |
| |
| | | |
| | |
Provision for income taxes | |
| 0.0 | % | |
| 0.0 | % |
The
tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:
SCHEDULE
OF DEFERRED TAX ASSETS
| |
2023 | | |
2022 | |
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Deferred tax assets: | |
| | | |
| | |
Net operating loss carry forwards | |
$ | 2,781,577 | | |
$ | 1,674,531 | |
Accrued payroll | |
| 203,771 | | |
| - | |
Stock-based compensation | |
| 60,321 | | |
| - | |
Depreciation and amortization | |
| (21,911 | ) | |
| - | |
Valuation allowance | |
| (3,023,758 | ) | |
| (1,674,531 | ) |
| |
| | | |
| | |
Total | |
$ | - | | |
$ | - | |
Major
tax jurisdictions are the United States and California. All of the tax years will remain open three and four years for examination by
the Federal and state tax authorities, respectively, from the date of utilization of the net operating loss. There are no tax audits
pending.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
EARNINGS PER SHARE
|
12 Months Ended |
Dec. 31, 2023 |
Earnings Per Share [Abstract] |
|
EARNINGS PER SHARE |
NOTE
12 – EARNINGS PER SHARE
FASB
ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings
(loss) per share (EPS) computations.
Basic
earnings (loss) per share are computed by dividing net earnings available to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the
denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares
had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number
of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
Convertible notes payable | |
| 365,274 | | |
| 293,174 | |
Restricted stock units | |
| 17,178 | | |
| - | |
Warrants to purchase shares of common stock | |
| 78,000 | | |
| 379,812 | |
Total potentially dilutive shares | |
| 460,452 | | |
| 672,986 | |
The
following table sets forth the computation of basic and diluted net income per share:
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Net loss attributable to the common stockholders | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
| |
| | | |
| | |
Basic weighted average outstanding shares of common stock | |
| 1,100,372 | | |
| 934,915 | |
Dilutive effect of options and warrants | |
| - | | |
| - | |
Diluted weighted average common stock and common stock equivalents | |
| 1,100,372 | | |
| 934,915 | |
| |
| | | |
| | |
Loss per share: | |
| | | |
| | |
Basic and diluted | |
$ | (3.77 | ) | |
$ | (3.13 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
COMMITMENTS AND CONTINGENCIES
|
12 Months Ended |
Dec. 31, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
COMMITMENTS AND CONTINGENCIES |
NOTE
13 – COMMITMENTS AND CONTINGENCIES
Legal
From
time to time, various lawsuits and legal proceedings may arise in the ordinary course of business. However, litigation is subject to
inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are
currently not aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial
condition or operating results.
Board
of Directors Compensation
Effective
October 10, 2022, the Company’s Board of Directors appointed Ms. Richa Nand, Mr. Jim Dorst, and Mr. Chris Wetzel as non-executive
members to the Company’s Board of Directors (“Director”). Each Director shall receive an annual retainer of $30,000
paid in equal quarterly amounts at the end of each quarter. In addition, each Director shall receive a grant of restricted stock units
of $50,000, or at the discretion of the Board of Directors, options to acquire shares of common stock. Restricted stock units will be
valued based on the average of the five trading days preceding and including the date of grant and will vest at a rate determined by
the Board of Directors over one year. If options are granted, the options will be valued at the exercise price based on the average of
the five trading days preceding and including the date of grant, have a ten-year term, and will vest at a rate determined by the Board
of Directors.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
SUBSEQUENT EVENTS
|
12 Months Ended |
Dec. 31, 2023 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
NOTE
14 – SUBSEQUENT EVENTS
The
Company evaluated all events or transactions that occurred after December 31, 2023 up through the date the financial statements were
available to be issued. During this period, the Company did not have any material recognizable subsequent events required to be disclosed
as of and for the period ended December 31, 2023, except for the following:
Brio
– $44,000
On
January 8, 2024, the Company entered into an Original Issue Discount Senior Convertible Debenture (the “Note”) with respect
to the sale and issuance to institutional investor Brio Capital Master Fund Ltd (“Brio”) of (i) $44,000 aggregate principal
amount of Note due January 8, 2025 based on $1.00 for each $0.90909 paid by Brio and (ii) five-year Common Stock Purchase Warrants (“Warrants”)
to purchase up to an aggregate of 7,333 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The aggregate
cash subscription amount received by the Company from Brio for the issuance of the Note and Warrants was $40,000 which was issued at
a $4,000 original issue discount from the face value of the Note. The conversion price for the principal in connection with voluntary
conversions by a holder of the convertible notes is $6.00 per share, subject to adjustment as provided therein, such as stock splits
and stock dividends.
Shares
Cancelled
On
January 9, 2024, the Company’s CTO agreed to surrender 64,100 common shares held by him and were cancelled by the Company.
Reverse
Stock Split
Effective
January 19, 2024, Board of Directors declared a one-for-forty reverse stock split to shareholders of record on or before January 31,
2024 of the Company’s issued and outstanding shares of common stock, outstanding warrants and options, and the Series B Convertible
Preferred Stock. The number of shares of common stock obtainable upon exercise or conversion and the exercise prices and conversion rate
have been equitably adjusted, and convertible preferred shares. As such, all share and per share amounts have been retroactively adjusted
to reflect the reverse stock split.
Advance
from Shareholder
In
January 2024, the Company received an additional advance of $25,000 from the Company’s CEO for working capital purposes with a
balance due of $105,000 as of February 15, 2024.
2024 Convertible Notes
In
February 2024, the Company entered into an Original Issue Discount Senior Convertible Debentures (the “2024 Notes”) totaling
(i) $50,050 aggregate principal amount of Note (total of $45,500 cash was received) due in February 2025 based on $1.00 for each $0.90909
paid by the noteholder and (ii) five-year Common Stock Purchase Warrants (“Warrants”) to purchase up to an aggregate of 8,343
shares of the Company’s Common Stock at an exercise price of $10.00 per share. The conversion
price for the principal in connection with voluntary conversions by the holders of the convertible notes is $6.00 per share.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
|
12 Months Ended |
Dec. 31, 2023 |
Accounting Policies [Abstract] |
|
Use of Estimates |
Use
of Estimates
The
preparation of these financial statements in accordance with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and
expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the
financial statements. The more significant estimates and assumptions by management include among others: warrant valuation. The
Company calculates the fair value of warrants using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method
requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest
rate and the fair value of the underlying common stock on the date of grant. The current economic environment has increased the
degree of uncertainty inherent in these estimates and assumptions.
|
Cash |
Cash
The
Company’s cash is held in bank accounts in the United States and is insured by the Federal Deposit Insurance Corporation (FDIC)
up to $250,000. The Company has not experienced any cash losses.
|
Income Taxes |
Income
Taxes
Income
taxes are accounted for under an asset and liability approach. This process involves calculating the temporary and permanent differences
between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Balance Sheets in accordance
with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The likelihood that its
deferred tax assets will be recovered from future taxable income must be assessed and, to the extent that recovery is not likely, a valuation
allowance is established. Changes in the valuation allowance in a period are recorded through the income tax provision in the consolidated
Statements of Operations.
ASC
740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s consolidated financial statements and
prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to
be taken on a tax return. Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized
at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on
derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation
of ASC 740-10 and currently, the Company does not have a liability for unrecognized income tax benefits.
|
Advertising and Marketing Costs |
Advertising
and Marketing Costs
Advertising
expenses are recorded as general and administrative expenses when they are incurred. The Company had $392 of advertising expenses for
the year ended December 31, 2023 and had $457 of advertising expenses for the year ended December 31, 2022.
|
Research and Development |
Research
and Development
All
research and development costs are expensed as incurred. The Company incurred research and development expense of $798,165 and $657,657
for the years ended December 31, 2023 and 2022, respectively.
|
Inventories |
Inventories
In
conjunction with the October 19, 2020 Share Exchange Agreement, the Company kept the gem inventory of Reign Resources Corporation. Inventories
are stated at the lower of cost or market (net realizable value) on a lot basis each quarter. A lot is determined by the cut, clarity,
size, and weight of the sapphires. Inventory consists of sapphire jewels that meet rigorous grading criteria and are of cuts and sizes
most commonly used in the jewelry industry. As of December 31, 2023 and 2022, the Company carried primarily loose sapphire jewels, jewelry
for sale, and jewelry held as samples. Samples are used to show potential customers what the jewelry would look like. Promotional items
given to customers that are not expected to be returned will be removed from inventory and expensed. There have been no promotional items
given to customers as of December 31, 2023. The Company performs its own in-house assessment based on gem guide and the current market
price for metals to value its inventory on an annual basis or if circumstances dictate sooner to determine if the estimated fair value
is greater or less than cost. In addition, the inventory is reviewed each quarter by the Company against industry prices from gem-guide
and if there is a potential impairment, the Company would appraise the inventory. The estimated fair value is subject to significant
change due to changes in popularity of cut, perceived grade of the clarity of the sapphires, the number, type and size of inclusions,
the availability of other similar quality and size sapphires, and other factors. As a result, the internal assessed value of the sapphires
could be significantly lower from the current estimated fair value. Loose sapphire jewels do not degrade in quality over time.
|
Property and Equipment |
Property
and Equipment
Property
and equipment are carried at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets, generally
five years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets
are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are
included in income in the year of disposition.
|
Intangible Assets |
Intangible
Assets
Intangible
assets consist primarily of website development costs. Our intangible assets are being amortized on a straight-line basis over a period
of three years.
|
Impairment of Long-lived Assets |
Impairment
of Long-lived Assets
We
periodically evaluate whether the carrying value of property, equipment and intangible assets has been impaired when circumstances indicate
the carrying value of those assets may not be recoverable. The carrying amount is not recoverable if it exceeds the sum of the undiscounted
cash flows expected to result from the use and eventual disposition of the asset. If the carrying value is not recoverable, the impairment
loss is measured as the excess of the asset’s carrying value over its fair value.
Our
impairment analyses require management to apply judgment in estimating future cash flows as well as asset fair values, including forecasting
useful lives of the assets, assessing the probability of different outcomes, and selecting the discount rate that reflects the risk inherent
in future cash flows. If the carrying value is not recoverable, we assess the fair value of long-lived assets using commonly accepted
techniques, and may use more than one method, including, but not limited to, recent third-party comparable sales and discounted cash
flow models. If actual results are not consistent with our assumptions and estimates, or our assumptions and estimates change due to
new information, we may be exposed to an impairment charge in the future. As of December 31, 2023 and 2022, the Company had not experienced
impairment losses on its long-lived assets.
|
Fair Value of Financial Instruments |
Fair
Value of Financial Instruments
The
provisions of accounting guidance, FASB Topic ASC 825 requires all entities to disclose the fair value of financial instruments, both
assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines
fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing
parties. As of December 31, 2023 and 2022, the fair value of cash, accounts payable, accrued expenses, advance from shareholder, and
notes payable approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which
fluctuate with market rates.
|
Fair Value Measurements |
Fair
Value Measurements
Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable,
as follows:
|
● |
Level
1 – Quoted prices in active markets for identical assets or liabilities. |
|
|
|
|
● |
Level
2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets
or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or liabilities. |
|
|
|
|
● |
Level
3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the
fair value of the assets or liabilities |
The
carrying value of financial assets and liabilities recorded at fair value are measured on a recurring or nonrecurring basis. Financial
assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. There
were no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and
liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. There
have been no transfers between levels.
|
Debt |
Debt
The
Company issues debt that may have separate warrants, conversion features, or no equity-linked attributes.
Embedded
Conversion Features
The
Company evaluates embedded conversion features within convertible debt under ASC 815, Derivatives and Hedging, to determine whether
the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with
changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument
is evaluated under ASC 470-20, Debt with Conversion and Other Options, for consideration of any beneficial conversion feature.
Derivative
Financial Instruments
The
Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities,
the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair
value reported as charges or credits to income.
For
option-based simple derivative financial instruments, the Company uses the Monte Carlo simulations to value the derivative instruments
at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should
be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. There were no derivative financial instruments
as of December 31, 2023 and 2022 and no charges or credits to income for the years ended December 31, 2023 and 2022.
Debt
Issue Costs and Debt Discount
The
Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs
may be paid in the form of cash or equity (such as warrants). These costs are amortized to interest expense through the maturity of the
debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized debt issue costs and debt discount are presented net of the related debt on the consolidated balance sheets.
Original
Issue Discount
For
certain convertible debt issued, the Company may provide the debt holder with an original issue discount. The original issue discount
would be recorded to debt discount, reducing the face amount of the note and is amortized to interest expense through the maturity of
the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately
expensed. Any unamortized original issue discounts are presented net of the related debt on the consolidated balance sheets.
If
the conversion feature does not qualify for either the derivative treatment or as a beneficial conversion feature (“BCF”),
the convertible debt is treated as traditional debt.
|
Basic and diluted earnings per share |
Basic
and diluted earnings per share
Basic
net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period,
without consideration for common stock equivalents. Diluted earnings (loss) per share are computed on the basis of the weighted average
number of common shares (including common stock subject to redemption) plus dilutive potential common shares outstanding for the reporting
period. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents,
because their inclusion would be anti-dilutive.
Basic
and diluted earnings (loss) per share are the same since net losses for all periods presented and including the additional potential
common shares would have an anti-dilutive effect.
|
Stock Based Compensation |
Stock
Based Compensation
In
accordance with ASC No. 718, Compensation – Stock Compensation (“ASC 718”), we measure the compensation costs
of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over
the period during which employees are required to provide services. Share-based compensation arrangements include stock options, restricted
share plans, performance-based awards, share appreciation rights and employee share purchase plans. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.
|
Non-Employee Stock-Based Compensation |
Non-Employee
Stock-Based Compensation
In
accordance with ASC 505, Equity Based Payments to Non-Employees, issuances of the Company’s common stock or warrants for
acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants
or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached
(a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive
for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may
be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on
the date of the agreement. As a result, in this situation in which vesting periods do not exist as the instruments fully vested on the
date of agreement, the Company determines such date to be the measurement date and will record the estimated fair market value of the
instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement
of operations over the contract period. When it is appropriate for the Company to recognize the cost of a transaction during financial
reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is
measured at the then-current fair values at each of those interim financial reporting dates.
|
Concentrations, Risks, and Uncertainties |
Concentrations,
Risks, and Uncertainties
Business
Risk
Substantial
business risks and uncertainties are inherent to an entity, including the potential risk of business failure.
The
Company is headquartered and operates in the United States. To date, the Company has generated no revenues from operations. There can
be no assurance that the Company will be able to raise additional capital and failure to do so would have a material adverse effect on
the Company’s financial position, results of operations and cash flows. Also, the success of the Company’s operations is
subject to numerous contingencies, some of which are beyond management’s control. Currently, these contingencies include general
economic conditions, price of components, competition, and governmental and political conditions.
Interest
rate risk
Financial
assets and liabilities do not have material interest rate risk.
Credit
risk
The
Company is exposed to credit risk from its cash in banks. The credit risk on cash in banks is limited because the counterparties are
recognized financial institutions.
Seasonality
The
business is not subject to substantial seasonal fluctuations.
Major
Suppliers
Sigyn
Therapy is comprised of components that are supplied by various industry vendors. Additionally, the Company is reliant on a
third-party organization to conduct clinical development studies that are necessary to advance Sigyn Therapy toward the
marketplace.
Should
the relationship with an industry vendor or third-party clinical development organization be interrupted or discontinued, it is believed
that alternate component suppliers and third-party clinical development organizations could be identified to support the continued advancement
of Sigyn Therapy.
|
Recent Accounting Pronouncements |
Recent
Accounting Pronouncements
There
are no recently issued accounting updates that are expected to have a material impact on the Company’s consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for advertising cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//710/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//712/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//715/tableOfContent
+ Details
Name: |
us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for credit risk.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
+ Details
Name: |
us-gaap_ConcentrationRiskCreditRisk |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1
+ Details
Name: |
us-gaap_DebtPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
+ Details
Name: |
us-gaap_FairValueMeasurementPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 60 -Paragraph 1 -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1
+ Details
Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IntangibleAssetsFiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details
Name: |
us-gaap_InventoryPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
PROPERTY AND EQUIPMENT (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Property, Plant and Equipment [Abstract] |
|
SCHEDULE OF PROPERTY AND EQUIPMENT |
Property
and equipment consisted of the following as of:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
Estimated Life | |
December 31, 2023 | | |
December 31, 2022 | |
| |
| |
| | |
| |
Office equipment | |
5 years | |
$ | 29,041 | | |
$ | 29,041 | |
Computer equipment | |
3 years | |
| 3,157 | | |
| 3,157 | |
Property and equipment, gross | |
3 years | |
| 3,157 | | |
| 3,157 | |
Accumulated depreciation | |
| |
| (16,902 | ) | |
| (10,146 | ) |
Property and equipment, net | |
| |
$ | 15,296 | | |
$ | 22,052 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
CONVERTIBLE PROMISSORY DEBENTURES (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Debt Disclosure [Abstract] |
|
SCHEDULE OF CONVERTIBLE NOTES PAYABLE |
Convertible
notes payable consisted of the following:
SCHEDULE OF CONVERTIBLE NOTES PAYABLE
| |
December 31, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
January 28, 2020 ($564,138) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 1”) | |
$ | 564,138 | | |
$ | 457,380 | |
June 23, 2020 ($74,621) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 2”) | |
| 74,621 | | |
| 60,500 | |
September 17, 2020 ($225,377) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 3”). | |
| 225,377 | | |
| 182,936 | |
March 23, 2022 ($259,685) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 4”) | |
| 259,685 | | |
| 220,000 | |
April 28, 2022 ($127,979) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 5”) | |
| 127,979 | | |
| 110,000 | |
May 10, 2022 ($128,020) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 6”) | |
| 128,020 | | |
| 110,000 | |
June 1, 2022 ($63,301) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 7”) | |
| 63,302 | | |
| 55,000 | |
June 22, 2022 ($94,314) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 8”) | |
| 94,314 | | |
| 82,500 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $341,000 of principal of the Note into 17,050 common shares (“Note 9”) | |
| - | | |
| 341,000 | |
August 31, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 10”) | |
| 123,200 | | |
| 110,000 | |
September 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024 (“Note 11”) | |
| 92,400 | | |
| 82,500 | |
September 20, 2022 ($123,200) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 12”) | |
| 123,200 | | |
| 110,000 | |
October 20, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due October 20, 2023 (“Note 13”) | |
| 110,000 | | |
| 110,000 | |
November 9, 2022 ($92,400) – 0% interest per annum outstanding principal and interest due August 30, 2024, as amended (“Note 14”) | |
| 92,400 | | |
| 82,500 | |
November 14, 2022 ($55,000) – 0% interest per annum outstanding principal and interest due November 14, 2023 (“Note 15”) | |
| 55,000 | | |
| 55,000 | |
December 22, 2022 ($110,000) – 0% interest per annum outstanding principal and interest due December 22, 2023 (“Note 16”) | |
| 110,000 | | |
| 110,000 | |
July 2022 ($341,000) – 0% interest per annum outstanding principal and interest due various dates July 2023. During fiscal year 2023, the investors elected to convert $1,179,200 of principal of the Note into 196,534 common shares (“Note 17”) | |
| 264,000 | | |
| - | |
| |
| | | |
| | |
Total convertible notes payable | |
| 2,507,636 | | |
| 2,279,316 | |
Original issue discount | |
| (225,835 | ) | |
| (74,502 | ) |
Beneficial conversion feature | |
| (22,013 | ) | |
| (175,275 | ) |
Debt discount | |
| (49,489 | ) | |
| (392,883 | ) |
| |
| | | |
| | |
Total convertible notes payable | |
$ | 2,210,299 | | |
$ | 1,636,656 | |
|
SCHEDULE OF PRINCIPAL PAYMENTS DUE ON CONVERTIBLE PROMISSORY DEBENTURES |
Principal
payments on convertible promissory debentures are due as follows:
SCHEDULE OF PRINCIPAL PAYMENTS DUE ON CONVERTIBLE PROMISSORY DEBENTURES
Year ending December 31, | |
| |
2024 | |
$ | 2,507,636 | |
Long-Term Debt | |
$ | 2,507,636 | |
|
SCHEDULE OF CHANGES IN CONVERTIBLE NOTES |
Changes
in convertible notes were as follows:
SCHEDULE OF CHANGES IN CONVERTIBLE NOTES
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Convertible notes payable, net, as of December 31, 2021 | |
| 457,380 | | |
| 60,500 | | |
| 182,936 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 700,816 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2022 | |
| - | | |
| - | | |
| - | | |
| 220,000 | | |
| 110,000 | | |
| 110,000 | | |
| 55,000 | | |
| 82,500 | | |
| 341,000 | | |
| 110,000 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,578,500 | |
Convertible notes payable as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
Convertible notes payable, Begining balance | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 220,000 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 55,000 | | |
$ | 82,500 | | |
$ | 341,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 110,000 | | |
$ | 110,000 | | |
$ | 82,500 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | - | | |
$ | - | | |
$ | 2,279,316 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable issued in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Convertible notes payable issued | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,443,200 | | |
| - | | |
| 1,748,520 | |
Conversion of debt for common stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (341,000 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,179,200 | ) | |
| - | | |
| (1,520,200 | ) |
Convertible notes payable as of December 31, 2023 | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
Convertible notes payable, Ending balance | |
$ | 564,138 | | |
$ | 74,621 | | |
$ | 225,377 | | |
$ | 259,685 | | |
$ | 127,979 | | |
$ | 128,020 | | |
$ | 63,302 | | |
$ | 94,314 | | |
$ | - | | |
$ | 123,200 | | |
$ | 92,400 | | |
$ | 123,200 | | |
$ | 110,000 | | |
$ | 92,400 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 264,000 | | |
$ | - | | |
$ | 2,507,636 | |
|
SCHEDULE OF CHANGES IN NOTE DISCOUNTS |
Changes
in note discounts were as follows:
SCHEDULE OF CHANGES IN NOTE DISCOUNTS
| |
Note 1 | | |
Note 2 | | |
Note 3 | | |
Note 4 | | |
Note 5 | | |
Note 6 | | |
Note 7 | | |
Note 8 | | |
Note 9 | | |
Note 10 | | |
Note 11 | | |
Note 12 | | |
Note 13 | | |
Note 14 | | |
Note 15 | | |
Note 16 | | |
Note 17 | | |
Other | | |
Totals | |
Note discounts as of December 31, 2021 | |
| 34,176 | | |
| 4,521 | | |
| 14,917 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 53,614 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2022 | |
| - | | |
| - | | |
| - | | |
| 113,418 | | |
| 44,786 | | |
| 44,787 | | |
| 22,794 | | |
| 34,861 | | |
| 140,289 | | |
| 64,104 | | |
| 82,500 | | |
| 110,000 | | |
| 110,000 | | |
| 82,500 | | |
| 55,000 | | |
| 110,000 | | |
| - | | |
| - | | |
| 1,015,039 | |
2022 accretion of note discounts | |
| (34,176 | ) | |
| (4,521 | ) | |
| (14,917 | ) | |
| (87,938 | ) | |
| (30,308 | ) | |
| (28,836 | ) | |
| (13,301 | ) | |
| (18,336 | ) | |
| (70,720 | ) | |
| (32,316 | ) | |
| (39,994 | ) | |
| (49,874 | ) | |
| (23,671 | ) | |
| (12,822 | ) | |
| (7,726 | ) | |
| (6,537 | ) | |
| - | | |
| 50,000 | | |
| (425,993 | ) |
Note discounts as of December 31, 2022 | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
Note discounts, Begining balance | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 25,480 | | |
$ | 14,478 | | |
$ | 15,951 | | |
$ | 9,493 | | |
$ | 16,525 | | |
$ | 69,569 | | |
$ | 31,788 | | |
$ | 42,506 | | |
$ | 60,126 | | |
$ | 86,329 | | |
$ | 69,678 | | |
$ | 47,274 | | |
$ | 103,463 | | |
$ | - | | |
$ | 50,000 | | |
$ | 642,660 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Note discounts issued in conjunction with debt in 2023 | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
Note discounts issued in conjunction with debt | |
| 106,758 | | |
| 14,121 | | |
| 42,441 | | |
| 39,685 | | |
| 17,979 | | |
| 18,020 | | |
| 8,302 | | |
| 11,814 | | |
| - | | |
| 13,200 | | |
| 9,900 | | |
| 13,200 | | |
| - | | |
| 9,900 | | |
| - | | |
| - | | |
| 1,390,539 | | |
| - | | |
| 1,695,859 | |
2023 accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Accretion of note discounts | |
| (31,589 | ) | |
| (4,178 | ) | |
| (12,558 | ) | |
| (37,223 | ) | |
| (19,799 | ) | |
| (21,283 | ) | |
| (11,949 | ) | |
| (20,019 | ) | |
| (69,569 | ) | |
| (35,694 | ) | |
| (45,435 | ) | |
| (64,032 | ) | |
| (86,329 | ) | |
| (71,785 | ) | |
| (47,274 | ) | |
| (103,463 | ) | |
| (1,309,003 | ) | |
| (50,000 | ) | |
| (2,041,182 | ) |
Note discounts as of December 31, 2023 | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
Note discounts, Ending balance | |
$ | 75,169 | | |
$ | 9,943 | | |
$ | 29,883 | | |
$ | 27,942 | | |
$ | 12,658 | | |
$ | 12,688 | | |
$ | 5,846 | | |
$ | 8,320 | | |
$ | - | | |
$ | 9,294 | | |
$ | 6,971 | | |
$ | 9,294 | | |
$ | - | | |
$ | 7,793 | | |
$ | - | | |
$ | - | | |
$ | 81,536 | | |
$ | - | | |
$ | 297,337 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Convertible notes payable, net, as of December 31, 2022 | |
$ | 457,380 | | |
$ | 60,500 | | |
$ | 182,936 | | |
$ | 194,520 | | |
$ | 95,522 | | |
$ | 94,049 | | |
$ | 45,507 | | |
$ | 65,975 | | |
$ | 271,431 | | |
$ | 78,212 | | |
$ | 39,994 | | |
$ | 49,874 | | |
$ | 23,671 | | |
$ | 12,822 | | |
$ | 7,726 | | |
$ | 6,537 | | |
$ | - | | |
$ | (50,000 | ) | |
$ | 1,636,656 | |
Convertible notes payable, net, as of December 31, 2023 | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
Convertible notes payable, net | |
$ | 488,969 | | |
$ | 64,678 | | |
$ | 195,494 | | |
$ | 231,743 | | |
$ | 115,321 | | |
$ | 115,332 | | |
$ | 57,456 | | |
$ | 85,994 | | |
$ | - | | |
$ | 113,906 | | |
$ | 85,429 | | |
$ | 113,906 | | |
$ | 110,000 | | |
$ | 84,607 | | |
$ | 55,000 | | |
$ | 110,000 | | |
$ | 182,464 | | |
$ | - | | |
$ | 2,210,299 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
2022 Effective interest rate | |
| 7 | % | |
| 7 | % | |
| 8 | % | |
| 40 | % | |
| 28 | % | |
| 26 | % | |
| 24 | % | |
| 22 | % | |
| 21 | % | |
| 29 | % | |
| 48 | % | |
| 45 | % | |
| 22 | % | |
| 16 | % | |
| 14 | % | |
| 6 | % | |
| -% | | |
| -% | | |
| 19 | % |
2023 Effective interest rate | |
| 6 | % | |
| 6 | % | |
| 6 | % | |
| 14 | % | |
| 15 | % | |
| 17 | % | |
| 19 | % | |
| 21 | % | |
| - | % | |
| 29 | % | |
| 49 | % | |
| 52 | % | |
| 78 | % | |
| 78 | % | |
| 86 | % | |
| 94 | % | |
| 496 | % | |
| -% | | |
| 81 | % |
|
X |
- DefinitionSchedule Of Changes In Note Discounts [Table Text Block]
+ References
+ Details
Name: |
SIGYD_ScheduleOfChangesInNoteDiscountsTableTextBlock |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.
+ References
+ Details
Name: |
us-gaap_ConvertibleDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
+ Details
Name: |
us-gaap_ScheduleOfDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
OPERATING LEASES (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Operating Leases |
|
SCHEDULE OF OPERATING LEASE COST AND SUPPLEMENTAL CASH FLOW INFORMATION |
In
accordance with ASC 842, the components of lease expense were as follows:
SCHEDULE OF OPERATING LEASE COST AND SUPPLEMENTAL CASH FLOW INFORMATION
| |
2023 | | |
2022 | |
| |
Years ended December 31, | |
| |
2023 | | |
2022 | |
Operating lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
Short term lease cost | |
$ | - | | |
$ | - | |
Total lease expense | |
$ | 71,676 | | |
$ | 71,676 | |
In
accordance with ASC 842, other information related to leases was as follows:
Years ended December 31, | |
2023 | | |
2022 | |
Operating cash flows from operating leases | |
$ | 54,263 | | |
$ | 72,714 | |
Cash paid for amounts included in the measurement of lease liabilities | |
$ | 54,263 | | |
$ | 72,714 | |
| |
| | | |
| | |
Weighted-average remaining lease term—operating leases | |
| 2.67 years | | |
| 3.67 years | |
Weighted-average discount rate—operating leases | |
| 10 | % | |
| 10 | % |
|
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES |
In
accordance with ASC 842, maturities of operating lease liabilities as of December 31, 2023 were as follows:
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating | |
Year ending: | |
Lease | |
2024 | |
$ | 77,142 | |
2026 | |
| 79,456 | |
2027 | |
| 54,225 | |
Total undiscounted cash flows | |
$ | 210,823 | |
| |
| | |
Reconciliation of lease liabilities: | |
| | |
Weighted-average remaining lease terms | |
| 2.67
years | |
Weighted-average discount rate | |
| 10 | % |
Present values | |
$ | 187,425 | |
| |
| | |
Lease liabilities—current | |
| 61,123 | |
Lease liabilities—long-term | |
| 126,302 | |
Lease liabilities—total | |
$ | 187,425 | |
| |
| | |
Difference between undiscounted and discounted cash flows | |
$ | 23,398 | |
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCostTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
INCOME TAXES (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Income Tax Disclosure [Abstract] |
|
SCHEDULE OF RECONCILIATION OF STATUTORY INCOME TAX RATES AND EFFECTIVE TAX RATE |
A
reconciliation of the statutory income tax rates and the effective tax rate is as follows:
SCHEDULE
OF RECONCILIATION OF STATUTORY INCOME TAX RATES AND EFFECTIVE TAX RATE
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Statutory U.S. federal rate | |
| 21.0 | % | |
| 21.0 | % |
State income tax, net of federal benefit | |
| 7.0 | % | |
| 7.0 | % |
Permanent differences | |
| - | % | |
| (7.5 | )% |
Valuation allowance | |
| (28.0 | )% | |
| (20.5 | )% |
| |
| | | |
| | |
Provision for income taxes | |
| 0.0 | % | |
| 0.0 | % |
|
SCHEDULE OF DEFERRED TAX ASSETS |
The
tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following:
SCHEDULE
OF DEFERRED TAX ASSETS
| |
2023 | | |
2022 | |
| |
December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Deferred tax assets: | |
| | | |
| | |
Net operating loss carry forwards | |
$ | 2,781,577 | | |
$ | 1,674,531 | |
Accrued payroll | |
| 203,771 | | |
| - | |
Stock-based compensation | |
| 60,321 | | |
| - | |
Depreciation and amortization | |
| (21,911 | ) | |
| - | |
Valuation allowance | |
| (3,023,758 | ) | |
| (1,674,531 | ) |
| |
| | | |
| | |
Total | |
$ | - | | |
$ | - | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 12 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
EARNINGS PER SHARE (Tables)
|
12 Months Ended |
Dec. 31, 2023 |
Earnings Per Share [Abstract] |
|
SCHEDULE OF ANTI DILUTIVE SECURITIES |
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because the effects were anti-dilutive
based on the application of the treasury stock method and because the Company incurred net losses during the period:
SCHEDULE
OF ANTI DILUTIVE SECURITIES
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
Convertible notes payable | |
| 365,274 | | |
| 293,174 | |
Restricted stock units | |
| 17,178 | | |
| - | |
Warrants to purchase shares of common stock | |
| 78,000 | | |
| 379,812 | |
Total potentially dilutive shares | |
| 460,452 | | |
| 672,986 | |
|
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE |
The
following table sets forth the computation of basic and diluted net income per share:
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE
| |
2023 | | |
2022 | |
| |
Years Ended December 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Net loss attributable to the common stockholders | |
$ | (4,145,936 | ) | |
$ | (2,929,817 | ) |
| |
| | | |
| | |
Basic weighted average outstanding shares of common stock | |
| 1,100,372 | | |
| 934,915 | |
Dilutive effect of options and warrants | |
| - | | |
| - | |
Diluted weighted average common stock and common stock equivalents | |
| 1,100,372 | | |
| 934,915 | |
| |
| | | |
| | |
Loss per share: | |
| | | |
| | |
Basic and diluted | |
$ | (3.77 | ) | |
$ | (3.13 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - USD ($)
|
|
12 Months Ended |
|
Oct. 19, 2020 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Feb. 16, 2024 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
Converted liabilities |
|
$ 1,520,200
|
$ 145,200
|
|
Common stock, issued |
|
1,288,415
|
956,595
|
|
Common stock, outstanding |
|
1,288,415
|
956,595
|
|
Subsequent Event [Member] |
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
Common stock, issued |
|
|
|
1,224,315
|
Common stock, outstanding |
|
|
|
1,224,315
|
Common stock, shares held |
|
|
|
647,415
|
Share Exchange Agreement [Member] |
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
Percentage of common stock outstanding |
75.00%
|
|
|
|
Converted liabilities |
$ 3,429,516
|
|
|
|
Conversion shares |
7,907,351
|
|
|
|
Share Exchange Agreement [Member] | Sigyn Stockholders [Member] |
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
Percentage of acquisition ownership interest |
75.00%
|
|
|
|
Share Exchange Agreement [Member] | Issued and Outstanding Shares [Member] |
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
Percentage of acquisition ownership interest |
100.00%
|
|
|
|
X |
- DefinitionCommon stock, shares held
+ References
+ Details
Name: |
SIGYD_CommonStockSharesHeld |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPurchase price of common stock expressed as a percentage of its fair value.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=SIGYD_ShareExchangeAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=SIGYD_SigynStockholdersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=SIGYD_IssuedAndOutstandingSharesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
BASIS OF PRESENTATION (Details Narrative) - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
Accumulated deficit |
$ 11,341,512
|
$ 7,195,576
|
Working capital |
3,489,941
|
|
Net loss |
4,145,936
|
2,929,817
|
Net cash provided by used in operating activities |
$ 1,383,210
|
$ 1,830,242
|
X |
- DefinitionWorking capital (deficit).
+ References
+ Details
Name: |
SIGYD_WorkingCapitalDeficit |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.0.1
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
+ Details
Name: |
us-gaap_CashFDICInsuredAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.0.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] |
|
|
Estimated useful life |
5 years
|
|
Accumulated depreciation |
$ (16,902)
|
$ (10,146)
|
Property and equipment, net |
15,296
|
22,052
|
Office Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
$ 29,041
|
29,041
|
Estimated useful life |
5 years
|
|
Computer Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
$ 3,157
|
$ 3,157
|
Estimated useful life |
3 years
|
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)
|
Dec. 31, 2023 |
Oct. 31, 2023 |
Dec. 31, 2022 |
Dec. 22, 2022 |
Nov. 14, 2022 |
Nov. 09, 2022 |
Oct. 20, 2022 |
Sep. 20, 2022 |
Sep. 09, 2022 |
Aug. 31, 2022 |
Jul. 31, 2022 |
Jun. 22, 2022 |
Jun. 01, 2022 |
May 10, 2022 |
Apr. 28, 2022 |
Mar. 23, 2022 |
Dec. 31, 2021 |
Sep. 17, 2020 |
Jun. 23, 2020 |
Jan. 28, 2020 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
$ 2,507,636
|
|
$ 2,279,316
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 700,816
|
|
|
|
Original issue discount |
(225,835)
|
|
(74,502)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beneficial conversion feature |
(22,013)
|
|
(175,275)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount |
(49,489)
|
|
(392,883)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total convertible notes payable |
2,210,299
|
|
1,636,656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
564,138
|
|
457,380
|
|
|
|
|
|
|
|
|
|
|
|
|
|
457,380
|
|
|
$ 564,138
|
Convertible Promissory Note Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
74,621
|
|
60,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,500
|
|
$ 74,621
|
|
Convertible Promissory Note Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
225,377
|
|
182,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
182,936
|
$ 225,377
|
|
|
Convertible Promissory Note Four [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
259,685
|
|
220,000
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 259,685
|
|
|
|
|
Convertible Promissory Note Five [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
127,979
|
|
110,000
|
|
|
|
|
|
|
|
|
|
|
|
$ 127,979
|
|
|
|
|
|
Convertible Promissory Note Six [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
128,020
|
|
110,000
|
|
|
|
|
|
|
|
|
|
|
$ 128,020
|
|
|
|
|
|
|
Convertible Promissory Note Seven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
63,302
|
|
55,000
|
|
|
|
|
|
|
|
|
|
$ 63,301
|
|
|
|
|
|
|
|
Convertible Promissory Note Eight [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
94,314
|
|
82,500
|
|
|
|
|
|
|
|
|
$ 94,314
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Nine [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
341,000
|
|
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Ten [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
123,200
|
|
110,000
|
|
|
|
|
|
|
$ 123,200
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eleven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
92,400
|
|
82,500
|
|
|
|
|
|
$ 92,400
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Twelve [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
123,200
|
|
110,000
|
|
|
|
|
$ 123,200
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Thirteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
110,000
|
|
110,000
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fourteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
92,400
|
|
82,500
|
|
|
$ 92,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fifteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
55,000
|
|
55,000
|
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Sixteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
110,000
|
|
110,000
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seventeen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
$ 264,000
|
|
|
|
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
|
|
Debt discount |
|
$ (997,700)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionBeneficial conversion feature.
+ References
+ Details
Name: |
SIGYD_BeneficialConversionFeature |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionDebtInstrument Original Discount.
+ References
+ Details
Name: |
SIGYD_DebtInstrumentOriginalDiscount |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteElevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwelveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThirteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFifteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSeventeenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
Dec. 22, 2022 |
Nov. 14, 2022 |
Nov. 09, 2022 |
Oct. 20, 2022 |
Sep. 20, 2022 |
Sep. 09, 2022 |
Jul. 31, 2022 |
Jun. 22, 2022 |
Jun. 01, 2022 |
May 10, 2022 |
Apr. 28, 2022 |
Mar. 23, 2022 |
Sep. 17, 2020 |
Jun. 23, 2020 |
Jan. 28, 2020 |
Aug. 31, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,507,636
|
$ 2,279,316
|
$ 700,816
|
Convertible Promissory Note One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 564,138
|
|
564,138
|
457,380
|
457,380
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
Convertible Promissory Note Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 74,621
|
|
|
74,621
|
60,500
|
60,500
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
Convertible Promissory Note Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
$ 225,377
|
|
|
|
225,377
|
182,936
|
182,936
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
Convertible Promissory Note Four [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
$ 259,685
|
|
|
|
|
259,685
|
220,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
Convertible Promissory Note Five [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
$ 127,979
|
|
|
|
|
|
127,979
|
110,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Six [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
$ 128,020
|
|
|
|
|
|
|
128,020
|
110,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
$ 63,301
|
|
|
|
|
|
|
|
63,302
|
55,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eight [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
$ 94,314
|
|
|
|
|
|
|
|
|
94,314
|
82,500
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Nine [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
|
|
|
341,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity period |
|
|
|
|
|
|
July 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 341,000
|
|
|
Debt conversion converted instrument shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,050
|
|
|
Convertible Promissory Note Ten [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 123,200
|
$ 123,200
|
110,000
|
|
Debt instrument interest rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
Convertible Promissory Note Eleven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
$ 92,400
|
|
|
|
|
|
|
|
|
|
|
92,400
|
82,500
|
|
Debt instrument interest rate |
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Twelve [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
$ 123,200
|
|
|
|
|
|
|
|
|
|
|
|
123,200
|
110,000
|
|
Debt instrument interest rate |
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Thirteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
110,000
|
110,000
|
|
Debt instrument interest rate |
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
Oct. 20, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fourteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
$ 92,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92,400
|
82,500
|
|
Debt instrument interest rate |
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fifteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
55,000
|
55,000
|
|
Debt instrument interest rate |
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
Nov. 14, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Sixteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
110,000
|
110,000
|
|
Debt instrument interest rate |
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
Dec. 22, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seventeen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible notes payable |
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
|
|
264,000
|
|
|
Debt instrument interest rate |
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity period |
|
|
|
|
|
|
July 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,179,200
|
|
|
Debt conversion converted instrument shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
196,534
|
|
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteElevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwelveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThirteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFifteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSeventeenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1
+ Details
Name: |
us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.0.1
SCHEDULE OF CHANGES IN CONVERTIBLE NOTES (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
$ 2,279,316
|
$ 700,816
|
Convertible notes payable issued |
1,748,520
|
1,578,500
|
Conversion of debt for common stock |
(1,520,200)
|
|
Convertible notes payable, Ending balance |
2,507,636
|
2,279,316
|
Convertible Promissory Note One [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
457,380
|
457,380
|
Convertible notes payable issued |
106,758
|
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
564,138
|
457,380
|
Convertible Promissory Note Two [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
60,500
|
60,500
|
Convertible notes payable issued |
14,121
|
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
74,621
|
60,500
|
Convertible Promissory Note Three [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
182,936
|
182,936
|
Convertible notes payable issued |
42,441
|
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
225,377
|
182,936
|
Convertible Promissory Note Four [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
220,000
|
|
Convertible notes payable issued |
39,685
|
220,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
259,685
|
220,000
|
Convertible Promissory Note Five [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
17,979
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
127,979
|
110,000
|
Convertible Promissory Note Six [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
18,020
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
128,020
|
110,000
|
Convertible Promissory Note Seven [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
55,000
|
|
Convertible notes payable issued |
8,302
|
55,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
63,302
|
55,000
|
Convertible Promissory Note Eight [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
82,500
|
|
Convertible notes payable issued |
11,814
|
82,500
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
94,314
|
82,500
|
Convertible Promissory Note Nine [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
341,000
|
|
Convertible notes payable issued |
|
341,000
|
Conversion of debt for common stock |
(341,000)
|
|
Convertible notes payable, Ending balance |
|
341,000
|
Convertible Promissory Note Ten [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
13,200
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
123,200
|
110,000
|
Convertible Promissory Note Eleven [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
82,500
|
|
Convertible notes payable issued |
9,900
|
82,500
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
92,400
|
82,500
|
Convertible Promissory Note Twelve [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
13,200
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
123,200
|
110,000
|
Convertible Promissory Note Thirteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
110,000
|
110,000
|
Convertible Promissory Note Fourteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
82,500
|
|
Convertible notes payable issued |
9,900
|
82,500
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
92,400
|
82,500
|
Convertible Promissory Note Fifteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
55,000
|
|
Convertible notes payable issued |
|
55,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
55,000
|
55,000
|
Convertible Promissory Note Sixteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
110,000
|
|
Convertible notes payable issued |
|
110,000
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
110,000
|
110,000
|
Convertible Promissory Note Seventeen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
|
|
Convertible notes payable issued |
1,443,200
|
|
Conversion of debt for common stock |
(1,179,200)
|
|
Convertible notes payable, Ending balance |
264,000
|
|
Convertible Promissory Note Other [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Convertible notes payable, Begining balance |
|
|
Convertible notes payable issued |
|
|
Conversion of debt for common stock |
|
|
Convertible notes payable, Ending balance |
|
|
X |
- DefinitionConversion of debt for common stock.
+ References
+ Details
Name: |
SIGYD_ConversionOfDebtForCommonStock |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionConvertible notes payable issued.
+ References
+ Details
Name: |
SIGYD_ConvertibleNotesPayableIssued |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteElevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwelveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThirteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFifteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSeventeenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOtherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
SCHEDULE OF CHANGES IN NOTE DISCOUNTS (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 642,660
|
$ 53,614
|
Note discounts issued in conjunction with debt |
1,695,859
|
1,015,039
|
Accretion of note discounts |
(2,041,182)
|
(425,993)
|
Note discounts, Ending balance |
297,337
|
642,660
|
Convertible notes payable, net |
$ 2,210,299
|
$ 1,636,656
|
Effective interest rate |
81.00%
|
19.00%
|
Convertible Promissory Note One [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
|
$ 34,176
|
Note discounts issued in conjunction with debt |
106,758
|
|
Accretion of note discounts |
(31,589)
|
(34,176)
|
Note discounts, Ending balance |
75,169
|
|
Convertible notes payable, net |
$ 488,969
|
$ 457,380
|
Effective interest rate |
6.00%
|
7.00%
|
Convertible Promissory Note Two [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
|
$ 4,521
|
Note discounts issued in conjunction with debt |
14,121
|
|
Accretion of note discounts |
(4,178)
|
(4,521)
|
Note discounts, Ending balance |
9,943
|
|
Convertible notes payable, net |
$ 64,678
|
$ 60,500
|
Effective interest rate |
6.00%
|
7.00%
|
Convertible Promissory Note Three [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
|
$ 14,917
|
Note discounts issued in conjunction with debt |
42,441
|
|
Accretion of note discounts |
(12,558)
|
(14,917)
|
Note discounts, Ending balance |
29,883
|
|
Convertible notes payable, net |
$ 195,494
|
$ 182,936
|
Effective interest rate |
6.00%
|
8.00%
|
Convertible Promissory Note Four [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 25,480
|
|
Note discounts issued in conjunction with debt |
39,685
|
113,418
|
Accretion of note discounts |
(37,223)
|
(87,938)
|
Note discounts, Ending balance |
27,942
|
25,480
|
Convertible notes payable, net |
$ 231,743
|
$ 194,520
|
Effective interest rate |
14.00%
|
40.00%
|
Convertible Promissory Note Five [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 14,478
|
|
Note discounts issued in conjunction with debt |
17,979
|
44,786
|
Accretion of note discounts |
(19,799)
|
(30,308)
|
Note discounts, Ending balance |
12,658
|
14,478
|
Convertible notes payable, net |
$ 115,321
|
$ 95,522
|
Effective interest rate |
15.00%
|
28.00%
|
Convertible Promissory Note Six [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 15,951
|
|
Note discounts issued in conjunction with debt |
18,020
|
44,787
|
Accretion of note discounts |
(21,283)
|
(28,836)
|
Note discounts, Ending balance |
12,688
|
15,951
|
Convertible notes payable, net |
$ 115,332
|
$ 94,049
|
Effective interest rate |
17.00%
|
26.00%
|
Convertible Promissory Note Seven [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 9,493
|
|
Note discounts issued in conjunction with debt |
8,302
|
22,794
|
Accretion of note discounts |
(11,949)
|
(13,301)
|
Note discounts, Ending balance |
5,846
|
9,493
|
Convertible notes payable, net |
$ 57,456
|
$ 45,507
|
Effective interest rate |
19.00%
|
24.00%
|
Convertible Promissory Note Eight [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 16,525
|
|
Note discounts issued in conjunction with debt |
11,814
|
34,861
|
Accretion of note discounts |
(20,019)
|
(18,336)
|
Note discounts, Ending balance |
8,320
|
16,525
|
Convertible notes payable, net |
$ 85,994
|
$ 65,975
|
Effective interest rate |
21.00%
|
22.00%
|
Convertible Promissory Note Nine [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 69,569
|
|
Note discounts issued in conjunction with debt |
|
140,289
|
Accretion of note discounts |
(69,569)
|
(70,720)
|
Note discounts, Ending balance |
|
69,569
|
Convertible notes payable, net |
|
$ 271,431
|
Effective interest rate |
|
21.00%
|
Convertible Promissory Note Ten [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
31,788
|
|
Note discounts issued in conjunction with debt |
13,200
|
64,104
|
Accretion of note discounts |
(35,694)
|
(32,316)
|
Note discounts, Ending balance |
9,294
|
31,788
|
Convertible notes payable, net |
$ 113,906
|
$ 78,212
|
Effective interest rate |
29.00%
|
29.00%
|
Convertible Promissory Note Eleven [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 42,506
|
|
Note discounts issued in conjunction with debt |
9,900
|
82,500
|
Accretion of note discounts |
(45,435)
|
(39,994)
|
Note discounts, Ending balance |
6,971
|
42,506
|
Convertible notes payable, net |
$ 85,429
|
$ 39,994
|
Effective interest rate |
49.00%
|
48.00%
|
Convertible Promissory Note Twelve [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 60,126
|
|
Note discounts issued in conjunction with debt |
13,200
|
110,000
|
Accretion of note discounts |
(64,032)
|
(49,874)
|
Note discounts, Ending balance |
9,294
|
60,126
|
Convertible notes payable, net |
$ 113,906
|
$ 49,874
|
Effective interest rate |
52.00%
|
45.00%
|
Convertible Promissory Note Thirteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 86,329
|
|
Note discounts issued in conjunction with debt |
|
110,000
|
Accretion of note discounts |
(86,329)
|
(23,671)
|
Note discounts, Ending balance |
|
86,329
|
Convertible notes payable, net |
$ 110,000
|
$ 23,671
|
Effective interest rate |
78.00%
|
22.00%
|
Convertible Promissory Note Fourteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 69,678
|
|
Note discounts issued in conjunction with debt |
9,900
|
82,500
|
Accretion of note discounts |
(71,785)
|
(12,822)
|
Note discounts, Ending balance |
7,793
|
69,678
|
Convertible notes payable, net |
$ 84,607
|
$ 12,822
|
Effective interest rate |
78.00%
|
16.00%
|
Convertible Promissory Note Fifteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 47,274
|
|
Note discounts issued in conjunction with debt |
|
55,000
|
Accretion of note discounts |
(47,274)
|
(7,726)
|
Note discounts, Ending balance |
|
47,274
|
Convertible notes payable, net |
$ 55,000
|
$ 7,726
|
Effective interest rate |
86.00%
|
14.00%
|
Convertible Promissory Note Sixteen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 103,463
|
|
Note discounts issued in conjunction with debt |
|
110,000
|
Accretion of note discounts |
(103,463)
|
(6,537)
|
Note discounts, Ending balance |
|
103,463
|
Convertible notes payable, net |
$ 110,000
|
$ 6,537
|
Effective interest rate |
94.00%
|
6.00%
|
Convertible Promissory Note Seventeen [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
|
|
Note discounts issued in conjunction with debt |
1,390,539
|
|
Accretion of note discounts |
(1,309,003)
|
|
Note discounts, Ending balance |
81,536
|
|
Convertible notes payable, net |
$ 182,464
|
|
Effective interest rate |
496.00%
|
|
Convertible Promissory Note Other [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Note discounts, Begining balance |
$ 50,000
|
|
Note discounts issued in conjunction with debt |
|
|
Accretion of note discounts |
(50,000)
|
50,000
|
Note discounts, Ending balance |
|
50,000
|
Convertible notes payable, net |
|
$ (50,000)
|
Effective interest rate |
|
|
X |
- DefinitionAccretion of note discounts.
+ References
+ Details
Name: |
SIGYD_AccretionOfNoteDiscounts |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDebt instrument note discounts.
+ References
+ Details
Name: |
SIGYD_DebtInstrumentNoteDiscounts |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNote discounts issued in conjunction with debt.
+ References
+ Details
Name: |
SIGYD_NoteDiscountsIssuedInConjunctionWithDebt |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateEffectivePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteElevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwelveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThirteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFifteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSeventeenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOtherMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
CONVERTIBLE PROMISSORY DEBENTURES (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
Oct. 31, 2023 |
Dec. 22, 2022 |
Dec. 22, 2022 |
Nov. 21, 2022 |
Nov. 14, 2022 |
Nov. 09, 2022 |
Oct. 20, 2022 |
Sep. 20, 2022 |
Sep. 09, 2022 |
Aug. 31, 2022 |
Jul. 31, 2022 |
Jun. 22, 2022 |
Jun. 01, 2022 |
May 10, 2022 |
Apr. 28, 2022 |
Mar. 23, 2022 |
Oct. 28, 2021 |
Oct. 22, 2021 |
Oct. 22, 2021 |
Oct. 20, 2020 |
Sep. 17, 2020 |
Sep. 17, 2020 |
Jun. 23, 2020 |
Jan. 28, 2020 |
Jan. 28, 2020 |
Aug. 31, 2022 |
Dec. 31, 2023 |
Oct. 03, 2023 |
Sep. 14, 2023 |
Jun. 02, 2023 |
Dec. 31, 2022 |
Nov. 23, 2022 |
Aug. 30, 2022 |
Aug. 20, 2020 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
559,839
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 49,489
|
|
|
|
$ 392,883
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
279,920
|
|
|
|
|
|
|
|
Convertible Promissory Note Seventeen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,179,200
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
July 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
$ 997,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of shares |
166,284
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
196,534
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seventeen [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,443,200
|
|
|
$ 181,500
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January
2024 through December 7, 2024 based on $1.00 for each $0.90909 paid by the previous noteholder
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 07, 2024
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
233,200
|
|
|
30,250
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,312,000
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 131,200
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
Convertible Promissory Note Seventeen [Member] | Brio Capital Master Fund Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
Convertible Promissory Note Sixteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
Dec. 22, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
0.00%
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Sixteen [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
$ 110,000
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
Dec. 22, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
18,334
|
18,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
$ 10.00
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
$ 10,000
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
$ 6.00
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
December 22, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fifteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
Nov. 14, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fifteen [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
Nov. 14, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
9,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
November 14, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fourteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Fourteen [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
$ 82,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
Nov. 09, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
13,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,900
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
November 9, 2023 based on $1.00 for each $0.90909 paid by Brio
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Thirteen [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
Oct. 20, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Thirteen [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
Oct. 20, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
18,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
October 20, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Twelve [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Twelve [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
Sep. 20, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
18,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,200
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
September 20, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eleven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eleven [Member] | Brio Capital Master Fund Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
$ 82,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
Sep. 09, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
13,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,900
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
September 9, 2023 based on $1.00 for each $0.90909 paid by Brio
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Ten [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Ten [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
Aug. 31, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
18,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,334
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
13,200
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
August 31, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Ten [Member] | Brio Capital Master Fund Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10.00
|
|
Convertible Promissory Note Nine [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
July 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,050
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Nine [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
$ 341,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 324,500
|
|
$ 16,500
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
16,923
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,225
|
|
825
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
$ 310,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
July 2023 based on $1.00
for each $0.90909 paid by the noteholder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eight [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Eight [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
$ 82,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
Jun. 22, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
4,125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
$ 7,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,814
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
June 22, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seven [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Seven [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
Jun. 01, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
2,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,302
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
June 1, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Six [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Six [Member] | Brio Capital Master Fund Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
May 10, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,020
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
May 10, 2023 based on $1.00 for each $0.90909 paid by Brio
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Five [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Five [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apr. 28, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,979
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
April 28, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Four [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Four [Member] | Osher Capital Partners LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mar. 23, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
19,721
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 23, 2023 based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Four [Member] | Brio Capital Master Fund Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 110,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mar. 23, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
19,964
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 23, 2023 based on $1.00 for each $0.90909 paid by Brio
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Three [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Three [Member] | Osher Capital Partners LLC [Member] | Securities Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 181,500
|
$ 181,500
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
206
|
206
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,200.00
|
$ 1,200.00
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 165,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16,500
|
$ 16,500
|
|
|
|
|
|
|
42,441
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15.60
|
$ 15.60
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September
30, 2021, based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Three [Member] | Osher Capital Partners LLC [Member] | Amended Convertible Debt Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
maturity date from October 20, 2021 to October 20, 2022
|
maturity date from September 30, 2021 to October 20, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,250
|
11,250
|
11,634
|
206
|
206
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40.00
|
$ 40.00
|
$ 23.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument carrying amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 199,650
|
$ 717,530
|
$ 717,530
|
$ 652,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 65,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt principal amount converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16,714
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon conversion of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,071
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Two [Member] | Osher Capital Partners LLC [Member] | Securities Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
maturity date from October 20, 2021 to October 20, 2022
|
maturity date from June 23, 2021 to October 20, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jun. 23, 2021
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
5 years
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,250
|
11,250
|
|
|
|
250
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40.00
|
$ 40.00
|
|
|
|
$ 1,200.00
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,005
|
|
|
$ 50,005
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
14,121
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15.60
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 23,
2021, based on $1.00 for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument carrying amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 717,530
|
$ 717,530
|
652,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 65,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note Two [Member] | Osher Capital Partners LLC [Member] | Amended Convertible Debt Agreement Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 23.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,995
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aug. 30, 2024
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.00%
|
0.00%
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note One [Member] | Osher Capital Partners LLC [Member] | Securities Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 385,000
|
$ 385,000
|
|
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
maturity date from October 20, 2021 to October 20, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jan. 26, 2021
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
5 years
|
|
|
|
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,250
|
11,250
|
|
|
|
|
2,005
|
2,005
|
|
|
|
|
|
|
|
|
102,827
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40.00
|
$ 40.00
|
|
|
|
|
$ 280.00
|
$ 280.00
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 350,005
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 34,995
|
$ 34,995
|
|
|
|
$ 106,758
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.76
|
$ 3.76
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 26, 2021, based on $1.00
for each $0.90909 paid by Osher
|
|
|
|
|
|
|
|
|
|
|
Debt instrument carrying amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 717,530
|
$ 717,530
|
$ 652,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 65,230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note One [Member] | Osher Capital Partners LLC [Member] | Amended Convertible Debt Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
maturity date from June 23, 2021 to October 20, 2021
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.60
|
$ 5.60
|
|
|
|
|
|
|
|
|
|
Interest percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.00%
|
8.00%
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, maturity date, description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
October 20, 2021 to October 20,
2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,250
|
11,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40.00
|
$ 40.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Promissory Note [Member] | Third Party Investor [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24,200
|
|
|
Convertible Promissory Note [Member] | Securities Purchase Agreement [Member] | Third Party Investor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate principal amount of debt |
|
|
|
$ 145,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 145,200
|
|
|
Debt instrument maturity date |
|
|
|
Nov. 21, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Term of warrants |
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
24,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
$ 10.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
|
$ 132,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Original issue discount amount |
|
|
|
$ 13,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt conversion, description |
|
|
|
November 21, 2023 based on $1.00 for each $0.90909 paid by the previous
noteholder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
+ Details
Name: |
us-gaap_DebtConversionDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionOriginalDebtAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentIncreaseAccruedInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSeventeenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=SIGYD_OsherCapitalPartnersLLCMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=SIGYD_BrioCapitalMasterFundLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFifteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThirteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwelveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteElevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteNineMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteEightMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSevenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteSixMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=SIGYD_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=SIGYD_AmendedConvertibleDebtAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=SIGYD_AmendedConvertibleDebtAgreementTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=SIGYD_ThirdPartyInvestorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
X |
- DefinitionAdvance from shareholder.
+ References
+ Details
Name: |
SIGYD_AdvanceFromShareholder |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureAdvanceFromShareholderAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)
|
|
|
12 Months Ended |
Jun. 02, 2023 |
Oct. 22, 2021 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Class of Stock [Line Items] |
|
|
|
|
Preferred stock shares, authorized |
|
|
10,000,000
|
10,000,000
|
Preferred stock, par or stated value per share |
|
|
$ 0.0001
|
$ 0.0001
|
Preferred stock shares issued |
|
|
32
|
0
|
Preferred stock shares outstanding |
|
|
32
|
0
|
Common stock shares authorized |
|
|
1,000,000,000
|
1,000,000,000
|
Common stock par value |
|
|
$ 0.0001
|
$ 0.0001
|
Common stock shares outstanding |
|
|
1,288,415
|
956,595
|
Number of securities called by warrants |
|
|
559,839
|
|
Aggregate principal amount |
$ 198,000
|
|
|
|
Restricted stock |
|
|
$ 50,000
|
|
Share based compensation |
|
|
$ 150,000
|
$ 0
|
Modification of warrants |
|
|
352,965
|
|
Convertible Promissory Note [Member] |
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
Number of securities called by warrants |
|
11,250
|
|
|
Debt maturity date, description |
|
October 20, 2021 to October 20,
2022
|
|
|
Stock issued during period shares |
|
11,250
|
|
|
Proceeds from issuance of common stock |
|
$ 197,501
|
|
|
Exercise price of warrants per share |
|
$ 40.00
|
|
|
Other expenses |
|
|
$ 0
|
$ 147,720
|
Common Stock [Member] |
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
Conversion of common stock for Series A preferred stock, shares |
|
|
(161,684)
|
|
Number of securities called by warrants |
|
|
279,920
|
|
Common stock issued to third parties in conjunction with conversion of debt, shares |
31,075
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
Preferred stock shares issued |
|
|
32
|
|
Conversion of common stock for Series A preferred stock, shares |
|
|
161,684
|
|
Preferred stock conversion, description |
|
|
Each Series B Convertible Preferred Share converts into 5,025.1 shares of the Company’s common stock
|
|
X |
- DefinitionStock issued during period shares conversion of convertible securities net of adjustments.
+ References
+ Details
Name: |
SIGYD_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesNetOfAdjustments |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionA unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of principal of debt issued.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_DebtInstrumentIssuedPrincipal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
SCHEDULE OF OPERATING LEASE COST AND SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Operating Leases |
|
|
Operating lease expense |
$ 71,676
|
$ 71,676
|
Short term lease cost |
|
|
Total lease expense |
71,676
|
71,676
|
Operating cash flows from operating leases |
54,263
|
72,714
|
Cash paid for amounts included in the measurement of lease liabilities |
$ 54,263
|
$ 72,714
|
Operating lease, weighted average remaining lease term |
2 years 8 months 1 day
|
3 years 8 months 1 day
|
Weighted-average discount rate - operating leases |
10.00%
|
10.00%
|
X |
- DefinitionCash paid for amounts included in measurement of lease liabilities.
+ References
+ Details
Name: |
SIGYD_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lease cost recognized by lessee for lease contract.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_ShortTermLeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.0.1
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details) - USD ($)
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Operating Leases |
|
|
2024 |
$ 77,142
|
|
2026 |
79,456
|
|
2027 |
54,225
|
|
Total undiscounted cash flows |
$ 210,823
|
|
Operating lease, weighted average remaining lease term |
2 years 8 months 1 day
|
3 years 8 months 1 day
|
Weighted-average discount rate |
10.00%
|
10.00%
|
Lease liabilities, current Present values |
$ 187,425
|
|
Lease liabilities—current |
61,123
|
$ 53,200
|
Lease liabilities—long-term |
126,302
|
$ 187,425
|
Lease liabilities—total |
187,425
|
|
Difference between undiscounted and discounted cash flows |
$ 23,398
|
|
X |
- References
+ Details
Name: |
SIGYD_DisclosureOperatingLeasesAbstract |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLease liability present values.
+ References
+ Details
Name: |
SIGYD_LeaseLiabilityPresentValues |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.0.1
OPERATING LEASES (Details Narrative) - USD ($)
|
|
12 Months Ended |
|
May 27, 2021 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Jun. 15, 2021 |
Lease monthly rent |
$ 5,955
|
|
|
|
Operating lease right-of-use assets |
|
$ 167,736
|
$ 217,718
|
|
Operating lease liability |
|
187,425
|
|
|
Operating lease cost |
|
$ 71,676
|
$ 71,676
|
|
ASC 842 [Member] |
|
|
|
|
Operating lease right-of-use assets |
|
|
|
$ 290,827
|
Operating lease liability |
|
|
|
$ 290,827
|
X |
- DefinitionAmount of lease cost recognized by lessee for lease contract.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_LeaseCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCash payments to lessor's for use of assets under operating leases.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForRent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis=SIGYD_ASC842Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
|
|
12 Months Ended |
Dec. 06, 2023 |
Apr. 01, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Related Party Transaction [Line Items] |
|
|
|
|
Stock based compensation |
|
|
$ 150,000
|
$ 0
|
Mr. Joyce [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Stock based compensation |
|
|
455,000
|
453,067
|
Accrued compensation |
|
|
284,375
|
|
Employment Agreements [Member] | Mr. Joyce [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Annual base salary |
|
|
$ 455,000
|
|
Maximum bonus compensation percentage |
|
|
50.00%
|
|
Beneficial ownership target percentage |
|
|
9.00%
|
|
Employment Agreements [Member] | Mr. DeCiccio [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Maximum bonus compensation percentage |
40.00%
|
|
|
|
Stock based compensation |
|
|
$ 9,000
|
|
Annual base salary |
$ 250,000
|
|
|
|
Options granted |
17,500
|
|
|
|
Purchase of shares |
17,500
|
|
|
|
Accounts payable |
|
|
35,242
|
0
|
Employment Agreements [Member] | Dr Marleau [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Maximum bonus compensation percentage |
|
40.00%
|
|
|
Stock based compensation |
|
|
225,000
|
0
|
Accrued compensation |
|
|
100,000
|
|
Annual base salary |
|
$ 300,000
|
|
|
Percentage of annual increase salary |
|
3.00%
|
|
|
Employment Agreements [Member] | Chief Technology Officer [Member] |
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
Stock based compensation |
|
|
240,000
|
$ 233,678
|
Accrued compensation |
|
|
$ 160,000
|
|
X |
- Definition
+ References
+ Details
Name: |
SIGYD_AccruedCompensation |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionBeneficial ownership target percentage.
+ References
+ Details
Name: |
SIGYD_BeneficialOwnershipTargetPercentage |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMaximum bonus compensation percentage.
+ References
+ Details
Name: |
SIGYD_MaximumBonusCompensationPercentage |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of annual increase salary.
+ References
+ Details
Name: |
SIGYD_PercentageOfAnnualIncreaseSalary |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of the total principal payments made during the annual reporting period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentAnnualPrincipalPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=SIGYD_EmploymentAgreementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
v3.24.0.1
SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
|
Dec. 31, 2023 |
Dec. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
|
Net operating loss carry forwards |
$ 2,781,577
|
$ 1,674,531
|
Accrued payroll |
203,771
|
|
Stock-based compensation |
60,321
|
|
Depreciation and amortization |
(21,911)
|
|
Valuation allowance |
(3,023,758)
|
(1,674,531)
|
Total |
|
|
X |
- DefinitionDeferred tax assets tax deferred expense depreciation and amortization.
+ References
+ Details
Name: |
SIGYD_DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization |
Namespace Prefix: |
SIGYD_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsLiabilitiesNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.0.1
X |
- DefinitionNet operating loss carryforward limitation percentage.
+ References
+ Details
Name: |
SIGYD_NetOperatingLossCarryforwardLimitationPercentage |
Namespace Prefix: |
SIGYD_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.24.0.1
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET INCOME PER SHARE (Details) - USD ($)
|
12 Months Ended |
Dec. 31, 2023 |
Dec. 31, 2022 |
Earnings Per Share [Abstract] |
|
|
Net loss attributable to the common stockholders |
$ (4,145,936)
|
$ (2,929,817)
|
Basic weighted average outstanding shares of common stock |
1,100,372
|
934,915
|
Dilutive effect of options and warrants |
|
|
Diluted weighted average common stock and common stock equivalents |
1,100,372
|
934,915
|
Loss per share, basic |
$ (3.77)
|
$ (3.13)
|
Loss per share, diluted |
$ (3.77)
|
$ (3.13)
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-26
+ Details
Name: |
us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.0.1
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for award of restricted stock or unit under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_RestrictedStockExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=SIGYD_MrChrisWetzelMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.0.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
|
|
|
|
1 Months Ended |
12 Months Ended |
|
|
Jan. 19, 2024 |
Jan. 09, 2024 |
Jan. 08, 2024 |
Feb. 29, 2024 |
Jan. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Feb. 15, 2024 |
Oct. 22, 2021 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
559,839
|
|
|
|
Original issue discount amount |
|
|
|
|
|
$ 49,489
|
$ 392,883
|
|
|
Proceeds from shareholder |
|
|
|
|
|
80,000
|
|
|
|
Due to shareholder |
|
|
|
|
|
$ 3,182
|
$ 1,197
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Shares cancelled |
|
64,100
|
|
|
|
|
|
|
|
Reverse stock split |
one-for-forty reverse stock split
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Chief Executive Officer [Member] |
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Proceeds from shareholder |
|
|
|
|
$ 25,000
|
|
|
|
|
Due to shareholder |
|
|
|
|
|
|
|
$ 105,000
|
|
Convertible Promissory Note [Member] |
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
|
|
|
|
|
11,250
|
Exercise price of warrants per share |
|
|
|
|
|
|
|
|
$ 40.00
|
Convertible Promissory Note [Member] | Brio Capital Master Fund Ltd. [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 44,000
|
|
|
|
|
|
|
Debt conversion, description |
|
|
January 8, 2025 based on $1.00 for each $0.90909 paid by Brio
|
|
|
|
|
|
|
Debt instrument maturity date |
|
|
Jan. 08, 2025
|
|
|
|
|
|
|
Term of warrants |
|
|
5 years
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
7,333
|
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
$ 10.00
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt |
|
|
$ 40,000
|
|
|
|
|
|
|
Original issue discount amount |
|
|
$ 4,000
|
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
$ 6.00
|
|
|
|
|
|
|
2024 Convertible Notes [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
$ 50,050
|
|
|
|
|
|
Debt conversion, description |
|
|
|
in February 2025 based on $1.00 for each $0.90909
paid by the noteholder
|
|
|
|
|
|
Term of warrants |
|
|
5 years
|
|
|
|
|
|
|
Aggregate number of warrants to purchase shares |
|
|
|
8,343
|
|
|
|
|
|
Exercise price of warrants per share |
|
|
|
$ 10.00
|
|
|
|
|
|
Debt instrument conversion price per share |
|
|
|
$ 6.00
|
|
|
|
|
|
Cash |
|
|
|
$ 45,500
|
|
|
|
|
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
+ Details
Name: |
us-gaap_DebtConversionDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares (or other type of equity) forfeited during the period.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=SIGYD_BrioCapitalMasterFundLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=SIGYD_TwentyTwentyFourConvertibleNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Sigyn Therapeutics (QB) (USOTC:SIGYD)
Historical Stock Chart
From May 2024 to Jun 2024
Sigyn Therapeutics (QB) (USOTC:SIGYD)
Historical Stock Chart
From Jun 2023 to Jun 2024